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Alcoholism is a chronic and progressive disorder characterized by periods of 
excessive drinking, withdrawal and abstinence, and eventual relapse. Both genetic and 
environmental factors contribute to the development of alcohol addiction, with stress 
being a critical environmental factor. Corticotropin-releasing hormone (CRH) is the key 
regulator of the mammalian stress response, and dysregulation of the CRH system is 
observed in binge drinking and alcohol dependence. CRH-binding protein (CRH-BP) is a 
secreted glycoprotein that binds CRH with a very high affinity, thereby regulating CRH 
receptor activation. Numerous studies have identified SNPs in the CRHBP gene that are 
associated with alcoholism, suggesting a role for CRH-BP in vulnerability to alcohol 
abuse.  
In this thesis, I investigated the role and regulation of CRH-BP in mouse models 
of binge drinking and alcohol dependence. Using in situ hybridization, I determined that 
repeated cycles of drinking in the dark, a mouse model of binge drinking, decrease CRH-
BP mRNA expression in the medial prefrontal cortex, a region involved in executive 
function and regulation of emotion and behavior, including responses to stress. In a 
mouse model of alcohol dependence, the chronic intermittent ethanol (CIE) vapor 
paradigm, I observed a decrease in CRH-BP mRNA at peak alcohol withdrawal in the 
anterior paraventricular nucleus of the thalamus, a novel participant in the stress/reward 
circuitry. In a CIE paradigm that included periods of voluntary ethanol drinking, I 
ix 
detected a decrease in CRH-BP mRNA in the ventral tegmental area and an increase in 
CRH-BP mRNA in the bed nucleus of the stria terminalis, two key brain regions in the 
CRH and reward systems that have been implicated in control of excessive ethanol 
consumption. Interestingly, studies using CRH-BP KO mice suggest that the complete 
absence of CRH-BP may prevent increases in dependence-induced alcohol consumption.  
Together, these studies demonstrate changes in CRH-BP levels that may result in altered 
CRH receptor signaling within the stress and reward pathways in both binge drinking and 
dependence.  
I also examined the cell type-specific expression of CRH-BP in the PFC to begin 
to define the neural circuits in which CRH-BP is expressed. Using dual in situ 
hybridization, I detected CRH-BP mRNA predominantly in inhibitory, somatostatin-
expressing interneurons of the PFC, suggesting that CRH-BP may be acting locally 
within the PFC to mediate its effects on CRH receptors on pyramidal neurons. These 
colocalization studies provide the basis for future studies to manipulate CRH-BP in a 
cell-type specific manner to further elucidate its role in mouse models of excessive 
alcohol consumption.  
Finally, I conducted signaling experiments that begin to address the mechanisms 
by which CRH-BP modulates CRH activity at the two CRH receptors. I demonstrated 
that CRH-BP inhibits CRH-mediated activation of CRH receptors and the resulting 
increases in cAMP in LβT2 cells, an effect that is partially reversed by the CRH-BP 
ligand inhibitor, CRH6-33. Lastly, I optimized a calcium assay for future experiments to 
assess CRH-BP modulation of CRH receptor signaling through the 
Gαq/PLC/PKC/calcium signaling pathway. Overall, the results from this thesis expand 
x 
our knowledge on the role of the CRH-BP and the CRH system in alcohol use and 
addiction and begin to define the potential roles of CRH-BP within circuits of the stress 









The Stress Response and CRH Family of Peptides 
Stress is defined as a complex series of physiological responses to both physical 
and psychological challenges. These challenges encompass a variety of stimuli including 
injury, pain, infection, starvation, and predator threat. While acute activation of the stress 
response is adaptive and necessary for survival, chronic activation is unhealthy and has 
been implicated in a variety of diseases. Physiological responses to stress are mediated by 
both the autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis. 
Sympathetic nervous system activation results in adrenal epinephrine release, producing 
increases in heart rate and blood pressure. The HPA axis is the neuroendocrine 
component of the mammalian stress response and mediates the metabolic responses to 
stress (Figure 1.1). 
The HPA axis is largely regulated by corticotropin-releasing hormone (CRH), a 
41-amino acid peptide that was originally isolated and characterized from ovine 
hypothalami (Vale et al., 1981). In response to stress, CRH transcription in the 
paraventricular nucleus of the hypothalamus (PVN) is increased and CRH is released 
from the median eminence into the hypophyseal portal system, where it travels to the 
anterior pituitary and stimulates corticotropes to release ACTH into the blood (Figure  
*Note: Portions of this introduction were published previously in two articles entitled, “Corticotropin-
releasing hormone-binding protein and stress: from invertebrates to humans” (Ketchesin et al., 2017) 







Figure 1.1 – Schematic of the HPA axis. In response to stress, CRH is synthesized in the hypothalamus 
(PVN) and released from the median eminence into the hypophyseal portal system, where it travels to the 
anterior pituitary and stimulates corticotropes to release ACTH into the blood. ACTH stimulates the 
adrenal cortex to synthesize and release glucocorticoids, which mediate the metabolic responses to stress. 
Glucocorticoids can negatively feedback at multiple levels of the HPA axis to maintain homeostasis. 




1.1). ACTH stimulates the adrenal cortex to synthesize and release glucocorticoids 
(corticosterone or cortisol), which mediate the metabolic responses to stress. 
Glucocorticoids can then negatively feedback at multiple levels of the HPA axis to 
maintain homeostasis. CRH is also expressed in a variety of brain regions, including the 
cortex, amygdala, hippocampus, bed nucleus of the stria terminalis (BNST), 
hypothalamus, and various brain stem nuclei (Owens and Nemeroff, 1991), where it acts 
as a neurotransmitter to mediate the behavioral and autonomic responses to stress.  
In addition to CRH, a number of other CRH-like ligands have been discovered in 
mammals, including urocortin I, urocortin II/stresscopin-related peptide, and urocortin 
III/stresscopin (Figure 1.2; Hsu and Hsueh, 2001; Lewis et al., 2001; Reyes et al., 2001; 
Vaughan et al., 1995). Urocortin I shares 41.5 – 43.9% sequence identity with CRH, 
while urocortin II and urocortin III share 31.7% and 24.4 – 26.8% identity with CRH, 
respectively (Figure 1.2). The urocortins are expressed in distinct sites throughout the 
central nervous system and periphery (reviewed in Fekete and Zorrilla, 2007) and 
mediate diverse physiological functions, including appetite, energy metabolism, stress- 
and anxiety-related behaviors, and cardiovascular, intestinal, and immune function 
(reviewed in Fekete and Zorilla, 2007; Oki and Sasano, 2004; Ryabinin et al., 2012). 
CRH Receptors 
Pharmacology of CRH Receptors  
CRH and the urocortins mediate their effects through two receptors, CRH 
Receptor 1 (CRH-R1) and CRH Receptor 2 (CRH-R2). These receptors are members of 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































predominantly couple to Gαs, resulting in activation of the cAMP/PKA signaling pathway 
upon receptor binding. However, both receptors have been shown to couple to other G 
proteins in certain tissues or cell types, including Gαq, Gαo, and Gαi. Thus, the CRH 
receptors can activate a variety of intracellular signaling pathways, including not only 
PKA, but also PLC/PKC, PKB/akt, and ERK/MAPK (reviewed in Dautzenberg and 
Hauger, 2002; Hillhouse and Grammatopoulos, 2006).  
CRH-R1 and CRH-R2 share approximately 70% amino acid identity, with the 
lowest degree of homology in the N-terminal sequence. This divergence largely accounts 
for the distinct pharmacological profiles between the two receptors. CRH-R1 binds both 
CRH and urocortin I with nanomolar affinity and urocortin II with a lower affinity (Table 
1.1; Jahn et al., 2004). CRH-R2 binds all three urocortins with high affinity, but binds 
CRH with a lower affinity than CRH-R1 (Table 1.1; Jahn et al., 2001; Jahn et al., 2004). 
CRH Receptor Expression 
In addition to their distinct pharmacological profiles, CRH-R1 and CRH-R2 also 
differ in their expression patterns in the brain and periphery. In rodents, CRH-R1 is 
highly expressed in regions such as the cortex, amygdala, cerebellum, various brain stem 
nuclei, and anterior pituitary, with lower levels of expression in a variety of peripheral 
tissues (Figure 1.3; Van Pett et al., 2000; Westphal et al., 2009). In rodents, there are two 
major splice variants of CRH-R2, CRH-R2α and CRH-R2β Lovenberg et al., 1995. CRH-
R2α is mainly localized in the brain, while CRH-R2β is more widely expressed in 
peripheral tissues such as the heart, thymus, and spleen. In the brain, CRH-R2α is 











CRH 1.6 33.6 0.54 
UCN I 0.17 0.6 0.98 
UCN II 350 4.9 4.4 
UCN III >2000 8.1 >2000 
CRH6-33 >1000 - 3.5 
 
 
Table 1.1 – Binding affinities of the CRH family of peptides with CRH-R1, CRH-R2, and CRH-BP. 
Values were taken from multiple sources (Dautzenberg et al., 2004; Eckart et al., 2001; Jahn et a., 2001; 





Figure 1.3 – CRH-R1 and CRH-R2 mRNA expression in a sagittal section of the rodent brain. CRH-
R1 mRNA (referred to as CRF1 in the figure) is highly expressed in the cortex, amygdala, cerebellum, 
various brain stem nuclei, and anterior pituitary. In the brain, CRH-R2α (referred to as CRF2 in the figure) 
is expressed in a discrete pattern, with high levels of expression in the lateral septum, BNST, 




BNST, hypothalamus, and amygdala (Figure 1.3).  
Role of CRH Receptors in Stress-Related Behaviors 
The differential pharmacological and expression profiles between the two CRH 
receptors have resulted in diverse physiological functions. CRH-R1 activation initiates 
the stress response and promotes stress- and anxiety-related behaviors. For example, 
CRH-R1 deficient mice show decreased anxiety-like behavior and have an impaired 
stress response (Smith et al., 1998; Timpl et al., 1998). Other studies have shown an 
important role for CRH-R1 in both addiction and stress-induced reinstatement to drug 
seeking (Blacktop et al., 2011). For example, CRH-R1 activation promotes excessive 
alcohol drinking in rodents (reviewed in Lowery and Thiele, 2010; Phillips et al., 2015). 
In humans, CRHR1 SNPs have been associated with anxiety, major depression, and 
excessive alcohol consumption (Chen et al., 2010; Liu et al., 2006; Treutlein et al., 2006; 
Weber et al., 2016), supporting a role for CRH-R1 in stress-related psychiatric disorders. 
In contrast, it has been proposed that CRH-R2 activation promotes stress recovery and 
homeostasis. For example, CRH-R2 deficient mice display increased anxiety-like 
behavior, as well as an enhanced stress response (Bale et al., 2000; Kishimoto et al., 
2000). However, the role of CRH-R2 in stress-related behaviors appears to be complex, 
as results from pharmacological studies are mixed and suggest that the effects of CRH-
R2 may be brain region-specific (reviewed in Henckens et al., 2016). CRH-R2 has also 
been shown to have a variety of roles in the periphery likely related to the actions of 
urocortin, including gastrointestinal and cardiovascular function (Boonprasert et al., 





 The CRH family also includes the CRH-Binding Protein (CRH-BP), an 
evolutionarily conserved 37 kDa glycoprotein that is structurally distinct from the CRH 
receptors. The CRH-BP cDNA encodes a 322-amino acid protein that lacks hydrophobic 
transmembrane domains and signal motifs for lipid anchors (i.e. GPI, farnesyl), 
suggesting that it does not associate directly with the cell membrane. The mature protein 
is highly folded with 10 conserved cysteine residues that form 5 consecutive disulfide 
bonds. CRH-BP also encodes a signal peptide that targets it to the endoplasmic reticulum 
where the signal peptide is cleaved, allowing the mature CRH-BP to transit through the 
secretory pathway. Studies in cell culture suggest that CRH-BP is secreted via 
constitutive and regulated secretory pathways, depending on the cell type (Behan et al., 
1995c; Blanco et al., 2011; Westphal and Seasholtz, 2005).  
Pharmacology of CRH-BP  
CRH-BP binds CRH and urocortin I with a higher or equal affinity to the CRH 
receptors, but binds urocortin II and urocortin III with variable or much lower affinity, 
respectively (Table 1.1; Jahn et al., 2001; Jahn et al., 2004). Studies using various peptide 
fragments of CRH have shown that CRH-BP and the CRH receptors bind to different 
regions of CRH (Sutton et al., 1995). For example, CRH6-33 and CRH9-33 bind CRH-BP 
with an affinity similar to CRH, but do not bind to CRH receptors (Sutton et al., 1995). 
Thus, CRH fragments, such as CRH6-33, have been utilized as CRH-BP-specific ligands 
to displace endogenous ligand and prevent additional binding of ligand to CRH-BP. 
Further analysis by Sutton et al. (1995) has shown that amino acids 22, 23, and 25 in 
CRH are critical for binding to CRH-BP, while less important for binding to the CRH 
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receptors. Therefore, while the N- and C-terminus of CRH are required for receptor 
binding and activation, respectively, central residues (9-28) appear to be necessary for 
binding to CRH-BP.  
CRH-BP Expression  
In humans, CRH-BP is expressed in the brain, pituitary, liver, and placenta. CRH-
BP produced in the liver is secreted into the plasma, where it is thought to play an 
important role in pregnancy and the timing of parturition (Linton et al., 1990; Saphier et 
al., 1992; Suda et al., 1988). In rodents, CRH-BP expression is restricted to the brain and 
the pituitary. CRH-BP is widely expressed throughout the brain, including the cerebral 
cortex, hippocampus, amygdala, ventral tegmental area (VTA), and a variety of 
brainstem nuclei (Figure 1.4a; Chan et al., 2000; Potter et al., 1992). CRH-BP expression 
colocalizes to several sites of CRH expression, such as the bed nucleus of the stria 
terminalis (BNST) and the central nucleus of the amygdala, suggesting potential sites of 
interaction (Figure 1.4b; Potter et al., 1992). Furthermore, CRH-BP is expressed in 
several CRH target sites where the CRH receptors are expressed, including the anterior 
pituitary, basolateral amygdala, ventral tegmental area (VTA), and medial prefrontal 
cortex (Ketchesin et al., 2016; Potter et al., 1992; Stinnett et al., 2015; Westphal et al., 
2009). In the mouse pituitary, there is sexually dimorphic expression of CRH-BP, with 
200-fold higher CRH-BP mRNA levels in females compared to males (Speert et al., 
2002; Stinnett et al., 2015). CRH-BP is highly expressed in corticotropes, lactotropes, 
and gonadotropes in female pituitary, with low levels of expression in corticotropes alone 
in the male pituitary. Much less is known about the sexual dimorphism of CRH-BP 







Figure 1.4 – Distribution of CRH-BP (A) and CRH (B) expression in sagittal sections of the rodent 
brain. CRH-BP expression colocalizes to multiple sites of CRH expression, such as the bed nucleus of the 
stria terminalis (BNST) and the central nucleus of the amygdala (CeA). Reprinted from Behan et al., 1995a 






Regulation of CRH-BP Expression  
CRH-BP expression is highly regulated by a wide variety of factors, including 
stress, glucocorticoids, cytokines, estrogen, forskolin, and phorbol esters (reviewed in 
Westphal and Seasholtz, 2006). Stress is a positive regulator of CRH-BP expression in 
rodents, with the pituitary and amygdala being key sites of regulation (Table 1.2). In the 
male rat pituitary, acute restraint stress significantly increases CRH-BP steady-state 
mRNA levels, an effect that persists for 2 hours after the onset of stress (Mcclennen et 
al., 1998). These data are consistent with studies in mice demonstrating that acute 
restraint stress increases pituitary CRH-BP mRNA levels 3.2-fold in males and 11.8-fold 
in females (Stinnett et al., 2015). While CRH-BP mRNA levels return to baseline 4 hours 
after acute restraint stress, CRH-BP protein levels are elevated in the female pituitary 4–6 
hours after stress, suggesting that pituitary CRH-BP may play an important role in 
modulating CRH activity after prolonged or repeated stressors, especially in females. 
Similar to pituitary studies, acute restraint stress significantly increases CRH-BP mRNA 
in the rat basolateral amygdala (BLA), a stress-responsive region that is a critical target 
site of CRH (Herringa et al., 2004; Lombardo et al., 2001). This effect is time-dependent, 
as enhanced CRH-BP mRNA persisted for 21 hours after the onset of acute stress, 
indicating that CRH-BP may function in the BLA to modulate future responses to stress 
(Herringa et al., 2004).  
 CRH-BP regulation by CRH and glucocorticoids has also been investigated, as 
both of these hormones are increased in response to stress (Table 1.2). Adrenalectomy 
decreases rat pituitary CRH-BP mRNA levels to about 8% of control levels, suggesting 






Table 1.2 – Stress Regulation of CRH-BP Expression in Rodents. Reprinted from Ketchesin et al., 2017 









expression by stress (McClennen et al., 1998). The regulation of amygdalar CRH-BP 
expression by corticosterone was also investigated, but corticosterone administration was 
not found to alter CRH-BP mRNA expression in the BLA (Herringa et al., 2006). In 
contrast, intracerebroventricular administration of CRH significantly increased CRH-BP 
mRNA expression in the BLA (Herringa et al., 2006).  
The regulation of CRH-BP by stress hormones has also been investigated in 
amygdalar and pituitary cell lines in vitro. CRH-BP is positively regulated by 
glucocorticoids and CRH in amygdalar cells (Kasckow et al., 1999; Mulchahey et al., 
1999). In pituitary AtT-20 cells, CRH positively regulates CRH-BP promoter activity 
(Cortright et al., 1997). Together, these data reveal that stress, likely through increased 
CRH and glucocorticoid release, positively regulates CRH-BP expression in the pituitary 
and amygdala.  
Finally, in primary rat astrocyte cultures, CRH-BP is also positively regulated by 
CRH. However, in these cells, glucocorticoids negatively regulate CRH-, forskolin-, or 
TPA-induced CRH-BP mRNA or protein, suggesting that glucocorticoid regulation of 
CRH-BP expression may be context- and cell type-dependent (Maciejewski et al., 1996; 
Mcclennen and Seasholtz, 1999). 
Functional Roles of CRH-BP 
CRH-BP has been studied for over 20 years with many postulated roles (Figure 
1.5). In an inhibitory role, CRH-BP reduces CRH receptor activation, likely by 




role, early studies showed that approximately 40 – 60% of CRH in the human brain is 
bound by CRH-BP, indicating that CRH-BP may limit the bioavailability of CRH (Behan 
et al., 1995b). Other studies in human have shown that plasma CRH-BP binds placental 
CRH that is released into the plasma during the third trimester of pregnancy, reducing its 
bioactivity and preventing overactivation of the pituitary and the stress response (Linton 
et al., 1990; Saphier et al., 1992; Suda et al., 1988). An inhibitory role for CRH-BP is 
also supported by studies using CRH-BP knockout (CRH-BP KO) mice that lack CRH-
BP throughout the brain and pituitary (Karolyi et al., 1999). Male CRH-BP KO mice 
display increased anxiety-like behavior and a significant reduction in weight gain 
(Karolyi et al., 1999), consistent with the anxiogenic and anorectic effects of CRH and 
further supporting the hypothesis that CRH-BP is a negative regulator of CRH. Other 
studies have shown that CRH-BP inhibits the cytoprotective effects of CRH on Xenopus 
laevis tail and promotes tail regression (Boorse et al., 2006), consistent with the large 
upregulation of CRH-BP mRNA in the tail during spontaneous or T3-induced 
metamorphosis (Brown et al., 1996; Valverde et al., 2001). A variety of in vitro studies in 
pituitary cell lines also support an inhibitory role for CRH-BP. Purified CRH-BP reduces 
CRH-R1-mediated ACTH release from anterior pituitary cultures or AtT-20 cells 
(Cortright et al., 1995; Potter et al., 1991; Sutton et al., 1995). CRH-BP also attenuates 
CRH-R1- and CRH-R2-mediated increases in cAMP (Boorse et al., 2006; Huising et al., 
2008; Ryan Evans, unpublished data.) 
In contrast, several recent studies have suggested a potential facilitatory role for 
CRH-BP in enhancing CRH-R2 signaling (Figure 1.5), specifically in the VTA. Studies 




   
Figure 1.5 – Potential roles for CRH-BP. (A) CRH-BP may bind CRH and inhibit CRH receptor 
activation and downstream signaling. (B) CRH-BP may bind CRH and enhance activation of CRH-R2 and 
downstream signaling. (C) CRH-BP may have CRH receptor-independent signaling roles. (D) CRH-BP 
may act as an escort protein to traffic CRH-R2α to the plasma membrane. Reprinted from Ketchesin et al., 




decreases CRH-mediated potentiation of NMDA excitatory postsynaptic currents on 
VTA dopamine neurons (Ungless et al., 2003). Moreover, the authors showed that this 
effect occurred through CRH-R2 and the downstream PLC/PKC signaling pathway, 
suggesting that CRH-BP may be required for CRH activation of CRH-R2. Consistent 
with these data, in vivo studies have shown that intra-VTA administration of CRH6-33 
decreased binge drinking (Albrechet-Souza et al., 2015) and CRH-induced relapse to 
cocaine seeking (Wang et al., 2007). Interestingly, both effects were also reduced by 
CRH-R2 antagonist administration into the VTA (Albrechet-Souza et al., 2015; Wang et 
al., 2007). Together, these data suggest that CRH-BP may have an enhancing role at 
CRH-R2 in the VTA. 
 Additional roles have been proposed for CRH-BP, including a CRH-receptor 
independent and an intracellular trafficking role (Figure 1.5). A CRH-receptor 
independent role was proposed following observations that CRH-BP is expressed in 
regions of the brain that do not express CRH receptors or ligand. In support of this role, 
intracerebroventricular administration of CRH6-33 was shown to activate c-Fos expression 
not only in CRH receptor-expressing cells (via increased free CRH levels), but also in 
CRH-BP-expressing cells that do not express CRH receptors, suggesting CRH-BP may 
have actions independent of CRH receptor (Chan et al., 2000). Additionally, a recent 
study shows that CRH-BP may act as an escort protein to traffic CRH-R2α to the cell 
surface (Slater et al., 2016). Thus, it appears that the functional role of CRH-BP is 
complex and could depend upon cellular context. This is supported by ultrastructural 
analyses in brain and pituitary that show the subcellular expression pattern of CRH-BP is 
region-specific (Peto et al., 1999. Altogether, the current data suggest that the role of 
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CRH-BP and its mechanism of action may depend on a variety of factors, including CRH 
receptor subtype, brain region, or specific cell type. 
Role of CRH-BP in Vulnerability to Affective Disorders and Addiction 
The link between stress and affective disorders, such as anxiety and depression, 
has been well documented in both preclinical and clinical studies (McEwen, 2008). 
Dysregulation of the CRH system has specifically been implicated in anxiety, depression, 
and addiction (reviewed in Binder and Nemeroff, 2010; Logrip et al., 2011). Not 
surprisingly, a variety of studies have identified single nucleotide polymorphisms (SNPs) 
in both the CRHR1 and CRHBP genes that are associated with these disorders (reviewed 
in Binder and Nemeroff, 2010). Table 1.3 documents genetic associations of SNPs in the 
human CRHBP gene with stress-related psychiatric disorders and addiction. For example, 
three CRHBP SNPs (rs7728378, rs10474485, and rs6453267) were associated with 
suicide risk as a result of childhood trauma (Roy et al., 2012). Interestingly, two of these 
SNPS, rs7728378 and rs10474485, were associated with anxiety disorders in Plains 
Indians and rs7728378 was also associated with alcohol use disorders in Caucasians 
(Enoch et al., 2008). Furthermore, rs10474485 was associated with depressive symptoms 
in alcohol dependent individuals (Kertes et al., 2011) and antidepressant treatment 
response in depressed patients (Binder et al., 2010), indicating that CRH-BP may play a 
role in susceptibility to depression/anxiety and alcohol abuse, and perhaps the 
comorbidity between these disorders. A different CRHBP SNP, rs10055255, was 
associated with stress-induced craving for alcohol in non-treatment seeking heavy 





Table 1.3 – CRHBP SNPs in stress-related disorders. Modified from Ketchesin et al., 2017 with 
permission from Taylor & Francis. 
  
CRHBP SNPs Location Association Population Reference
  rs10055255  Intron 6 Depressive symptoms after citalopram Major depressive disorder (STAR*D) Binder et al., 2010
Stress-induced alcohol craving Heavy drinkers Ray, 2011
Post-ICU PTSD and depressive symptoms ICU patients Davydow et al., 2014
Stress-induced negative affect and
negative consequences of drinking
Heavy drinkers Tartter and Ray, 2012
  rs10473984  3'-Flanking Cortisol reactivity Three-year-old children Sheikh et al., 2013
Depressive symptoms after citalopram treatment Major depressive disorder (STAR*D) Binder et al., 2010
  rs10474485  3'-Flanking Depressive symptoms after citalopram treatment Major depressive disorder (STAR*D) Binder et al., 2010
Emotional state Irritable Bowel Syndrome patients, Japan Sasaki et al., 2016
Childhood trauma and suicide attempt African Americans Roy et al., 2012
Anxiety disorders Plains Indians Enoch et al., 2008
History of depressive symptoms Alcohol dependence, Ireland Kertes et al., 2011
  rs1715747*  3'-Flanking History of depressive symptoms Alcohol dependence, Ireland Kertes et al., 2011
Anxiety disorders, EEG alpha power Plains Indians Enoch et al., 2008
Alcohol use disorders, EEG alpha power U.S. Caucasians Enoch et al., 2008
  rs1875999  3'-UTR Major depressive disorder Major depressive disorder, Sweden Claes et al., 2003
Anxiety disorders, EEG alpha power Plains Indians Enoch et al., 2008
Alcohol use disorders U.S. Caucasians Enoch et al., 2008
Suicide attempt Schizophrenia De Luca et al., 2010
Cocaine and heroin addiction African Americans Levran et al., 2014
Major depressive disorder Major depressive disorder, Swedish males Van Den Eede et al., 2007
  rs7728378 Intron 6 Major depressive disorder Major depressive disorder, Swedish males Van Den Eede et al., 2007
Major depressive disorder Major depressive disorder, Sweden Claes et al., 2003
Anxiety disorders, EEG alpha power Plains Indians Enoch et al., 2008
Alcohol use disorders, EEG alpha power U.S. Caucasians Enoch et al., 2008
Childhood trauma and suicide attempt African Americans Roy et al., 2012
  rs6453267 Intron 5 Childhood trauma and suicide attempt African Americans Roy et al., 2012
  rs1500
 3'-Flanking




Schizophrenia (Gottingen Research 
Association for Schizophrenia sample)
Ribbe et al., 2011
   * Previously called rs7704995
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negative mood in response to a guided imagery stressor. A separate study found that the 
same CRHBP SNP was associated with the correlation between stress-induced negative 
mood and negative consequences of drinking in non-treatment-seeking heavy drinkers 
(Tartter and Ray, 2012). Lastly, a recent study showed a significant association between 
the CRHBP SNP rs1875999 and both cocaine and heroin addiction, suggesting that CRH-
BP may be involved in vulnerability to other drugs of abuse (Levran et al., 2014). 
Together, these genetic association studies suggest that CRH-BP may play a role in 
addiction, and they are consistent with studies in rodents indicating a role for CRH-BP in 
alcohol and cocaine addiction (Albrechet-Souza et al., 2015; Erb et al., 2004; Haass-
Koffler et al., 2016; Wang et al., 2007). The potential role of CRH-BP in alcohol use and 
addiction (binge drinking and alcohol dependence) has not been examined and is the 
focus of this dissertation.  
Role of the CRH System in Alcohol Addiction 
The World Health Organization estimates that alcohol consumption is the world’s 
third largest risk factor for disability and disease. A significant contribution to this risk is 
alcoholism, a chronic and progressive disorder that is characterized by periods of 
excessive drinking, withdrawal and abstinence, and eventual relapse. Alcohol dependence 
affects more than 12% of the population at some point in their life and current treatments 
are often ineffective. Both genetic and environmental factors contribute to the 
development of alcohol addiction, and stress is a key environmental factor that has been 
linked to binge drinking, drinking after dependence, and in relapse to drinking after 
abstinence in both humans and rodent model systems (reviewed in Lowery and Thiele, 
2010; Phillips et al., 2015; Ray, 2011). The National Institute on Alcohol Abuse and 
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Alcoholism defines binge drinking as a pattern of heavy drinking that produces blood 
ethanol concentrations of 80 mg/dl or higher. Binge drinking is linked to a multitude of 
adverse social and health consequences, as well as an increased risk of transitioning to 
alcohol dependence. Alcohol dependence is a state characterized by periods of heavy 
drinking, withdrawal and abstinence, followed by eventual relapse. Dysregulation of the 
CRH system has been implicated on both binge drinking and alcohol dependence, with a 
large focus in the literature on the role of the CRH receptors.  
Role of CRH-R1 in Binge Drinking and Alcohol Dependence 
 There is a large body of literature implicating a role for CRH-R1 in excessive 
alcohol drinking (reviewed in Lowery and Thiele, 2010; Phillips et al., 2015). Increased 
CRH-R1 mRNA expression is observed in the BLA and medial amygdala of alcohol 
dependent rats after three weeks of abstinence (Sommer et al., 2008), suggesting that 
alcohol dependence produces lasting changes in the CRH system in the amygdala. A 
number of pharmacological studies have shown that blockade of CRH-R1 reduces 
ethanol consumption, particularly when intake levels are high. For example, peripheral 
administration of a CRH-R1 antagonist reduced alcohol consumption in a drinking in the 
dark (DID) paradigm, in which mice are given limited access to 20% ethanol in the dark 
phase of their circadian cycle (Lowery et al., 2010; Sparta et al., 2008). Consistent with 
these data, peripheral CRH-R1 antagonist administration also decreases ethanol self-
administration in dependent rats (Funk et al., 2007), suggesting that CRH-R1 promotes 
alcohol seeking in dependence. CRH-R1 regulation of alcohol consumption appears to be 
brain region-specific, with the amygdala, VTA, and mPFC as major sites of action. 
Administration of a CRH-R1 antagonist into the central nucleus of the amygdala (CeA), 
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but not the BLA, decreased binge drinking in a DID paradigm (Lowery-Gionta et al., 
2012). Similarly, intra-CeA administration of a non-selective CRH receptor antagonist 
reduces alcohol self-administration in dependent rats (Funk et al., 2006). In the VTA, 
CRH-R1 antagonist administration decreases binge drinking (Rinker et al., 2017; Sparta 
et al., 2013) and excessive drinking in mice exposed to a 2-bottle choice intermittent 
access to alcohol paradigm (Hwa et al., 2013).  Lastly, a recent study showed that intra-
mPFC administration of a CRH-R1 antagonist attenuates early life stress-induced 
increases in alcohol self-administration in an operant binge drinking paradigm (Gondre-
Lewis et al., 2016). Consistent with these pharmacological studies, CRH-R1 KO mice 
show reduced alcohol intake in the DID paradigm (Kaur et al., 2012). Altogether, these 
studies reveal that CRH-R1 promotes excessive consumption.  
Role of CRH-R2 in Binge Drinking and Alcohol Dependence 
 Although less well-characterized, CRH-R2 has also been implicated in excessive 
alcohol drinking, but often in an inverse fashion to CRH-R1. For example, 
intracerebroventricular administration of the CRH-R2-selective agonist urocortin 3 dose-
dependently decreases binge drinking (Lowery et al., 2010; Sharpe and Phillips, 2009). 
Likewise, intra-CeA administration of urocortin 3 decreased alcohol self-administration 
in dependent rats (Funk and Koob, 2007). However, administration of a CRH-R2 
antagonist into VTA decreased binge drinking in a 2-bottle DID paradigm, suggesting 
that VTA CRH-R2 is facilitating drinking (Albrechet-Souza et al., 2015). Together, these 





Thesis Goals and Summary 
 It is clear from the studies described above that the CRH receptors play an 
important role in binge drinking and alcohol dependence. However, the role for CRH-BP, 
a key regulator of CRH receptor activity, had not been examined. As described above, 
numerous SNPs have been identified in the human CRHBP gene that are associated with 
stress and alcoholism, suggesting a role for CRH-BP in vulnerability to alcohol abuse. In 
this thesis, I investigate the role and regulation of CRH-BP in mouse models of binge 
drinking and alcohol dependence. Additionally, I examine the cell type-specific 
expression of CRH-BP to begin to define the neural circuits in which CRH-BP is acting. 
Finally, I present preliminary studies designed to address the molecular mechanisms of 
CRH-BP modulation of CRH-R1 and CRH-R2 signaling. These goals are addressed in 
the following data chapters outlined below. 
Chapter II: The Role of CRH-Binding Protein in Binge Drinking 
 In this chapter, I examine the regulation of the CRH system during binge 
drinking. I utilize in situ hybridization to determine changes in CRH, CRH-R1, and CRH-
BP mRNA levels in stress and reward pathways during drinking in the dark (DID), a 
mouse model of binge drinking. I then utilize CRH-BP KO mice to test whether 
manipulation of endogenous CRH-BP levels alters binge drinking. 
Chapter III: The Cell Type-Specific Expression of CRH-Binding Protein in the Prefrontal 
Cortex 
 While the anatomical expression of CRH-BP in the rodent brain is well-known, 
the molecular phenotype of CRH-BP-expressing neurons has not been well-characterized. 
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In this chapter, I determine the cell type-specific expression of CRH-BP in the PFC, a 
structure that functions to regulate emotion and behavior. I utilize dual in situ 
hybridization to determine the expression of CRH-BP mRNA in excitatory (VGLUT-
expressing) or inhibitory (GAD-expressing) neurons of the PFC to determine whether 
CRH-BP is acting locally within the PFC or projecting to other brain regions to mediate 
its effects. Based on the predominant colocalization of CRH-BP with GAD, I characterize 
the expression of CRH-BP in inhibitory interneuron subtypes of the PFC by examining 
the colocalization of CRH-BP with various interneuron molecular markers, including 
parvalbumin, somatostatin, cholecystokinin, and vasoactive intestinal peptide. The results 
from these studies begin to define the prefrontal cortical circuits in which CRH-BP is 
expressed. 
Chapter IV: The Role of CRH-Binding Protein in Alcohol Dependence 
 In this chapter, I examine the regulation of the CRH system during alcohol 
dependence. I use in situ hybridization to determine alterations in CRH, CRH-R1, and 
CRH-BP mRNA levels in stress and reward pathways in a mouse model of alcohol 
dependence, the chronic intermittent ethanol (CIE) paradigm (with or without voluntary 
drinking). I then utilize CRH-BP KO mice to test whether manipulation of CRH-BP 
levels alters dependence-induced alcohol consumption. 
Chapter V: CRH-BP Modulation of CRH receptor Signaling via cAMP and Calcium 
In this chapter, I conduct preliminary CRH receptor signaling experiments in 
LβT2 cells, a mouse pituitary gonadotroph cell line that endogenously expresses CRH-R1 
and CRH-R2. I treat cells with CRH or urocortin I in the presence or absence of CRH-BP 
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(and CRH6-33) and assay for changes in cAMP levels as an indicator of Gαs activation 
upon receptor binding. I also perform preliminary calcium signaling experiments to 
measure CRH receptor signaling through Gαq. I treat stably transfected HEK293 cells 
expressing CRH-R1 or CRH-R2 with various peptides including CRH, urocortin 1, or 
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The Role of CRH-Binding Protein in Binge Drinking* 
Abstract 
Dysregulation of the corticotropin-releasing factor (CRF)** system has been 
observed in rodent models of binge drinking, with a large focus on CRF receptor 1 (CRF-
R1). The role of CRF-binding protein (CRF-BP), a key regulator of CRF activity, in 
binge drinking is less well understood. In humans, single-nucleotide polymorphisms in 
CRHBP are associated with alcohol use disorder and stress-induced alcohol craving, 
suggesting a role for CRF-BP in vulnerability to alcohol addiction. The role and 
regulation of CRF-BP in binge drinking were examined in mice exposed to the drinking 
in the dark (DID) paradigm. Using in situ hybridization, the regulation of CRF-BP, CRF-
R1, and CRF mRNA expression was determined in the stress and reward systems of 
C57BL/6J mice after repeated cycles of DID. To determine the functional role of CRF-
BP in binge drinking, CRF-BP knockout (CRF-BP KO) mice were exposed to 6 cycles of 
DID, during which alcohol consumption was measured and compared to wild-type mice. 
CRF-BP mRNA expression was significantly decreased in the prelimbic (PL) and 
infralimbic medial prefrontal cortex (mPFC) of C57BL/6J mice after 3 cycles and in the 
PL mPFC after 6 cycles of DID. No significant changes in CRF or CRF-R1 mRNA levels 
were observed in mPFC, ventral tegmental area, bed nucleus of the stria terminalis, or 
*Note: This chapter was published previously as an article entitled, “Binge Drinking Decreases Corticotropin-
Releasing Factor-Binding Protein Expression in the Medial Prefrontal Cortex of Mice (Ketchesin et al., 2016). The 
text and figures are reprinted here with permission from the publisher, John Wiley & Sons. 
**CRH is referred to as CRF in this chapter.  
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amygdala after 3 cycles of DID. CRF-BP KO mice do not show significant alterations in 
drinking compared to wild-type mice across 6 cycles of DID. These results reveal that 
repeated cycles of binge drinking alter CRF-BP mRNA expression in the mPFC, a region 
responsible for executive function and regulation of emotion and behavior, including 
responses to stress. We observed a persistent decrease in CRF-BP mRNA expression in 
the mPFC after 3 and 6 DID cycles, which may allow for increased CRF signaling at 
CRF-R1 and contribute to excessive binge-like ethanol consumption. 
Introduction  
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) defines binge 
drinking as a pattern of drinking that results in blood ethanol concentrations (BECs) of 80 
mg/dl or higher. Binge drinking has been linked to many adverse social and health 
consequences, including an increased risk of transitioning to alcohol dependence. Stress 
is a key environmental factor in the development of alcohol addiction and has been linked 
to binge drinking, drinking during dependence, and relapse to drinking after abstinence in 
clinical and preclinical models (Keyes et al., 2012; Lowery and Thiele, 2010; Phillips et 
al., 2015; Uhart and Wand, 2009). The key central nervous system regulator of the stress 
response is corticotropin-releasing factor (CRF). This 41 amino acid peptide mediates its 
effects through 2 G-protein-coupled receptors, CRF receptor 1 (CRF-R1) and CRF 
receptor 2 (CRF-R2), and its activity is modulated by CRF-binding protein (CRF-BP). 
Single nucleotide polymorphisms in CRHBP and CRHR1 have been associated with 
alcohol use disorder and stress-induced alcohol craving or consumption (Blomeyer et al., 
2008; Enoch et al., 2008; Ray, 2011; Ray et al., 2013), supporting the role for these key 
molecules in vulnerability to alcohol addiction. 
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Dysregulation of the CRF system has been observed in rodent models of binge 
drinking and alcohol dependence, with a large focus in the literature on CRF-R1. For 
example, elevated CRF-R1 mRNA expression in the amygdala has been observed in rats 
with a history of alcohol dependence (Sommer et al., 2008). Furthermore, peripheral 
administration of CRF-R1 antagonists reduced binge drinking in a drinking in the dark 
(DID) paradigm (Sparta et al., 2008), as well as dependence-induced alcohol 
consumption (Funk et al., 2007). CRF receptor regulation of excessive alcohol 
consumption appears to be brain region-specific, with the amygdala, bed nucleus of the 
stria terminalis (BNST), ventral tegmental area (VTA), and medial prefrontal cortex 
(mPFC) as major sites of action. For example, injection of a CRF-R1 antagonist into the 
central nucleus of the amygdala (CeA), but not the basolateral amygdala (BLA), resulted 
in decreased binge drinking (Lowery-Gionta et al., 2012). Likewise, intra-VTA 
administration of a CRF-R1 antagonist led to decreased binge drinking (Sparta et al., 
2013). Silberman and colleagues (2013) have shown enhanced CRF activation of VTA-
projecting BNST neurons after alcohol withdrawal. Last, CRF neurons in the mPFC are 
up-regulated after abstinence from intermittent access to ethanol (EtOH) (George et al., 
2012). Although less well characterized, CRF-R2 has also been implicated in binge 
drinking (Albrechet-Souza et al., 2015; Lowery et al., 2010) and alcohol dependence 
(Funk and Koob, 2007). While it is clear that CRF and the CRF receptors play a role in 
alcohol addiction, the role of CRF-BP has been less studied. 
CRF-BP is a 37 kDa-secreted glycoprotein that binds CRF and the CRF-like 
ligand urocortin 1 with an equal or greater affinity than CRF receptors. It is estimated that 
40 to 60% of CRF in the human brain is bound by CRF-BP (Behan et al., 1997) and 
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CRF-BP colocalizes with CRF or CRF receptors at numerous sites (i.e., amygdala and 
BNST), suggesting potential sites of interaction in stress and reward pathways (Potter et 
al., 1992). Multiple roles for CRF-BP have been proposed. In cultured pituitary cells, 
CRF-BP attenuates CRF-R1 activity (Cortright et al., 1995; Potter et al., 1991; Sutton et 
al., 1995), suggesting an inhibitory role for CRF-BP. In support of this, CRF-BP deficient 
mice display increased anxiety (Karolyi et al., 1999), consistent with increased free levels 
of CRF. However, in vivo and slice studies have revealed a potential facilitatory role for 
CRF-BP, particularly in the VTA, with administration of the CRF-BP ligand inhibitor, 
CRF6-33, decreasing CRF-mediated potentiation of NMDA excitatory postsynaptic 
currents on VTA dopamine neurons (Ungless et al., 2003). Similarly, intra-VTA 
administration of CRF6-33 decreased binge drinking (Albrechet-Souza et al., 2015) and 
CRF-induced relapse to cocaine seeking (Wang et al., 2007). 
Thus, while a role for CRF receptors in binge drinking has been established, the 
role for CRF-BP, a key regulator of CRF receptor activity, has not been well 
characterized. Therefore, in this study, we sought to determine the role and regulation of 
CRF-BP in the DID mouse model of binge drinking. We examined the regulation of the 
CRF system, including CRF-BP, CRF-R1, and CRF mRNA expression, after repeated 
cycles of DID in brain regions of the stress and reward systems. Additionally, CRF-BP 
KO mice were utilized to determine the functional role of CRF-BP in modulating EtOH 






Animals—3-Cycle DID Experiment 
Six- to 8-week-old male C57BL/6J mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME) and used for a 3-cycle DID experiment. Mice were 
maintained on a 14/10 light/dark cycle and had access to food and water ad libitum, 
except when noted. Mice were acclimated to single housing for >2 weeks prior to the 
start of DID. All mouse experiments were conducted according to National Institutes of 
Health guidelines for animal care and were approved by the University of Michigan 
Committee on Use and Care of Animals. 
Animals—6-Cycle DID Experiment 
CRF-BP knockout mice (CRF-BP KO; Karolyi et al., 1999) were bred in our 
facility and have been backcrossed onto a C57BL/6J background for >17 generations. 
CRF-BP heterozygotes (Het) were crossed to generate wild-type, Het, and CRF-BP KO 
mice. To generate sufficient numbers of mice of similar age for the 6-cycle DID study, 
these wild-type progeny were crossed to generate wild-type mice, and Het x KO and KO 
x KO crosses were used to generate CRF-BP KO mice. Mice were 10 to 14 weeks old at 
the start of the experiment. These mice were switched on a 12/12 light/dark cycle to be 
more consistent with other DID studies in the literature. Mice had access to food and 
water ad libitum, except when noted, and were acclimated to single housing for >2 weeks 
prior to the start of DID. At the end of the 6-cycle DID experiment, the brains of the 




Drinking in the Dark 
Male C57BL/6J mice (3-cycle DID; n = 12 [6/group]) and male CRF-BP KO and 
wild-type controls (6-cycle DID; KO [EtOH: n = 17, H2O: n = 10]; wild-type [EtOH: n = 
13, H2O: n = 13]) were tested in a DID protocol (Rhodes et al., 2005). On days 1 to 3, 
mice were given access to a single 50-ml centrifuge tube of 20% EtOH (v/v) for 2 hours, 
starting 3 hours into the dark cycle. On day 4, mice were given access to 20% EtOH for 4 
hours. Control mice received a single 50-ml centrifuge tube of water instead of 20% 
EtOH. Mice received only water for the last 3 days (days 5 to 7) of each cycle. Repeated 
DID consisted of 3 or 6 cycles in total. Centrifuge bottles were fitted with a rubber 
stopper that contained a sipper tube with 2 ball bearings (Ancare Corp., Bellmore, NY). 
Two empty cages were placed in the experiment room, and each received a bottle of 20% 
EtOH during DID to control for spillage from the sipper tubes. These control volumes 
were averaged and subtracted from the experimental volumes before converting to g/kg. 
All bottles were weighed and recorded immediately before and after each drinking 
session. 
Blood Ethanol Concentration 
For the 3-cycle DID experiment, 40 µl of blood was collected via tail snip 
immediately after the drinking session on day 4 of cycle 3. For the 6-cycle DID 
experiment, 40 µl of blood was collected on day 4 of cycle 5 to eliminate any potential 
effects of blood collection on gene expression 24 hours later. Blood samples were placed 
into a tube that contained 1.5 µl 0.5M EDTA and centrifuged, and then, plasma was 
removed and stored at -20°C until use. BECs were determined by an Analox alcohol 
analyzer (Analox Instruments, Atlanta, GA) for the 3-cycle DID experiment and alcohol 
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dehydrogenase assay (Pointe Scientific Inc., Canton, MI; Cat. No.: A7504-39) for the 6-
cycle DID experiment. 
Tissue Processing and In situ Hybridization 
Mice were euthanized 24 hours after 3 or 6 cycles of DID to assess neuroadaptive 
changes that occur after binge drinking cycles (including consumption and withdrawal) 
rather than the direct effects of EtOH consumption. Brains were removed, frozen in 2-
methylbutane, and stored at -80°C until use. Brains were sectioned via cryostat at 14 µm 
and collected in series of 6 slides (4 sections/slide). Every sixth slide was stained with 
cresyl violet to determine anatomical location and orientation. For each brain region of 
interest, adjacent slides were analyzed for CRF, CRF-R1, and CRF-BP mRNA 
expression using in situ hybridization, similar to what has been described previously 
(Herman et al., 1990; Seasholtz et al., 1991). Brain sections were postfixed in 4% 
paraformaldehyde for 1 hour and washed 3 times in 2x saline sodium citrate (SSC) 
buffer. Sections were then incubated in 0.25% acetic anhydride in 0.1 M triethanolamine 
for 10 minutes, washed 3 times in 2x SSC, dehydrated in EtOH, and air-dried. CRF, 
CRF-R1, and CRF-BP antisense cRNA riboprobes were generated with 35S-UTP and 35S-
CTP (1,250 Ci/mmol; PerkinElmer Inc., Waltham, MA) from plasmids as described 
previously (pGem4ZPst578, Seasholtz et al., 1991; pTOPO CRF-R1, Westphal et al., 
2009; mCRFBP666, Burrows et al., 1998). Sections were hybridized with the 35S-labeled 
riboprobes (2 x 106 cpm/slide) in 50% formamide hybridization buffer (Ameresco, 
Framingham, MA) with 20 mM DTT overnight at 55°C. After hybridization, sections 
were washed 3 times with 2x SSC and treated with RNase A (200 µg/ml) for 1 hour at 
37°C. Slides were then washed in decreasing salt solutions (2x, 1x, and 0.5x SSC), and a 
43 
 
high stringency wash was performed in 0.1x SSC at 65°C for 1 hour. Slides were then 
dehydrated in EtOH, air-dried, and exposed to BioMax MR autoradiography film 
(Carestream Health Inc., Rochester, NY) for 3 to 14 days depending on riboprobe and 
brain region. 
In situ Hybridization Analyses 
Autoradiography films were scanned and analyzed using densitometry in ImageJ 
(NIH, Bethesda, MD). A set of macros were utilized that enabled background to be 
selected and a mask created so that only signal >3.5 SDs above background is measured. 
Mean optical density (mean OD), area, and integrated optical density (IOD; mean OD x 
area of signal) were calculated for each brain region (left and right hemispheres). Brain 
regions of interest for in situ hybridization analyses were selected based on anatomical 
landmarks (Paxinos and Franklin, 2001) from adjacent cresyl violet-stained sections. 
Spatial expression profiles were generated for each probe and brain region of interest to 
map IOD signal spanning the rostral to caudal extent of each brain region. These 
expression profiles were used to determine Bregma coordinates (Paxinos and Franklin, 
2001) for analysis of in situ hybridization experiments. If the IOD signal for a particular 
riboprobe varied significantly rostral to caudal, then the area where the signal was highest 
was also used for analysis. 
Statistical Analyses 
Given that the in situ hybridization experiments were performed independently 
for each riboprobe, brain region, and cycle number (3 or 6 DID cycles), these data were 
analyzed via independent Student’s t-tests. A 2-way repeated-measures analysis of 
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variance (ANOVA) was used to analyze the DID data. When significant main effects 
were observed, Tukey HSD post hoc analyses were performed for multiple comparisons. 
All data are reported as means ± SEM, and significant values were accepted at p < 0.05 
for all statistical tests. 
Results 
Regulation of CRF, CRF-R1, and CRF-BP mRNA Expression After 3 Cycles of DID 
To determine how CRF-BP, CRF-R1, and CRF are regulated within the stress and 
reward systems after binge drinking, male C57BL/6J mice underwent a 3-cycle DID 
paradigm. On the fourth day of cycle 3, mice consumed an average 5.45 ± 0.24 g/kg of 
EtOH and exhibited an average BEC of 84.1 ± 11.7 mg/dl. Mice were sacrificed 24 hours 
later, and in situ hybridization experiments were performed to determine CRF, CRF-R1, 
and CRF-BP mRNA expression in the BNST, VTA, mPFC, and amygdala. Spatial 
expression profiles were generated for each riboprobe and brain region of interest to map 
IODs spanning rostral to caudal for each brain region. These expression profiles were 
used to determine Bregma coordinates for further analysis of the in situ hybridization 
data. 
In the BNST, CRF, CRF-R1, and CRF-BP mRNA signal varied rostral to caudal 
(Figure 2.1). Interestingly, CRF mRNA expression (IOD) was highest between Bregma 
coordinates 0.38 and 0.14 mm in anterior nuclei, whereas the expression of CRF-R1 and 
CRF-BP mRNA was highest more caudally in posterior nuclei between Bregma 
coordinates -0.10 and -0.34 mm. IOD signal from sections within these designated 





Figure 2.1 – Representative in situ hybridization autoradiogram images for corticotropin-releasing 
factor (CRF) (A), CRF receptor 1 (CRF-R1) (B), and CRF-BP (CRF binding protein) (C) in the bed 
nucleus of the stria terminalis (BNST) of ethanol (EtOH)-treated mice 24 hours after 3 cycles of 
drinking in the dark (DID). Brain regions of interest are outlined in black. The coordinates for the 
autoradiograms are 0.26 mm for CRF and -0.22 mm for CRF-R1 and CRF-BP, relative to Bregma. Spatial 
expression profiles were generated (D) to compare rostral to caudal patterns of CRF, CRF-R1, and CRF-BP 
mRNA expression in the BNST of EtOH-treated mice after 3 cycles of DID (n = 4 to 5/probe; data 
represent the mean ± SEM). Integrated optical density (IOD) values in panel D are plotted relative to the 
lowest value for each riboprobe. Intensities in panels A to D cannot be directly compared, as riboprobes 
were not equal in specific activity and exposure times were varied to yield optimal quantitative results. 
Note: CRH is referred to as CRF in figure. Reprinted from Ketchesin et al., 2016 with permission from 
John Wiley & Sons.  
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Independent Student’s t-tests revealed that there were no differences in CRF, CRF-R1, 
and CRF-BP expression between EtOH and control mice after 3 cycles of DID (Table 
2.1; representative in situ autoradiograms in Figure 2.1). Additionally, further analyses 
revealed that CRF expression was unaltered in the dorsal and ventral BNST nuclei of 
EtOH mice compared to controls (data not shown). 
 Expression profiles of CRF and CRF-R1 in the VTA did not show significant 
variation in expression, so signal was averaged across the rostral to caudal extent of the 
VTA. CRF and CRF-R1 expression in the VTA did not differ between EtOH and control 
mice (Table 2.1; representative in situ autoradiograms in Figure 2.2). CRF-BP IOD was 
highest from Bregma coordinates -3.28 to -3.52 mm in the mid-to-posterior VTA, where 
IOD signal was averaged for analysis (Figure 2.2). There was a trend for a decrease in 
CRF-BP IOD in EtOH mice compared to control mice, but this did not reach statistical 
significance (Table 1; t(8) = 2.25, p = 0.055). However, CRF-BP mean OD was 
significantly decreased in the VTA of EtOH mice compared to control mice (p < 0.05; 
data not shown). 
 CRF, CRF-R1, and CRF-BP mRNA expression patterns in the prelimbic (PL) and 
infralimbic (IL) mPFC did not vary rostral to caudal, so signal was averaged from 
multiple sections to generate one value (representative autoradiograms in Figure S2.1). 
Expression in the PL and IL mPFC was analyzed from coordinates 2.34 to 1.54 mm and 
1.98 to 1.54 mm, respectively. Independent Student’s t-tests revealed that CRF-BP IOD 
in the PL and IL mPFC was significantly decreased in EtOH mice compared to control 





Table 2.1 – Summary of in situ hybridization data (represented as integrated optical density) for 
CRF, CRF-R1, and CRF-BP 24 hours after 3 cycles of Drinking in the Dark. Data represent the mean 
± SEM (n = 4–5 per group). *p < 0.05 and #p = 0.055 compared to respective water controls using 
independent Student’s t-tests. Values within bolded lines represent independent experiments. Integrated 
optical density values should not be directly compared across independent experiments as riboprobe 
specific activity and exposure times are not equal. CRF, corticotropin-releasing factor; CRF-R1, CRF 
receptor 1; CRF-BP, CRF binding protein; BNST, bed nucleus of the stria terminalis; VTA, ventral 
tegmental area; PL mPFC, prelimbic medial prefrontal cortex; IL mPFC, infralimbic medial prefrontal 
cortex; BLA, basolateral amygdala; LA, lateral amygdala; CeA, central nucleus of the amygdala; BMA, 
basomedial amygdala; ND, not detected. Note: CRH is referred to as CRF in table. Reprinted from 





Figure 2.2 – Representative in situ hybridization autoradiogram images for corticotropin-releasing 
factor (CRF) (A), CRF receptor 1 (CRF-R1) (B), and CRF binding protein (CRF-BP) (C) in the 
ventral tegmental area (VTA) of water-treated mice. Brain regions of interest are outlined in black. The 
coordinates for each autoradiogram are -3.40 mm relative to Bregma. Expression profiles were generated 
(D) to compare rostral to caudal patterns of CRF, CRF-R1, and CRF-BP expression in the VTA of control 
mice after 3 cycles of drinking in the dark (n = 4 to 5/probe; data represent the mean ± SEM). Integrated 
optical density (IOD) values in panel D are plotted relative to the lowest value for each riboprobe. Note: 
CRH is referred to as CRF in figure. Reprinted from Ketchesin et al., 2016 with permission from John 




There were no significant differences in CRF and CRF-R1 mRNA expression levels in 
the mPFC between EtOH and control mice. 
In the BLA/lateral amygdala (LA), CeA, and basomedial amygdala (BMA), CRF-
R1 and CRF-BP expression were analyzed from Bregma coordinates -0.94 to -1.82 mm, 
and in the CeA, CRF expression was analyzed from coordinates -0.82 to -1.82 mm 
(representative autoradiograms in Figure S2.2). CRF mRNA was not detectible in the 
BLA/LA and BMA and therefore was not included in the analysis. There were some 
rostral to caudal variations in CRF, CRF-R1, and CRF-BP signal in the amygdala; 
however, no significant changes in expression were observed in any of the amygdala 
nuclei after 3 cycles of DID (Table 2.1). 
Regulation of CRF-BP mRNA Expression After 6 Cycles of DID 
To test whether altered CRF-BP expression in the mPFC persists beyond 3 cycles 
of DID, male mice underwent a 6-cycle DID paradigm and in situ hybridization was 
performed on brains collected 24 hours after the last exposure to alcohol to determine 
changes in CRF-BP mRNA expression in the BNST, VTA, mPFC, and amygdala. 
Similar to 3 cycles of DID, there was a significant decrease in CRF-BP in the PL mPFC 
of EtOH-treated mice compared to controls (Table 2.2 and Figure 2.4; t(10) = 2.6, p < 
0.05). However, CRF-BP mRNA expression was unchanged in the IL mPFC of EtOH-
treated mice after 6 cycles of DID. CRF-BP was not significantly altered in the BNST, 
VTA, and amygdala of EtOH-treated mice compared to controls (Table 2.2), similar to 
























Figure 2.3 – Decreased CRF binding protein (CRF-BP) expression in the medial prefrontal cortex 
(mPFC) after 3 cycles of drinking in the dark (DID). Coronal section from the Paxinos and Franklin 
(2001) mouse brain atlas (A) at Bregma coordinate 1.54 mm and corresponding representative in situ 
hybridization autoradiogram images (B) comparing CRF-BP expression in ethanol (EtOH)-treated mice to 
water controls at 24 hours after 3 cycles of DID. CRF-BP integrated optical density (IOD) was significantly 
decreased in the prelimbic (PL) and infralimbic (IL) mPFC of EtOH-treated mice compared to water 
controls (C). The boxed areas for quantification of PL and IL mPFC were determined using the 
characteristics of cells in layer 2 of the cortex from adjacent cresyl violet-stained sections (Van De Werd et 
al., 2010). Data represent the mean ± SEM. *p < 0.05 and **p < 0.01 compared to respective water controls 
using independent Student’s t-tests. Note: CRH is referred to as CRF in figure. Reprinted from Ketchesin et 












Table 2.2 – Summary of in situ hybridization data (represented as integrated optical density) for 
CRF-BP after 6 cycles of DID. Data represent the mean ± SEM (n = 4–6 per group). *p < 0.05 compared 
to respective water control using an independent Student’s t-test. Values within bolded lines represent 
independent experiments. Integrated optical density values should not be directly compared across 
independent experiments as riboprobe specific activity and exposure times are not equal. CRF-BP, CRF 
binding protein; BNST, bed nucleus of the stria terminalis; VTA, ventral tegmental area; PL mPFC, 
prelimbic medial prefrontal cortex; IL mPFC, infralimbic medial prefrontal cortex; BLA, basolateral 
amygdala; LA, lateral amygdala; CeA, central nucleus of the amygdala; BMA, basomedial amygdala. Note: 





Functional Role of CRF-BP in DID Using CRF-BP KO Mice 
To test the functional role of CRF-BP in binge drinking, CRF-BP KO mice 
(Karolyi et al., 1999) and wild-type mice underwent a 6-cycle DID paradigm. Overall, 
alcohol consumption did not significantly differ between CRF-BP KO and wild-type 
mice across 6 cycles of DID, as revealed by a lack of a main effect of genotype in a 2-
way repeated-measures ANOVA (Figure 2.5; data shown for day 4 of each cycle). 
However, there was a significant main effect of cycle number, F(5, 140) = 6.97, p < 
0.0001, and a significant interaction effect, F(5, 140) = 2.46, p < 0.05. Post hoc analyses 
revealed that wild-type mice drank significantly more EtOH on day 4 of cycle 5 
compared to cycle 2 (p < 0.001) and CRF-BP KO mice drank more EtOH on cycles 4, 5, 
and 6 compared to cycle 1 (cycles 4 and 5, p < 0.05; cycle 6, p < 0.0001), and cycle 6 
compared to cycle 2 (p < 0.01). CRF-BP KO and wild-type mice did not display 
significant differences in alcohol consumption at any of the 6 DID cycles. Additionally, 
there were no differences in average BEC between wild-type (78.5 ± 11.7 mg/dl) and 
CRF-BP KO mice (72.4 ± 8.5 mg/dl). These results suggest that the total absence of 
CRF-BP does not significantly alter binge drinking in the DID paradigm. 
Discussion 
In this study, we examined the regulation of CRF-BP, CRF-R1, and CRF mRNA 
expression in brain regions of the stress and reward systems after repeated cycles of binge 
drinking. While there were no detectable changes in CRF or CRF-R1 mRNA levels in 
amygdala, VTA, BNST, or mPFC after 3 cycles of DID, we provide the first evidence 
























Figure 2.4 – Decreased CRF binding protein (CRF-BP) expression in the medial prefrontal cortex 
(mPFC) after 6 cycles of drinking in the dark (DID). Coronal section from the Paxinos and Franklin 
(2001) mouse brain atlas (A) at Bregma coordinate 1.54 mm and corresponding representative in situ 
hybridization autoradiogram images (B) comparing CRF-BP expression in ethanol (EtOH)-treated mice to 
water controls at 24 hours after 6 cycles of DID. CRF-BP integrated optical density (IOD) was significantly 
decreased in the prelimbic (PL) mPFC of EtOH-treated mice compared to water controls (C). The boxed 
areas for quantification of PL and infralimbic mPFC were determined using the characteristics of cells in 
layer 2 of the cortex from adjacent cresyl violet-stained sections (Van De Werd et al., 2010). Data represent 
the mean ± SEM. *p < 0.05 compared to respective water control using an independent Student’s t-test. 
Note: CRH is referred to as CRF in figure. Reprinted from Ketchesin et al., 2016 with permission from 















Figure 2.5 – Comparison of ethanol consumption between CRF binding protein knock out (CRF-BP 
KO) and wild-type (WT) mice after 6 cycles of drinking in the dark (DID). A 2-way repeated-measures 
ANOVA did not reveal a significant genotype effect; however, there was a significant main effect of cycle 
number and interaction. Data represent the mean ± SEM on day 4 of each cycle (CRF-BP KO, n = 17; WT, 
n = 13). *p < 0.0001 main effect of cycle number; #p < 0.05 interaction effect. Note: CRH is referred to as 




CRF-BP mRNA expression was significantly decreased in the PL and IL mPFC after 3 
cycles of DID and in the PL mPFC after 6 cycles of DID. Decreased CRF-BP may allow 
for increased CRF signaling at CRF-R1 in this region, well known for its roles in 
executive function, impulse control, and stress response regulation. We also examined 
binge drinking in CRF-BP deficient mice and observed no detectable differences from 
wild-type mice across 6 DID cycles. 
 The CRF system is widely expressed throughout stress and reward pathways 
(Chan et al., 2000; Van Pett et al., 2000). In the present study, we characterized CRF, 
CRF-R1, and CRF-BP mRNA expression in serial sections throughout the mPFC, BNST, 
VTA, and amygdala, key brain regions that have been implicated in excessive alcohol 
consumption (George et al., 2012; Lowery-Gionta et al., 2012; Silberman et al., 2013; 
Sparta et al., 2013). In the BNST, the expression of CRF-R1 and CRF-BP mRNA is 
highest in the caudal aspects of the BNST in posterior nuclei, whereas CRF mRNA 
expression is highest at more rostral coordinates in anterior nuclei. In the amygdala, 
CRF-BP mRNA is detected in CeA, BLA/LA, and BMA, major sites of CRF (CeA) and 
CRF-R1 (BLA/LA, CeA, and BMA) mRNA expression (Chan et al., 2000; Van Pett et 
al., 2000). In the mPFC, we found that CRF-BP mRNA is expressed at high levels in the 
PL and IL mPFC. CRF-R1 is highly expressed in the PL mPFC, but expressed at lower 
levels in the IL mPFC, and CRF expression is low throughout the mPFC. These 
expression profiles reveal sites of coexpression of CRF-BP with CRF or CRF-R1, 
predicting sites for interactions and modulation of CRF-mediated activities. 
 In the VTA, CRF-BP expression is highly expressed in the mid-to-posterior VTA, 
consistent with previous studies in rat (Wang and Morales, 2008). We detected CRF-R1 
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mRNA in a similar region within the mouse VTA (Figure 2.2), whereas CRF mRNA is 
detected only at low levels throughout the VTA. While CRF mRNA expression is low in 
cell bodies of the VTA (Figure 2.2; Grieder et al., 2014), studies in rat have shown 
immunoreactive CRF peptide in axons and axon terminals that make contact with 
dopaminergic and nondopaminergic neurons in the VTA, suggesting CRF release in this 
region (Tagliaferro and Morales, 2008). Additionally, CRF-BP and CRF-R1 mRNA are 
expressed in dopaminergic neurons of the VTA (Refojo et al., 2011; Wang and Morales, 
2008). Together, these results suggest that CRF may regulate the activity of dopamine 
neurons in the VTA via interactions with CRF-BP and CRF receptors. Future studies in 
our laboratory will utilize dual in situ hybridization techniques to characterize the 
coexpression of CRF-BP with CRF, CRF-R1, and other neurotransmitters/neuropeptides 
at the cellular level in the VTA, BNST, amygdala, and mPFC to provide further insight 
into the functional role of CRF-BP at each site in stress and reward pathways. 
 Dysregulation of the CRF system in the VTA has been previously linked to binge 
drinking. Sparta and colleagues (2013) observed increased CRF-R1 activity in the VTA 
after DID, as determined by increased CRF-R1-mediated potentiation of NMDA currents 
by CRF. Moreover, injection of a CRF-R1 antagonist into VTA reduced binge drinking 
during DID (Sparta et al., 2013). In the current study, we observed a trend (p = 0.055) for 
a decrease in CRF-BP mRNA levels in the VTA after 3 cycles of DID. A decrease in 
CRF-BP expression in the VTA could lead to increased free CRF available for CRF-R1 
activation, which may contribute to excessive alcohol consumption during DID. 
However, other studies suggest a facilitatory role for CRF-BP in the VTA, particularly 
via CRF-R2. For example, in vitro slice studies have shown that both CRF and CRF-BP 
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are required for CRF-R2-mediated potentiation of NMDA currents in dopamine neurons 
of the VTA, an effect that occurred through the protein kinase C signaling pathway 
(Ungless et al., 2003). Similarly, pharmacological inhibition of CRF-BP via CRF6-33 in 
the VTA reduced binge drinking (Albrechet-Souza et al., 2015) and CRF-induced relapse 
to cocaine seeking (Wang et al., 2007), possibly via an interaction with CRF-R2. CRF-R2 
mRNA is detected in VTA by quantitative reverse transcription polymerase chain 
reaction (Korotkova et al., 2006; Ungless et al., 2003), but is not detected with in situ 
hybridization under basal conditions (Van Pett et al., 2000; Stinnett G, unpublished data). 
Together, these data suggest that the effects of CRF-BP on CRF receptor signaling may 
depend upon the cellular context, with CRF receptor subtype and signaling pathway as 
possible determinants. Additional studies will be required to determine the interactions 
between CRF, CRF-BP, and CRF receptors in the VTA and their regulation by binge 
drinking. 
 Strikingly, the largest change in CRF-BP expression in binge drinking occurred in 
the mPFC, with a significant decrease in CRF-BP mRNA levels while CRF-R1 and CRF 
mRNA levels remained unchanged. The mPFC is responsible for executive function and 
regulation of emotion and behavior, and impairment of this region has been linked to 
excessive alcohol consumption (George et al., 2012; Goldstein and Volkow, 2011). The 
mPFC is interconnected with numerous brain regions of the stress and reward systems, 
including the amygdala, BNST, and VTA, and therefore may represent a potential site 
where the stress system can influence maladaptive behaviors such as excessive alcohol 
intake. In support of this, dysregulation of the CRF system in the mPFC has been linked 
to excessive alcohol consumption. Rats genetically selected to prefer alcohol displayed 
58 
 
lower concentrations of CRF in the mPFC compared to non-preferring rats, suggesting 
that CRF levels in this region may contribute to alcohol preference (Ehlers et al., 1992). 
In a separate study, George and colleagues (2012) found that abstinence from intermittent 
access to EtOH in rats recruited both CRF and GABA neurons in the mPFC and resulted 
in a disconnection between the mPFC and CeA. In humans, a variant in the CRF-R1 
gene, CRFR1, was linked to increased right ventrolateral PFC activity, lower negative 
emotionality, and decreased binge drinking and alcohol-related problems (Glaser et al., 
2014). The present study extends our current knowledge on the role of the CRF system in 
the mPFC in excessive alcohol consumption, revealing that binge drinking regulates 
CRF-BP mRNA expression in this region. 
 The mPFC is also sensitive to stress, playing a key role in the limbic forebrain 
circuit that regulates stress systems including the hypothalamic–pituitary–adrenal axis 
(HPA). Activation of the PL mPFC has been shown to dampen the HPA axis (Jones et 
al., 2011), whereas lesions of the PL mPFC enhance activation of the HPA axis (Radley 
et al., 2006). Jaferi and Bhatnagar, 2007 determined that CRF receptors in the mPFC 
contribute to the regulation of the HPA axis, as administration of a nonselective CRF 
receptor antagonist decreased HPA activity after acute and chronic restraint stress. Acute 
and chronic administration of alcohol alters HPA axis activity, resulting in altered plasma 
corticosterone levels (Ellis, 1966; Richardson et al., 2008; Rivier, 1993). As stress, CRF, 
and glucocorticoids have been shown to regulate CRF-BP expression (reviewed in 
Westphal and Seasholtz, 2006), changes in CRF and/or corticosterone levels after binge 
drinking may contribute to altered CRF-BP mRNA expression in the mPFC. The 
observed decrease in CRF-BP mRNA expression could lead to increased free CRF 
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available to bind to and activate CRF-R1 receptors in the mPFC, which may contribute to 
excessive binge-like EtOH consumption. In support of this hypothesis, a recent study has 
shown that administration of a CRF-R1 antagonist into the mPFC attenuates the early life 
stress-induced increase in alcohol self-administration in an operant binge drinking 
paradigm (Gondre-Lewis et al., 2016). 
 It should be emphasized that the studies shown here evaluate CRF, CRF-R1, and 
CRF-BP mRNA levels. Changes in mRNA are not always revealed as changes in protein 
levels with a similar temporal pattern. It should also be noted that our expression studies 
examined mRNA changes at 24 hours after the last binge alcohol exposure to assess 
neuroadaptive changes rather than the acute effects of EtOH. This could account for 
differences between our data and other studies detecting changes in CRF mRNA or 
immunoreactivity at 0 to 2 hours after alcohol exposure (Funk et al., 2006; Lack et al., 
2005; Lowery-Gionta et al., 2012). Finally, it should be noted that CRF peptide levels in 
axon terminals of projection neurons are not assessed by our cellular mRNA measures. 
This may be particularly important when considering CRF levels in areas enriched with 
CRF terminals, such as VTA, CeA, and BNST (Beckerman et al., 2013; Tagliaferro and 
Morales, 2008). 
 We found no difference in alcohol consumption between male CRF-BP KO mice 
and wild-type mice after repeated cycles of DID, indicating that the total absence of 
CRF-BP does not alter binge drinking in this paradigm. In contrast to these results, 
Albrechet-Souza and colleagues (2015) found that administration of the CRF-BP ligand 
inhibitor, CRF6-33, into the VTA, but not the CeA, decreased alcohol consumption in a 
DID paradigm, suggesting that CRF-BP may facilitate binge-like EtOH consumption. 
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One significant difference between these studies is the method by which CRF-BP is 
inhibited. In the study by Albrechet-Souza and colleagues (2015), CRF-BP is site- 
specifically inhibited in the VTA or CeA using CRF6-33. In the present study, a 
constitutive CRF-BP KO mouse model was utilized, resulting in global alterations in 
CRF signaling that could mask the influence of one particular brain region on alcohol 
drinking behavior. Additionally, the CRF-BP KO mice are deficient in CRF-BP 
throughout development; therefore, compensatory changes in CRF signaling could be 
occurring. 
 Overall, the current results expand our knowledge on the role of the CRF system 
in alcohol binge drinking. We discovered an enduring decrease in CRF-BP mRNA 
expression in the mPFC after both 3 and 6 DID cycles, reflecting a dysregulation of the 
CRF system that could contribute to escalated EtOH intake. We also demonstrated that 
CRF-BP KO mice do not display altered binge drinking across 6 cycles of DID. Future 
studies will utilize viral and genetic approaches to conditionally and site-specifically 
knockdown and/or overexpress CRF-BP to further elucidate its role in binge drinking and 
alcohol dependence. 
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Figure S2.1 – Representative in situ hybridization autoradiogram images for CRF (A), CRF-R1 (B), 
and CRF-BP (C) in the medial prefrontal cortex (mPFC) of water control mice. Reprinted from 





Figure S2.2 – Representative in situ hybridization autoradiogram images for CRF (A), CRF-R1 (B), 
and CRF-BP (C) in the amygdala of EtOH-treated mice. Reprinted from Ketchesin et al., 2016 with 
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The Cell Type-Specific Expression of CRH-Binding Protein in the Prefrontal Cortex 
Abstract 
CRH-binding protein (CRH-BP) is a secreted glycoprotein that binds CRH with 
very high affinity to modulate CRH receptor activity. CRH-BP is widely expressed 
throughout the brain, with particularly high expression in regions such as the amygdala, 
hippocampus, ventral tegmental area, and prefrontal cortex. Recent studies suggest a role 
for CRH-BP in stress-related psychiatric disorders and addiction, with the prefrontal 
cortex being a potential site of interest. However, the molecular phenotype of CRH-BP-
expressing cells in this region has not been well-characterized. In the current study, we 
sought to determine the cell type-specific expression of CRH-BP in the PFC to begin to 
define the neural circuits in which this key regulator is acting. To characterize the 
expression of CRH-BP in excitatory and/or inhibitory neurons, we utilized dual in situ 
hybridization to examine the cellular colocalization of CRH-BP mRNA with VGLUT or 
GAD mRNA in different subregions of the PFC. We show that CRH-BP is expressed 
predominantly in GABAergic interneurons of the PFC, as revealed by the high degree of 
colocalization (> 85 %) between CRH-BP and GAD. To further characterize the 
expression of CRH-BP in this heterogenous group of inhibitory neurons, we examined 
the colocalization of CRH-BP with various molecular markers of GABAergic 
interneurons, including parvalbumin (PV), somatostatin (SST), vasoactive intestinal 
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peptide (VIP), and cholecystokinin (CCK). We demonstrate that CRH-BP is colocalized 
predominantly with SST in the PFC, with lower levels of colocalization in PV- and CCK-
expressing neurons. Our results provide a more comprehensive characterization of the 
cell type-specific expression of CRH-BP and begin to define its potential role within 
circuits of the PFC. These results will serve as the basis for future in vivo studies to 
manipulate CRH-BP in a cell type-specific manner to better understand its role in stress-
related psychiatric disorders, including anxiety, depression, and addiction.  
Introduction  
Corticotropin-releasing hormone (CRH) is the key central nervous system 
regulator of the mammalian stress response. CRH mediates its effects through binding to 
two G-protein-coupled receptors, CRH receptor 1 (CRH-R1) and CRH receptor 2 (CRH-
R2). The activity of CRH is also modulated by CRH-binding protein (CRH-BP), a 37-
kDa secreted glycoprotein that is structurally distinct from the CRF receptors. This 
evolutionarily conserved protein binds CRH and the CRH-like ligand urocortin 1 with a 
greater affinity than the CRH receptors. Multiple roles have been proposed for the CRH-
BP (reviewed in Ketchesin et al., 2017; Westphal and Seasholtz, 2006). In cultured 
pituitary cells, CRH-BP attenuates CRH-R1-mediated ACTH release, demonstrating an 
inhibitory role for CRH-BP at CRH-R1 (Cortright et al., 1995; Potter et al., 1991; Sutton 
et al., 1995). Other studies have suggested a potential facilitatory role for CRH-BP at 
CRH-R2, particularly in the VTA (Albrechet-Souza et al., 2015; Ungless et al., 2003; 
Wang et al., 2007).  Additional studies suggest that CRH-BP may have actions 
independent of CRH receptor (Chan et al., 2000) or may act as an escort protein to traffic 
CRH-R2α to the cell surface (Slater et al., 2016). Thus, the role of CRH-BP and its 
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mechanism of action may depend on a variety of factors, including CRH receptor 
subtype, brain region, or specific cell type. 
CRH-BP is widely expressed throughout the brain, including the cerebral cortex, 
amygdala, hippocampus, ventral tegmental area (VTA), and a variety of brainstem nuclei 
(Chan et al., 2000; Potter et al., 1992). CRH-BP is expressed in several regions where 
CRH is expressed, such as the bed nucleus of the stria terminalis (BNST) and the central 
nucleus of the amygdala, suggesting potential sites of interaction (Potter et al., 1992). 
Moreover, CRH-BP is expressed in a number of CRH target sites where the CRH 
receptors are expressed, including the anterior pituitary, basolateral amygdala, ventral 
tegmental area (VTA), and medial prefrontal cortex (Ketchesin et al., 2016; Potter et al., 
1992; Stinnett et al., 2015; Westphal et al., 2009). Both rodent and human studies have 
implicated a role for CRH-BP in stress-related psychiatric disorders, including anxiety, 
depression, and addiction (Albrechet-Souza et al., 2015; Binder et al., 2010; Enoch et al., 
2008; Haass-Koffler et al., 2016; Ketchesin et al., 2016; Ketchesin et al., 2017). We have 
recently shown that repeated cycles of binge drinking in mice decrease CRH-BP mRNA 
expression in the mPFC (Ketchesin et al., 2016), a region involved in executive function 
and regulation of emotion and behavior, including responses to stress (Jaferi and 
Bhatnagar, 2007; Mcklveen et al., 2015). Other studies have shown that the CRH system 
in this region plays an important role in stress-related behaviors, including anxiety, 
learning and memory, and excessive alcohol consumption (George et al., 2012; Glaser et 
al., 2014; Gondre-Lewis et al., 2016; Jaferi and Bhatnagar, 2007; Uribe-Marino et al., 
2016). However, the molecular phenotype of CRH-BP-expressing cells in the PFC has 
not been well-characterized. 
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The PFC contains two broad classes of neurons: glutamatergic excitatory 
pyramidal neurons and GABAergic inhibitory interneurons. Although GABAergic 
interneurons represent only 10 – 20% of neurons in the cortex, they play a critical role in 
modulating the output of the cortical excitatory pyramidal neurons (Xu et al., 2010). 
Interneurons are highly diverse and can be subdivided into different classes based on 
properties such as morphology, electrophysiology, connectivity, and 
neuropeptide/calcium-binding protein marker expression (Petilla Interneuron 
Nomenclature et al., 2008). Molecular markers commonly used to identify interneurons 
include the calcium-binding protein parvalbumin (PV) and the neuropeptides 
somatostatin (SST), vasoactive intestinal peptide (VIP), and cholecystokinin (CCK), 
which account for the majority of interneurons in the frontal cortex (Kawaguchi and 
Kubota, 1997). SST, PV, and VIP compose three distinct non-overlapping classes of 
interneurons, while there is partial overlap between CCK and VIP interneurons 
(Kawaguchi and Kubota, 1997; Xu et al., 2010). 
The goal of the current study was to determine the cell type-specific expression of 
CRH-BP in the PFC to begin to define the neural circuits in which CRH-BP is acting. We 
utilized dual in situ hybridization to determine the expression of CRH-BP mRNA in 
excitatory (VGLUT-positive) or inhibitory (GAD-positive) neurons in different regions 
of the PFC to determine whether CRH-BP is acting locally within the PFC or projecting 
to other brain regions to mediate its effects. We find that CRH-BP mRNA colocalizes 
predominantly with GAD, revealing the presence of CRH-BP in inhibitory interneurons 
of the PFC. To further characterize the expression of CRH-BP in inhibitory neurons of 
the PFC, we examined the colocalization of CRH-BP with the interneuron molecular 
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 Male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) were used for 
all experiments. Mice (n = 10) were 10- to 20-weeks old at the time of experiments. Mice 
were maintained on a 14-hour light/10-hour dark cycle and had access to food and water 
ad libitum. All mouse experiments were conducted according to National Institutes of 
Health guidelines for animal care and were approved by the University of Michigan 
Committee on Use and Care of Animals. 
 In situ hybridization riboprobes  
A VGLUT1 antisense cRNA riboprobe was generated from a pCRII-TOPO 
plasmid containing a 745-bp fragment of mouse VGLUT1 cDNA (mVGLUT1-pTOPO; 
GenBank accession no. NM_182993, nucleotides 209 – 953). A VGLUT2 antisense 
cRNA riboprobe was synthesized from a pCRII-TOPO plasmid containing a 840-bp 
fragment of mouse VGLUT2 cDNA (mVGLUT2-pTOPO; accession no. NM_080853, 
nucleotides 901 – 1741). For antisense riboprobe synthesis, the mVGLUT1-pTOPO and 
mVGLUT2-pTOPO plasmids were linearized with HindIII and BamHI, respectively, and 
transcribed with T7 RNA polymerase (Promega, Madison, WI). A GAD65 antisense 
cRNA riboprobe was generated from a BSSK plasmid containing a 613-bp fragment of 
mouse GAD65 cDNA (mGAD65-BSSK; accession no. NM_008078, nucleotides 1221 – 
1834). A GAD67 antisense cRNA riboprobe was synthesized from a BSSK plasmid 
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containing a 651-bp fragment of mouse GAD67 cDNA (mGAD67-BSSK; accession no. 
NM_008077, nucleotides 2354 – 3005). mGAD65-BSSK and mGAD67-BSSK plasmids 
were kindly provided by Dr. Stanley Watson, University of Michigan, Ann Arbor, MI. 
For antisense riboprobe synthesis, the mGAD65-BSSK and mGAD67-BSSK plasmids 
were linearized with BamHI and transcribed with T7 RNA polymerase. VGLUT1, 
VGLUT2, GAD65, and GAD67 riboprobes were generated with the following 
transcription reaction: 6 µl 5x transcription buffer, 2 µl 100 mM DTT, 1 µl each 10 mM 
ATP, CTP, and GTP, 1 µl 10 mM digoxigenin-11-UTP (4:6 digoxigenin-11-UTP:UTP 
ratio; Roche Diagnostics, Indianapolis, IN), 1.5 µl linearized DNA (1µg/µl) , 1 µl RNA 
polymerase (20 units/µl), and 1 µl RNase inhibitor (RNaseOUT; 40 units/µl) in a 30 µl 
reaction volume. All riboprobes were purified using Micro Bio-Spin P-30 columns (Bio-
Rad Laboratories, Hercules, CA) and recovered in a 40 µl volume. 
 PV, VIP, and CCK cDNA sequences were isolated from mouse cortex cDNA by 
PCR using Taq polymerase. The primers used to isolate PV, VIP, and CCK cDNA were 
as follows: PV – 5’-TTTGCTGCTGCAGACTCCTT-3’ and 5’-
TCTACTATACCCCCACTGCCC-3’ (555-bp product, accession no. NM_013645.3, 
nucleotides 77 – 631); VIP – 5’-TTGGCAAACGAATCAGCAGC -3’ and 5’-
TCCTCGATTGCTACCCTTGC-3’ (531 bp-product, accession no. NM_011702.2, 
nucleotides 486 – 1016); CCK – 5’-GGTGATGGCAGTCCTAGCTG-3’ and 5’-
AAGGAAACACTGCCTTCCGA-3’ (508 bp-product, accession no. NM_031161.4, 
nucleotides 126 – 633). The PCR products were subcloned into the pCR-II TOPO vector 
(TOPO-TA kit; 45-0640, Invitrogen, Carlsbad CA) and confirmed by restriction digests 
and DNA sequencing. For riboprobe synthesis, the mCCK-pTOPO and mVIP-pTOPO 
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plasmids were linearized with BamHI and transcribed with T7 RNA polymerase. The 
mPV-pTOPO plasmid was linearized with XhoI and transcribed with SP6 RNA 
polymerase (Promega, Madison, WI). A SST antisense cRNA riboprobe was generated 
from a BSSK plasmid containing a 390-bp fragment of rat SST cDNA (rSST; accession 
no. NM_012659, nucleotides 110-500; kindly provided by Dr. Stanley Watson, 
University of Michigan, Ann Arbor, MI). The rSST plasmid was linearized with BamHI 
and transcribed with T7 RNA polymerase. SST, PV, CCK, and VIP riboprobes were 
labeled with digoxigenin-11-UTP (4:6 digoxigenin-11-UTP:UTP ratio) as described 
above. A CRH-BP antisense cRNA riboprobe was synthesized from a pGEM-3Z plasmid 
containing a 666-bp fragment of mouse CRH-BP cDNA (mCRHBP666; accession no. 
NM_198408, nucleotides 372 – 1037; Cortright et al., 1995). The mCRHBP666 plasmid 
was linearized with XhoI and transcribed with T7 RNA polymerase. The CRH-BP 
riboprobe was generated with the following transcription reaction: 6.4 µl 35S-UTP (1,250 
Ci/mmol; PerkinElmer Inc., Waltham, MA), 6 µl 5x transcription buffer, 2 µl 100 mM 
DTT, 1 µl each 10mM CTP, ATP and GTP, 1.5 µl linearized DNA (1µg/µl), 1 µl T7 
RNA polymerase (20 units/µl), and 1 µl RNase inhibitor (RNaseOUT; 40 units/µl) in a 
30 µl reaction volume. All riboprobes were purified using Micro Bio-Spin P-30 columns 
(Bio-Rad Laboratories, Hercules, CA) and recovered in a 40 µl volume. 
Tissue Processing and Dual In Situ Hybridization 
Brains from male mice were sectioned at 14 µm and collected in a series of 6 
slides (4 sections/slide). Every sixth slide was stained with cresyl violet to determine 
anatomical location. The cell type-specific expression of CRH-BP in the PFC was 
determined using dual in situ hybridization, similar to what has been described previously 
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(Speert et al., 2002). Slides were postfixed in 4% paraformaldehyde for 1 hour, followed 
by 3 washes in 2x saline sodium citrate (SSC) buffer. Slides were then incubated in 
0.25% acetic anhydride in 0.1 M triethanolamine (pH 8) for 10 minutes, washed 3 times 
in 2x SSC, dehydrated in ethanol, and then air-dried. To determine the cellular 
colocalization of CRH-BP with VGLUT or GAD, adjacent slides containing PFC were 
hybridized with the 35S-labeled CRH-BP riboprobe (2 x 106 cpm/slide) and a 
digoxigenin-labeled riboprobe (1.5 l/slide) in 50% formamide hybridization buffer 
(Ameresco, Framingham, MA) with 20 mM DTT at 55C overnight. For the VGLUT 
hybridization reaction, the 35S-labeled CRH-BP riboprobe (2 x 106 cpm/slide) was 
combined with the digoxigenin-labeled VGLUT1 (1.5 l/slide) and VGLUT2 (1.5 
l/slide) riboprobes. For the GAD hybridization reaction, the 35S-CRH-BP riboprobe was 
combined with the digoxigenin-labeled GAD65 and GAD67 riboprobes (1.5 l 
each/slide). To determine the cellular colocalization of CRH-BP with various interneuron 
molecular markers, adjacent slides were hybridized with the 35S-labeled CRH-BP 
riboprobe (2 x 106 cpm/slide) and a single digoxigenin-labeled riboprobe (CCK, VIP, PV, 
or SST; 1.5 l/slide) in 50% formamide hybridization buffer with 20 mM DTT at 55C 
overnight. After hybridization, excess unhybridized probe was removed by three 2x SSC 
washes and sections were incubated in RNase A (200 µg/ml; Sigma Life Science, St. 
Louis, MO) at 37C for 1 hour. Slides were then washed in decreasing salt solutions (2x, 
1x, and 0.5x SSC) and a high-stringency wash was performed in 0.1x SSC at 65C for 1 
hour. The slides were then cooled to room temperature before being washed twice in 
Buffer 1 (100mM Tris, 150mM NaCl, pH 7.5). The slides were blocked in Buffer 1 
containing 1% goat serum and 0.1% Triton X-100 for 1 hour. Slides were incubated 
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overnight at room temperature with a sheep anti-digoxigenin antibody conjugated to 
alkaline phosphatase (Anti-Digoxigenin-AP Fab fragments, Roche Diagnostics, 
Indianapolis, IN) diluted 1:5,000 in fresh blocking buffer. The next day the slides were 
washed 3 times in Buffer 1, followed by 1 wash in alkaline substrate buffer (ASB; 100 
mM NaCl, 100 mM Tris, 50 mM MgCl2, pH 9.5). Digoxigenin-labeled products were 
revealed by a color reaction that contained 5% polyvinyl alcohol, 1 mM levamisole, and 
2% NBT/BCIP (Roche Diagnostics, Indianapolis, IN) in ASB buffer. Color reactions 
were stored in the dark until the cells were labeled dark purple. The length of the color 
reaction was probe specific and varied between 6-8 hours. To terminate the reaction, the 
slides were washed extensively in deionized water and the antibody was stripped with a 
10-minute incubation in 0.2M glycine, pH ~2. Slides were then fixed in 2.5% 
glutaraldehyde in Buffer 1 for 1 hour. Slides were washed extensively in deionized water, 
ethanol dehydrated, and then air-dried. For detection of 35S-CRH-BP signal, slides were 
dipped in Ilford K5D nuclear emulsion (Polyscience, Warrington, PA) and stored in the 
dark for 2-3 weeks at 4C. Slides were developed in Kodak D19 developer for 3 minutes, 
rinsed in water for 30 seconds, and fixed in Kodak Rapid Fixer for 4 minutes. Slides were 
then washed extensively in deionized water, ethanol dehydrated, and coverslipped with 
Permount. 
Data Analysis 
 The emulsion dipped slides were viewed and analyzed using a Leica DMR 
microscope (Leica, Wetzlar, Germany). Images were captured using brightfield 
microscopy (40x objective) and a Zeiss Axiocam 506 color camera. Images were 
adjusted in Adobe Photoshop (Adobe Systems Inc., San Jose, CA) to increase the 
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detection of signal above background. The cell type-specific expression of CRH-BP in 
the PFC was quantified at two different bregma coordinates (Paxinos and Franklin, 
2001), 1.94 mm and 2.10 mm relative to bregma. The following regions of the PFC were 
quantified: 1.94 mm – cingulate, prelimbic, infralimbic, dorsal peduncular, lateral orbital, 
agranular insular ventral (AIV), agranular insular dorsal (AID), and dysgranular insular 
(DI) cortices; 2.10 mm – cingulate, prelimbic, medial orbital, dorsal peduncular, ventral 
orbital, lateral orbital, and agranular insular cortices. To demarcate the different 
subregions of the prefrontal cortex, adjacent cresyl violet-stained sections were viewed at 
1.6x and regions of interest were outlined according to Paxinos and Franklin (2001) using 
Stereo Investigator (MBF Bioscience, Williston, VT). This outline was then 
superimposed on the respective experimental section for analysis. The cell type-specific 
expression of CRH-BP within each outlined region of the PFC was quantified using a 20x 
objective and marking positive cells in Stereo Investigator (n = 2-3 mice for parvalbumin; 
n = 4 mice for all remaining probes). A cell was considered to express CRH-BP mRNA 
when it contained greater than 6 silver grains/cell (at least 3 times above background). A 
cell was considered digoxigenin-positive when it was clearly labeled purple. Dual labeled 
cells were purple with silver grains directly overlaying them. In each region of the PFC, 
the number of CRH-BP-positive, digoxigenin-positive (PV, SST, VIP, and GAD), and 
dual labeled cells were counted. The percentage of CRH-BP-positive cells that were dual 
labeled was determined (number of dual labeled cells / the total number of CRH-BP-
positive cells x 100). This percentage was averaged between animals for each probe and 
brain region. For the analysis of CRH-BP mRNA expression in VGLUT/GAD neurons at 
1.94 mm, both the right and the left hemispheres were quantified and averaged to 
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generate one value per animal. For the remaining analyses, only one hemisphere (right or 
left) was quantified, as we did not observe significant differences in colocalization 
between sides for any probe. 
 Data were analyzed using a 2-way (brain region x cell type) analysis of variance 
(ANOVA) and Bonferroni post hoc analyses were performed for multiple comparisons 
when appropriate. All data are reported as means ± SEM and significant values were 
accepted at p<0.05 for all statistical tests. 
Results 
Colocalization of CRH-BP with VGLUT and GAD  
CRH-BP mRNA is readily detected in layers II – VI of the PFC (in situ 
autoradiogram in Figure 3.1B), consistent with previous studies (Chan et al., 2000; Potter 
et al., 1992). To determine the cell type-specific expression of CRH-BP in excitatory 
and/or inhibitory neurons of the PFC, dual in situ hybridization was performed to 
examine the cellular colocalization of CRH-BP mRNA with VGLUT 
(VGLUT1/VGLUT2) and GAD (GAD65/GAD67) mRNA, respectively. As expected, 
VGLUT-expressing cells were more prevalent than GAD-expressing cells in the PFC 
(Figures 3.1C,D). For each subregion of the PFC, the percentage of CRH-BP-positive 
cells that co-expressed GAD or VGLUT was calculated. In the caudal PFC (bregma 
coordinate 1.94 mm), the colocalization between CRH-BP mRNA and GAD mRNA 
(Figure 3.1C) was significantly higher than the colocalization between CRH-BP mRNA 
and VGLUT mRNA (Figures 3.1D; quantified in Figure 3.2A), as revealed by a 
significant main effect of cell type (F (1, 48) = 9591, p < 0.0001). Post hoc analyses 
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revealed that CRH-BP mRNA is significantly more colocalized with GAD compared to 
VGLUT in all regions of the PFC at this bregma coordinate (p < 0.0001). The percentage 
of CRH-BP-expressing cells colocalized with GAD mRNA did not vary greatly between 
PFC regions (Figure 3.2A), with the highest percentage of colocalization in the dorsal 
peduncular cortex (92.1 ± 1.4%) and the lowest percentage in the prelimbic cortex (86.5 
± 1.2%). Likewise, the percentage of CRH-BP-expressing cells colocalized with VGLUT 
mRNA did not vary greatly between brain regions (Figure 3.2A); the highest degree of 
colocalization was detected in the prelimbic cortex (16.5 ± 0.8%) compared to the lowest 
degree of colocalization in the dorsal agranular insular cortex (11.1 ± 2.2%).  
At a more rostral portion of the PFC (bregma coordinate 2.10 mm), there was a 
similar pattern of colocalization, with a higher degree of colocalization between CRH-BP 
and GAD compared to VGLUT (Figure 3.2B), as revealed by a significant main effect of 
cell type (F (1, 42) = 5675, p < 0.0001). Post hoc analyses revealed that CRH-BP mRNA 
is significantly more colocalized with GAD compared to VGLUT in all regions of the 
PFC at this bregma coordinate (p < 0.0001). Similar to PFC at bregma 1.94 mm, the 
percentage of CRH-BP-expressing neurons colocalized with GAD did not vary greatly 
between each PFC regions (Figure 3.2B); the highest degree of colocalization was 
detected in the ventral orbital cortex (92 ± 0.7%) compared to the lowest percentage in 
the dorsal peduncular cortex (85.6 ± 2.5%). Similarly, the percentage of CRH-BP-
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Figure 3.1 – The expression of CRH-BP mRNA in excitatory (VGLUT-expressing) and 
inhibitory (GAD-expressing) neurons in the PFC. Coronal section from the Paxinos and 
Franklin (2001) mouse brain atlas (A) at Bregma coordinate 1.94 mm, highlighting the 
prelimbic region of the PFC where the images in C and D were captured. An in situ 
autoradiogram (B) shows abundant CRH-BP mRNA expression throughout the PFC. Higher 
magnification bright field images show a high degree of colocalization between CRH-BP and 
GAD (GAD65/GAD67) mRNA (C) and a low degree of colocalization between CRH-BP and 
VGLUT (VGLUT1/VGLUT2) mRNA (D) in the prelimbic PFC. Cells labeled for CRH-BP 
only (silver grains) are indicated with blue arrows, cells labeled for GAD or VGLUT only 
(purple digoxigenin signal) are indicated with red arrows, and dual-labeled cells are indicated 
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Figure 3.2 – CRH-BP mRNA colocalizes predominantly with GAD in the PFC. 
Quantification of CRH-BP mRNA colocalization with GAD and VGLUT in the caudal PFC 
(A, Bregma coordinate 1.94 mm) and a more rostral region of the PFC (B, Bregma coordinate 
2.10 mm). Data represent the percentage of CRH-BP-positive cells colocalized with VGLUT 
or GAD mRNA. The colocalization between CRH-BP and GAD was significantly higher than 
the colocalization between CRH-BP and VGLUT at both Bregma coordinates (A, B), as 
revealed by a significant main effect of cell type (# p < 0.0001). Post hoc analyses showed that 
the degree of colocalization was significantly higher for GAD compared to VGLUT in all 
subregions of the PFC at both Bregma coordinates (A, B; * p < 0.0001). ^ p < 0.05 interaction 
effect. Data represent the mean ± SEM. AIV, agranular insular ventral; AID, agranular insular 
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region (Figure 3.2B), with the highest degree of colocalization in the medial orbital 
cortex (16.6 ± 1.6%) and the lowest degree of colocalization in the agranular insular 
cortex (9.5 ± 2.2%). 
Colocalization of CRH-BP with Interneuron Molecular Markers 
To further characterize the cell type-specific expression of CRH-BP in inhibitory 
neurons of the PFC, dual in situ hybridization was performed to examine the cellular 
colocalization of CRH-BP with molecular markers of GABAergic interneurons, including 
the calcium-binding protein PV and the neuropeptides CCK, SST, and VIP (Figure 3.3). 
These markers represent 4 largely distinct subclasses of interneurons (partial overlap 
between CCK and VIP) that account for the majority of interneurons in the frontal cortex 
(Kawaguchi and Kubota, 1997; Tremblay et al., 2016). CCK-expressing cells were the 
most abundant in the PFC, followed by SST, PV, and VIP. PV-expressing cells were 
more prevalent in the lateral PFC compared to the medial PFC. For each subregion of the 
PFC, the percentage of CRH-BP-positive cells that expressed each interneuron marker 
was calculated (Figure 3.4). In the caudal PFC (bregma coordinate 1.94 mm), a 2-way 
ANOVA revealed a significant main effect of cell type (F (3, 80) = 477, p < 0.0001). Post 
hoc analyses revealed that the colocalization between CRH-BP and SST (Figure 3.3B) is 
significantly higher than the colocalization between CRH-BP and CCK (Figure 3.3C), 
PV (Figure 3.3D), or VIP (Figure 3.3E) in all regions of the PFC at this bregma 
coordinate (p < 0.0001; Figure 3.4A). The percentage of CRH-BP-expressing cells 
colocalized with SST ranged between 49.7 – 60.8% (Figure 3.4A). The percentage of 
CRH-BP-positive cells colocalized with CCK did not significantly differ from the 
percentage colocalized with PV within each region of the PFC (Figure 3.4A). The range 
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of colocalization in the PFC was 5.5 – 20.7% for CCK and 10.4 – 25.3% for PV. There 
were no CRH-BP-positive cells that expressed VIP in the PFC at this bregma coordinate, 
therefore the percent colocalization was 0% for all regions. 
At the more rostral portion of the PFC (bregma coordinate 2.10 mm), a 2-way 
ANOVA also revealed a significant main effect of cell type (F (3, 68) = 748, p < 0.0001). 
Post hoc analyses showed that the colocalization between CRH-BP and SST is 
significantly higher than the colocalization between CRH-BP and VIP, CCK, or PV in all 
regions of the PFC at this bregma coordinate (p < 0.001; Figure 3.4B). The percentage of 
CRH-BP-expressing cells colocalized with SST ranged between 36.6 – 65.6% (Figure 
3.4B). The percentage of CRH-BP-positive cells colocalized with CCK did not 
significantly differ from the percentage colocalized with PV, except in the dorsal 
peduncular cortex, where the percentage of CRH-BP colocalization with CCK was 
significantly higher than PV (p < 0.01), and the lateral orbital cortex, where the 
percentage of CRH-BP colocalization with PV was significantly higher than CCK (p < 
0.001; Figure 3.4B). The range of colocalization in the PFC was 7.6 – 22.7% for CCK 
and 9.6 – 22.3% for PV. There were no CRH-BP-positive cells that expressed VIP in the 
PFC at this bregma coordinate, except for 1 cell in the agranular insular cortex (0.26% 
colocalization; not included in Figure 3.4B). 
The percentage of SST- and PV-positive cells that expressed CRH-BP mRNA 
was also calculated for each subregion of the PFC. In the caudal PFC (bregma coordinate 
1.94 mm), the range of colocalization was 38.9 – 56.3% for SST and 33.5 – 64.6% for 
PV (data not shown). At the more rostral portion of the PFC (bregma coordinate 2.10 











Figure 3.3 – The expression of CRH-BP mRNA in various GABAergic interneuron 
subtypes in the PFC. Coronal section from the Paxinos and Franklin (2001) mouse brain atlas 
(A) at Bregma coordinate 1.94 mm, highlighting the prelimbic region of the PFC where the 
images in B – E were captured. High magnification bright field images show a high degree of 
colocalization between CRH-BP and SST mRNA (B) and a low degree of colocalization 
between CRH-BP and CCK (C), PV (D), and VIP (E) in the prelimbic PFC. Cells labeled for 
CRH-BP only (silver grains) are indicated with blue arrows, cells labeled for SST, CCK, PV, 
or VIP only (purple digoxigenin signal) are indicated with red arrows, and dual-labeled cells 






































Figure 3.4 – CRH-BP mRNA colocalizes predominantly with SST interneurons in the 
PFC. Quantification of CRH-BP mRNA colocalization with CCK, PV, and SST in the caudal 
PFC (A, Bregma coordinate 1.94 mm) and a more rostral region of the PFC (B, Bregma 
coordinate 2.10 mm). Data represent the percentage of CRH-BP-positive cells colocalized with 
interneuron marker. Data for the colocalization between CRH-BP and VIP is not shown, as 
colocalization was barely detectable (see text). There was a significant main effect of cell type 
(# p < 0.0001) at both bregma coordinates (A, B). Post hoc analyses showed that the 
colocalization between CRH-BP and SST was significantly higher than the colocalization of 
CRH-BP with CCK, PV, or VIP in all subregions of the PFC at both Bregma coordinates (* p 
< 0.001 compared to CCK, PV, and VIP). ^ p < 0.0001 interaction effect. + p < 0.05 main 
effect of PFC region. a – p < 0.01 compared to respective PV group. Data represent the mean ± 
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not shown). Lastly, the percentage of GAD-positive cells expressing CRH-BP mRNA in 
the PFC was estimated to be ~20 – 40%. 
Discussion 
In the current study, we characterized the expression of CRH-BP in excitatory and 
inhibitory neurons of the PFC. First, we examined the cellular colocalization of CRH-BP 
mRNA with GAD (GAD65/GAD67) and/or VGLUT (VGLUT1/VGLUT2) in different 
regions of the PFC. We found that CRH-BP is highly colocalized with GAD in all 
regions of the PFC at both bregma coordinates. To further characterize the expression of 
CRH-BP in inhibitory interneurons, we examined the colocalization of CRH-BP with 
various interneuron molecular markers, including SST, CCK, PV, and VIP. CRH-BP was 
colocalized predominantly with SST in all regions of the PFC, while the degree of 
colocalization was lower for CCK and PV, and barely detectable for VIP. To our 
knowledge, this study represents the first anatomical characterization of CRH-BP 
expression in the rodent PFC. 
 The PFC contains both glutamatergic pyramidal neurons and GABAergic 
inhibitory neurons. GABAergic interneurons project locally within the PFC and function 
to regulate the output of cortical pyramidal neurons. In the present study, we found that 
CRH-BP mRNA is highly colocalized with GAD, revealing the presence of CRH-BP in 
GABAergic interneurons of the PFC. Previous characterization of CRH-BP expression in 
inhibitory neurons of the rodent brain has focused on the VTA. Wang and Morales, 2008 
demonstrated by dual in situ hybridization that CRH-BP mRNA is present in both 
GABAergic interneurons and dopaminergic neurons of the VTA. The authors found that 
27% of CRH-BP-expressing cells co-expressed GAD, and 28% of GAD-expressing cells 
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colocalized with CRH-BP. The presence of CRH-BP in inhibitory interneurons suggests 
that CRH-BP may act locally within the PFC and VTA to produce some its effects. 
Future studies should investigate the expression of CRH-BP in excitatory and inhibitory 
neurons in other regions of the stress and reward system.  
The specific interneuron subtype in which CRH-BP is expressed has important 
implications for its role within circuits of the PFC, as each interneuron subtype exhibits 
unique morphology, physiology, and connectivity, allowing for precise spatiotemporal 
control over pyramidal cell activity (Reviewed in Tremblay et al., 2016). For example, 
PV-expressing neurons consist of fast-spiking basket cells or chandelier cells that tend to 
innervate the soma and proximal dendrites or the axon initial segment of pyramidal 
neurons, respectively, resulting in strong inhibition (Kawaguchi and Kubota, 1997). SST 
neurons are adapting regular-spiking or burst spiking Martinotti cells that innervate the 
distal dendrites of pyramidal cells in layer 1 of the cortex (Kawaguchi and Kubota, 1997). 
There are also non-Martinotti SST-expressing cells that innervate pyramidal neurons or 
PV interneurons in other layers of the cortex (Ma et al., 2006; Xu et al., 2013). Based on 
the strong excitatory input they receive, SST neurons tend to exhibit activity-dependent 
inhibition of pyramidal neurons (Silberberg and Markram, 2007). VIP neurons are often 
bipolar and have a variety of firing patterns, including irregular spiking, bursting, and 
rapidly adapting (Kawaguchi and Kubota, 1997). Interestingly, VIP neurons tend to 
preferentially target SST neurons in the cortex, which may result in disinhibition and 
increased pyramidal cell activity (Pi et al., 2013). Lastly, CCK neurons are regular or 
burst spiking basket cells that target the soma and proximal dendrites of pyramidal cells 
(Kawaguchi and Kubota, 1997). In the current study, we examined the cellular 
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colocalization of CRH-BP with SST, PV, CCK, and VIP in the PFC. SST, PV, and VIP 
represent non-overlapping classes of interneurons in the cortex (Kawaguchi and Kubota, 
1997; Xu et al., 2010). CCK and VIP belong to a larger class of interneurons, those that 
express the ionotropic serotonin receptor 5HT3aR. These interneurons are distinct from 
the PV and SST interneuron classes, but CCK and VIP interneurons do show some 
overlap; small CCK basket cells are VIP-positive and large CCK basket cells are VIP-
negative (Kawaguchi and Kubota, 1997; Lee et al., 2010). The 5HT3aR class of 
interneurons includes neurons that express other markers, such as calretinin and Reelin 
(Lee et al., 2010), which were not included in our analyses. In the present study, we 
determined that CRH-BP is largely expressed in SST interneurons in all regions of the 
PFC, and to a far lower degree in PV and CCK interneurons. Given that we observed 
essentially no colocalization between CRH-BP and VIP in the PFC, it is likely that CRH-
BP is expressed in CCK-expressing neurons that do not express VIP.  
The observation that CRH-BP is localized in SST neurons is consistent with a 
recent study by Li et al., 2016. In this study, the authors utilized oxytocin receptor-Cre 
mice crossed to EGFP-L10a mice and translational ribosome affinity purification 
profiling to find that CRH-BP is highly enriched in oxytocin receptor interneurons of the 
mPFC. Interestingly, these neurons were identified as a specific subpopulation of SST 
interneurons (Li et al., 2016; Nakajima et al., 2014), demonstrating the presence of both 
CRH-BP, SST, and oxytocin receptors within the same interneurons in the mPFC. The 
authors further show that in the male mPFC, CRH enhances the activity of layer II/III 
pyramidal neurons, an effect that is blocked by application of CRH-R1 antagonist (Li et 
al., 2016). This finding is supported by previous studies that have demonstrated the 
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presence of CRH-R1 on glutamatergic neurons of the PFC, and that CRH enhances 
cortical pyramidal cell activity through CRH-R1 (Gallopin et al., 2006; Refojo et al., 
2011). Strikingly, inhibition of CRH-BP with CRH6-33, both alone and in the presence of 
CRH, significantly increased pyramidal cell activity in the male mPFC (Li et al., 2016), 
suggesting that CRH-BP normally inhibits CRH-R1 activation on layer II/III pyramidal 
neurons. These data, and our observation of high CRH-BP and SST colocalization, 
suggest that CRH-BP may be released from SST interneurons and bind CRH to inhibit 
CRH-R1 activation on prefrontal pyramidal neurons, thus regulating their activity. CRH-
BP modulation of CRH-R1 activity on pyramidal neurons may mediate anxiety-like 
behavior, as conditional knockdown of CRH-BP in oxytocin receptor interneurons in the 
mPFC increased anxiety in male (but not female) mice (Li et al., 2016). In support of this, 
selective deletion of CRH-R1 in forebrain glutamatergic neurons reduces anxiety-like 
behavior (Refojo et al., 2011). Interestingly, CRH is expressed in a subset of SST and 
VIP interneurons (Gallopin et al., 2006). Thus, CRH-BP and CRH may be released from 
the same SST interneurons or from different classes of SST and/or VIP interneurons. 
Future studies will investigate the colocalization between CRH-BP, CRH, and various 
interneuron subtypes in the mouse PFC to begin to address these questions. 
 In the current study, we find a low degree of colocalization between CRH-BP and 
PV (about 10 – 25% of CRH-BP-expressing cells colocalize with PV). In a recent study, 
Lake and colleagues (2016) sequenced RNA molecules from individual neuronal nuclei 
of a human postmortem brain to begin to define neuronal subtypes in the human cortex. 
In their data set, they discovered an interneuron subtype that expresses both PV and 
CRH-BP. Interestingly, they did not observe CRH-BP and SST co-expression in their 
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samples (Lake et al., 2016). Our contrasting results may reflect species differences or 
perhaps region-specific differences, as the sequencing data originated from six different 
regions of the cerebral cortex (Lake et al., 2016). It should be noted that PV expression is 
enriched in areas of the cortex that were not quantitated in our study, including the motor 
and sensory cortices (Whissell et al., 2015). We also observed greater PV expression in 
the lateral PFC compared to the mPFC, which may have contributed to the greater 
colocalization observed between CRH-BP and PV in the lateral PFC compared to the 
mPFC. 
 In summary, the current results expand our knowledge on the molecular 
phenotype of CRH-BP neurons and begin to define the prefrontal cortical circuits in 
which it’s expressed. We found that CRH-BP is expressed predominantly in GABAergic 
interneurons of the PFC, particularly SST-expressing interneurons. Based on findings 
from previous studies (Gallopin et al., 2006; Li et al., 2016; Refojo et al., 2011), we 
postulate that CRH-BP may be released from SST interneurons to regulate the activity of 
pyramidal neurons via CRH-R1, potentially influencing anxiety-like behavior. SST 
interneurons are sensitive to stress and have been implicated in a variety of stress-related 
psychiatric disorders, including anxiety and depression (Fuchs et al., 2017; Lin and 
Sibille, 2015; Soumier and Sibille, 2014; Stengel et al., 2013). The current 
characterization of the cell type-specific expression of CRH-BP in the PFC will serve as 
the basis for future studies to manipulate CRH-BP in a cell type-specific manner to begin 
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The Role of CRH-Binding Protein in Alcohol Dependence* 
Abstract 
Dysregulation of the CRH system is observed in rodent models of excessive 
drinking, including binge drinking and alcohol dependence, with a particular role for 
CRH-R1. Recent studies have identified single nucleotide polymorphisms (SNPs) in the 
human CRHR1 and CRHBP genes associated with stress and alcohol use and abuse, 
suggesting that in addition to CRH-R1, CRH-BP may play a role in vulnerability to 
alcohol addiction. However, the role of CRH-BP in excessive alcohol consumption has 
not been well-characterized. In this study, we sought to determine the role and regulation 
of CRH-BP in a mouse model of alcohol dependence, using the chronic intermittent 
ethanol (CIE) vapor paradigm. In situ hybridization was utilized to determine how CRH-
BP, CRH-R1, and CRH mRNA expression are regulated within stress and reward 
pathways in CIE. Two variations of the CIE paradigm were used to model different 
aspects of ethanol exposure in CIE. The first CIE paradigm did not include periods of 
voluntary ethanol drinking and was used to determine the effects of forced CIE vapor 
exposure on CRH-BP expression. The second CIE paradigm contained periods of 2-bottle 
choice limited access to ethanol and was used to determine the effects of voluntary 
ethanol drinking on CRH-BP expression in dependence. CRH-BP KO mice were then 
utilized to determine the function role of CRH-BP in CIE. In the CIE paradigm without 
*Note: The behavioral experiments in this chapter (CIE exposure) were conducted by Dr. Howard 
Becker and Dr. Marcelo Lopez at Medical University of South Carolina 
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voluntary drinking, we observe a decrease in CRH-BP mRNA expression in the anterior 
paraventricular nucleus of the thalamus (aPVT) of CIE mice at peak alcohol withdrawal. 
In the CIE paradigm with voluntary drinking we observe decreased CRH-BP expression 
in the ventral tegmental area (VTA) of CIE mice 8 days into abstinence. However, CRH-
BP mRNA expression is increased in the bed nucleus of the stria terminalis (BNST) of 
CIE mice compared to controls in this paradigm. These data suggest differential 
regulation of CRH-BP between brain regions and CIE paradigms. Finally, CRH-BP KO 
mice exposed to CIE do not show hallmark increases in ethanol consumption, suggesting 
that total loss of CRH-BP in brain and pituitary may prevent escalations in ethanol during 
dependence. 
Introduction 
Alcohol consumption is responsible for 4.6% of global burden of disease and 
injury (Rehm et al., 2009). A significant portion of this risk is due to alcohol use disorder, 
a chronic relapsing disorder characterized by periods of excessive and compulsive 
drinking, withdrawal and abstinence, and eventual relapse. Stress is a significant risk 
factor for alcohol use that has been linked to binge drinking, drinking after dependence, 
and in relapse to drinking after abstinence (reviewed in Lowery and Thiele, 2010; Phillips 
et al., 2015; Ray, 2011). The stress response in mammals is controlled by the 
corticotropin-releasing hormone (CRH) system. Not surprisingly, the CRH system has 
also been linked to excessive alcohol use and addiction (reviewed in Lowery and Thiele, 
2010; Phillips et al., 2015). This system includes two G-protein-coupled receptors, CRH 
receptor 1 (CRH-R1) and CRH receptor 2 (CRH-R2), and the CRH-binding protein 
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(CRH-BP), a secreted glycoprotein that binds CRH with very high affinity and regulates 
CRH receptor activation. 
Dysregulation of the CRH system has been implicated in both human alcohol use 
disorders and rodent models of excessive drinking, including binge drinking and alcohol 
dependence, with a particular focus on CRH-R1 (Lowery and Thiele, 2010; Phillips et al., 
2015; Ray, 2011). Peripheral administration of CRH-R1 antagonists has been shown to 
reduce binge drinking in mice and ethanol self-administration in dependent rats (Funk et 
al., 2007; Lowery et al., 2010; Sparta et al., 2008). A number of brain regions within the 
stress and reward system have been implicated in CRH-R1-mediated regulation of 
alcohol consumption, including the amygdala, VTA, and mPFC. Intra-CeA 
administration of a CRH-R1 antagonist deceased binge drinking in mice (Lowery-Gionta 
et al., 2012), and administration of non-selective CRH receptor antagonist into the CeA 
reduced ethanol self-administration in dependent rats (Funk et al., 2006). In the VTA, 
administration of a CRH-R1 antagonist decreased binge drinking in a drinking in the dark 
paradigm (Rinker et al., 2017; Sparta et al., 2013) and drinking in a 2-bottle choice 
intermittent access paradigm (Hwa et al., 2013). Finally, intra-mPFC administration of a 
CRH-R1 antagonist attenuated early life stress-induced increases in alcohol self-
administration (Gondre-Lewis et al., 2016). Several studies also suggest a role for CRH-
R2 in binge drinking (Albrechet-Souza et al., 2015; Lowery et al., 2010; Sharpe and 
Phillips, 2009; Rinker et al., 2017) and alcohol dependence (Funk and Koob, 2007), with 
both positive and negative effects on drinking being reported. 
While CRH receptors clearly play a role in binge drinking and alcohol 
dependence, the role for CRH-BP, a key regulator of CRH receptor activity, in alcohol 
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addiction has not been well-characterized. Recently, SNPs have been identified in the 
human CRHBP gene that are associated with stress and alcohol use (Enoch et al., 2008; 
Ray, 2011), suggesting a role for CRH-BP in vulnerability to alcohol addiction. We have 
recently shown that repeated cycles of binge drinking in mice decrease CRH-BP mRNA 
expression in the mPFC (Ketchesin et al., 2016). These data are supported by additional 
studies in rodents suggesting a role for CRH-BP in binge drinking (Albrechet-Souza et 
al., 2015; Haass-Koffler et al., 2016). However, the role for CRH-BP in alcohol 
dependence has not been well-characterized.  
A variety of animal models have been developed to model alcohol dependence in 
rodents (reviewed in Becker, 2013). A model that has been commonly used is the chronic 
intermittent ethanol (CIE) vapor paradigm, in which mice are exposed to chronic alcohol 
vapor inhalation in an intermittent fashion, resulting in multiple episodes of withdrawal 
(Lopez and Becker, 2005; Griffin et al., 2009). Delivering chronic alcohol via an 
inhalation route allows for high and sustained blood alcohol levels in a controlled 
manner. In the CIE model, voluntary ethanol consumption can be measured by 
alternating periods of limited access to ethanol between each vapor cycle (Becker and 
Lopez, 2004; Lopez and Becker, 2005). Mice exposed to CIE display escalations in 
alcohol intake across CIE cycles and show higher blood alcohol levels compared to 
nondependent control mice (Becker and Lopez, 2004).  
The goal of the current study was to determine the role and regulation of CRH-BP 
in alcohol dependence, using the CIE vapor paradigm. In situ hybridization was utilized 
to determine how CRH-BP, as well as CRH-R1 and CRH, mRNA expression is regulated 
within stress and reward pathways after CIE. Two variations of the CIE paradigm were 
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employed. The first CIE paradigm did not include periods of voluntary ethanol drinking 
and was used to determine the effects of forced CIE exposure on CRH-BP expression. 
The second CIE paradigm included periods of limited access to ethanol and was used to 
determine the effects of voluntary ethanol drinking on CRH-BP expression in 
dependence. Finally, CRH-BP KO mice were utilized to determine the functional role of 
CRH-BP in modulating ethanol consumption during CIE. 
Methods 
Animals 
 Male C57BL/6J mice were ordered from The Jackson Laboratory (Bar Harbor, 
ME) and used for the in situ hybridization studies (Experiments 1 & 2). CRH-BP 
knockout mice (CRH-BP KO; Karolyi et al., 1999) were bred in our facility and have 
been backcrossed onto a C57BL/6J background for >18 generations. Male CRH-BP KO 
mice and wild-type (WT) littermates for the CIE drinking study (Experiment 3) were 
generated by heterozygous x heterozygous crosses. Mice were 10- to 15-weeks old at the 
time of experiments. Mice were maintained on a 12-hour light/12-hour dark cycle and 
had access to food and water ad libitum. Mice were acclimated to single housing prior to 
the start of experiments. All mouse experiments were conducted according to National 
Institutes of Health guidelines for animal care and were approved by the University of 
Michigan Committee on Use and Care of Animals and the Institutional Animal Care and 






Experiment 1: Regulation of CRH-BP, CRH-R1, and CRH mRNA expression following 
CIE exposure (without drinking sessions) 
 C57BL6/J mice (n = 48) were exposed to CIE vapor or air in Plexiglas inhalation 
chambers as described previously (Griffin et al., 2009; Lopez and Becker, 2005). For the 
CIE group, ethanol was volatized by passing air through an air stone submerged in 95% 
ethanol. Chamber ethanol concentrations were measured daily and the air flow rate was 
adjusted to maintain blood ethanol concentrations of 175 – 225 mg/dl. To initiate and 
stabilize blood ethanol concentration, mice were injected intraperitoneally (0.02 ml/g) 
with ethanol (1.6 g/kg; or saline for control mice) combined with the alcohol 
dehydrogenase inhibitor pyrazole (1 mmol/kg) before entering the inhalation chambers. 
The CIE group (n = 24) was exposed to ethanol vapor for 16 hours/day for 4 days 
followed by 3 days of abstinence. The control group (CTL; n = 24) was handled similarly 
but exposed to air instead of ethanol vapor. This pattern of ethanol/air exposure was 
repeated for a total of 4 weekly cycles (Figure 4.1). Following the last vapor exposure, 
the mice were sacrificed at the following time points: 0, 8 (peak withdrawal), 72 hours, 
and 5 days (n = 6 for each time point and treatment). However, the hour 0 group was 
removed from the study due to elevated corticosterone levels in the CTL group at this 
time point. Brains from the 8 hr, 72 hr, and 5-day groups were used for in situ 
hybridization (described below) to compare CRH-BP, CRH-R1, and CRH mRNA levels 




Experiment 2: Regulation of CRH-BP mRNA expression following CIE exposure (with 
drinking sessions) 
 C57BL6/J mice (n = 60) were trained to establish stable baseline ethanol drinking 
in their home cage via a limited access, 2-bottle choice paradigm as described previously 
(Griffin et al., 2009; Becker and Lopez, 2005). Mice were given two-hour access to 15% 
(v/v) ethanol and tap water as the alternative fluid for 5 days/week (Monday – Friday) for 
a total of 4 weeks. The drinking sessions initiated 30 minutes prior to the start of the dark 
cycle. The positions of the ethanol and water bottles were alternated to prevent a side 
preference from developing. Once stable ethanol drinking was established, mice were 
separated into CIE and CTL groups and exposed to 4 weekly CIE (or air for CTL) 
exposure cycles (+ 3 days of abstinence) alternating with the 5-day limited access 
drinking sessions described above (Figure 4.1). Both the CIE and CTL groups received 
ethanol during the 5-day limited access drinking sessions. Following the fifth vapor 
exposure, the mice were sacrificed at the following time points: 0, 8 (peak withdrawal), 
72 hours, and day 8 (day 5 of the 5-day drinking session after 3 days of abstinence). For 
the day 5 time point, one group of mice received limited access to alcohol during the last 
5-day drinking session, while the other group did not receive access to alcohol during this 
last 5-day time period, allowing for comparisons of 8 days of abstinence in dependence 
and voluntary ethanol drinking in dependence. Brains from these mice were used for in 
situ hybridization (described below) to compare CRH-BP mRNA levels between CIE and 




Experiment 3: Functional role of CRH-BP in CIE (with drinking sessions) using CRH-BP 
KO mice 
 This experiment followed a similar CIE procedure described for Experiment 2. 
CRH-BP KO mice (n = 20), WT littermates (n = 20), and C57BL6/J mice (n = 10) were 
trained to establish stable baseline ethanol drinking using the 2-bottle choice paradigm 
described above. Mice then underwent a 4-cycle CIE paradigm with alternating 5-day 
limited access drinking sessions as described above (Figure 4.1). Half of the mice in each 
group were sacrificed 72 hours after the fourth CIE/air exposure (before the drinking 
session), and the other half were sacrificed on day 5 of test 4 (before day 5 ethanol 
drinking). The amount of ethanol consumed on every drinking day was recorded for each 
mouse and converted to g/kg.   
Tissue Processing and In Situ Hybridization 
 Mice were sacrificed at various time points following CIE exposure and brains 
were removed, frozen in 2-methylbutane, and stored at -80C until tissue processing. 
Brains were sectioned at 14 µm and collected in a series of 6 slides (4 sections/slide). The 
sixth slide from each series was stained with cresyl violet to determine anatomical 
location and orientation. In situ hybridization was used to analyze changes in CRH, 
CRH-R1, and CRH-BP mRNA expression in various regions of the stress and reward 
system, similar to what has been described previously (Herman et al., 1990; Ketchesin et 
al., 2016; Seasholtz et al., 1991). Slides were postfixed in 4% paraformaldehyde for 1 
hour and washed 3 times in 2x saline sodium citrate (SSC) buffer. Next, slides were 
incubated in 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8) for 10 minutes, 
washed 3 times in 2x SSC, dehydrated in ethanol, and air-dried. CRH, CRH-R1, and 
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CRH-BP antisense cRNA riboprobes were made with 35S-UTP and 35S-CTP (1,250 
Ci/mmol; PerkinElmer Inc., Waltham, MA) from plasmids as described previously 
(pGem4ZPst578, Seasholtz et al., 1991; pTOPO CRH-R1, Westphal et al., 2009; 
mCRHBP666, Burrows et al., 1998; Cortright et al., 1995). Brain sections were 
hybridized with the 35S-labeled riboprobes (2 x 106 cpm/slide) in 50% formamide 
hybridization buffer (Ameresco, Framingham, MA) with 20 mM DTT at 55C overnight. 
Following hybridization, slides were washed 3 times in 2x SSC and incubated in RNase 
A (200 µg/ml; Sigma Life Science, St. Louis, MO) at 37C for 1 hour. After washing the 
slides in decreasing salt solutions (2x, 1x, and 0.5x SSC), a high-stringency wash was 
performed in 0.1x SSC at 65C for 1 hour. Slides were dehydrated in ethanol, air-dried, 
and exposed to BioMax MR autoradiography film (Carestream Health Inc., Rochester, 
NY). The exposure time varied between 4 to 14 days depending on the riboprobe and 
brain region. 
In Situ Hybridization Analyses 
 The autoradiography films were analyzed using densitometry in ImageJ (NIH, 
Bethesda, MD), as described in Ketchesin et al. (2016). Briefly, a set of macros were 
used that enabled background selection and creation of a mask so that only signal >3.5 
standard deviations above background is measured. For each brain region, mean optical 
density (mean OD), area, and integrated optical density (IOD; mean OD x area of signal) 
were calculated. Adjacent cresyl violet-stained sections were used to select brain regions 
of interest, based on Paxinos and Franklin, 2001. Brain regions analyzed included the 
















Figure 4.1 – Schematic of CIE paradigms in each experiment. In Experiment 1 (A), male C57BL6/J 
mice in the CIE group were exposed to ethanol vapor for 16 hours/day for 4 days followed by 3 days of 
abstinence. The CTL group was exposed to air instead of ethanol vapor. This pattern of exposure was 
repeated for a total of 4 weekly cycles. Following the last vapor exposure, the mice were sacrificed at the 
following time points: 8, 72 hours, and 5 days. A group of mice were also sacrificed at hour 0, but were 
later removed from analyses due to elevated corticosterone levels in the CTL group at this time point. In 
Experiment 2 (B), C57BL6/J mice were trained to establish stable baseline drinking with a limited access, 
2-bottle choice paradigm. Once stable drinking was established, mice were exposed to CIE or air exposure 
(as in Experiment 1) alternating with 5-day limited access drinking sessions. Each session consisted of 2-
hour access to 15% ethanol and tap water. Both the CIE and CTL groups received ethanol during these 
drinking sessions. Following the fifth vapor exposure, mice were sacrificed at the following time points: 0, 
8, 72 hours, and day 8 (day 5 of the 5-day drinking session after 3 days of abstinence). For the day 5-time 
point, one group of mice received limited access to alcohol during the last 5-day drinking session, while the 
other group did not receive access to alcohol during this 5-day time period (“Day 5 +/- EtOH” in figure). In 
Experiment 3 (C), male CRH-BP KO and wild-type mice were exposed to a 4-cycle CIE procedure with 
alternating 5-day limited access drinking sessions as in Experiment 2. Half of the mice in each group were 
sacrificed 72 hours after the fourth CIE/air exposure (before the drinking session), and the other half were 
sacrificed on day 5 of test 4 (before 5-day drinking). 
Experiment 1: CIE exposure without drinking sessions A 
Experiment 2: CIE exposure with drinking sessions 
Experiment 3: CIE exposure with drinking sessions to evaluate voluntary 





nucleus of the thalamus (aPVT), amygdala [basolateral (BLA), central nucleus (CeA), 
and basomedial (BMA)], and VTA.  
Statistical Analysis 
A 2-way analysis of variance (ANOVA) was used to analyze the data, and 
Bonferroni post hoc analyses were performed for multiple comparisons when 
appropriate. For Experiment 2 (CIE exposure with drinking sessions), two separate 
statistical analyses were performed for each brain region, as one group of mice received 
limited access to ethanol during the last 5-day drinking session, while the other group did 
not. The first analysis compared hours 0, 8, 72, and day 5 (no ethanol drinking) to 
determine the effects of ethanol deprivation on CRH-BP expression, whereas the second 
analysis compared day 5 (no ethanol access) with day 5 (ethanol access) to determine the 
effects of voluntary ethanol drinking on CRH-BP expression in dependent animals. All 
data are reported as means ± SEM and significant values were accepted at p<0.05 for all 
statistical tests. 
Results 
Experiment 1: Regulation of CRH-BP, CRH-R1, and CRH mRNA expression following 
CIE exposure (without drinking sessions) 
 To determine how CRH-BP, CRH-R1, and CRH are regulated within stress and 
reward pathways after forced CIE exposure, C57BL/6J mice underwent 4 cycles of CIE 
exposure (without drinking sessions; Figure 4.1A). Mice were sacrificed at various time 
points (8 hrs – peak withdrawal, 72 hrs, and 5 days) following the last vapor exposure 





















Table 4.1 – Summary of in situ hybridization data for CRH-BP following CIE exposure (without 
drinking sessions; Experiment 1). Values in the table are IODs and represent the mean ± SEM. Values 
within bolded lines represent independent experiments. IOD values should not be directly compared across 
independent experiments as riboprobe specific activity and exposure times are not equal. Significant main 
effects of treatment and post hoc tests are included in the table, while main effects of time are only included 
in the text.  +p < 0.01 main effect of treatment *p < 0.01 compared to respective CTL. BNST, bed nucleus 
of the stria terminalis; aPVT, anterior paraventricular nucleus of the thalamus, VTA, ventral tegmental 
area; PL mPFC, prelimbic medial prefrontal cortex; IL mPFC, infralimbic medial prefrontal cortex; BLA, 





 Time Point CTL CIE 
BNST 8 hrs 
72 hrs 
5 days 
79.5 ± 21.4 
60.3 ± 10.1 
67.7 ± 4.2 
103.5 ± 7.9 
66.9 ± 13.8 
95.6 ± 15.0 




565.6 ± 77.9 
397.6 ± 46.2 
444.0 ± 56.1 
350.4 ± 23.0* 
275.4 ± 37.5 
370.0 ± 33.5 




46.6 ± 3.7 
56.8 ± 1.1 
57.5 ± 3.0 
59.5 ± 4.7 
52.8 ± 4.4 
53.3 ± 4.0 




40.3 ± 2.4 
33.2 ± 2.8 
37.8 ± 1.4 
39.6 ± 5.0 
37.5 ± 4.1 
40.5 ± 7.4 




76.5 ± 8.1 
52.7 ± 6.2 
57.5 ± 4.8 
 
57.3 ± 7.2 
61.9 ± 6.1 








5 days  
 
148.7 ± 5.5 
174.4 ± 25.1 
195.4 ± 12.8 
127.3 ± 9.8 
149.5 ± 14.0 









11.8 ± 1.3 
13.9 ± 3.0 
14.9 ± 2.1 
8.4 ± 0.7 
12.1 ± 1.5 
14.4 ± 2.8 
BMA 8 hrs 
72 hrs 
5 days  
 
31.6 ± 2.2 
37.3 ± 7.1 
33.7 ± 3.4 
32.4 ± 3.1 
32.9 ± 3.0 







Table 4.2 - Summary of in situ hybridization data for CRH and CRH-R1 following CIE exposure 
(without drinking sessions; Experiment 1). Values in the table are IODs and represent the mean ± SEM. 
Values within bolded lines represent independent experiments. IOD values should not be directly compared 
across independent experiments as riboprobe specific activity and exposure times are not equal. Significant 
main effects of time are not included in the table (see text). ND, not detected. 
 
  
 CRH CRH-R1 
 Time Point CTL CIE CTL CIE 
BNST 8 hrs 
72 hrs 
5 days 
450.5 ± 20.6 
356.2 ± 13.3 
427.8 ± 16.7 
427.4 ± 21.6 
370.8 ± 17.4 
397.1 ± 16.4 
145.1 ± 30.8 
89.2 ± 6.5 
149.4 ± 47.1 
112.3 ± 17.3 
95.9 ± 18.8 
76.9 ± 10.3 




78.3 ± 12.3 
50.2 ± 9.5 
50.2 ± 13.2 
69.0 ± 8.5 
41.0 ± 3.3 














26.6 ± 1.4 
24.6 ± 2.1 
28.1 ± 1.9 
27.8 ± 2.0 
24.0 ± 1.1 














23.6 ± 2.2 
27.9 ± 5.6  
16.1 ± 1.3 
20.8 ± 2.0 
24.3 ± 2.5 









63.0 ± 6.0 
36.8 ± 2.2 
42.0 ± 3.5 
56.3 ± 2.7 
41.2 ± 2.9 
40.4 ± 2.1 
7.2 ± 0.7 
7.4 ± 0.7 
5.0 ± 0.3 
6.3 ± 0.9 
6.9 ± 1.5 
5.6 ± 0.4 
BMA 8 hrs 
72 hrs 






17.7 ± 2.8 
19.7 ± 2.1 
9.6 ± 0.9 
15.5 ± 2.6 
13.6 ± 2.4 
13.2 ± 1.2 
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CRH mRNA expression between CIE and CTL mice in the BNST, aPVT, VTA, mPFC, 
and amygdala. Results for CRH-BP mRNA expression are shown in Table 4.1; Results 
for CRH and CRH-R1 mRNA expression are shown in Table 4.2. 
 In the BNST, CRH-BP and CRH-R1 mRNA expression (IOD) were analyzed 
between Bregma coordinates -0.10 and -0.34 mm (where expression is highest), as 
described previously (Ketchesin et al., 2016). CRH IOD was analyzed between 
coordinates 0.62 and -0.34 mm. A 2-way ANOVA revealed a trend for a main effect of 
treatment (CIE vs CTL) for CRH-BP IOD in the BNST, but this did not reach statistical 
significance (Table 4.1; F (1, 24) = 2.98, p = 0.097). No significant main effects or 
interactions were observed for CRH-R1 expression in the BNST (Table 4.2). A 
significant main effect of time point was observed for CRH expression in the BNST (F 
(2, 21) = 7.90, p < 0.01), however no treatment effects were detected (Table 4.2). In the 
aPVT, CRH-BP and CRH IOD were analyzed between Bregma coordinates -0.22 and -
0.46 mm, where expression is highest. A 2-way ANOVA revealed a significant main 
effect of treatment for CRH-BP IOD in the aPVT (Table 4.1; F (1,22) = 11.58, p < 0.01). 
Post hoc analyses showed that CRH-BP expression is significantly decreased in the aPVT 
of CIE mice compared to CTL mice at hour 8 (Figure 4.2; p < 0.01). A significant main 
effect of time point was observed for CRH expression in the aPVT (F (2, 24) = 6.37, p < 
0.01), but no main effect of treatment was detected (Table 4.2). 
 In the VTA, CRH-BP IOD was analyzed between coordinates -3.28 and -3.52 mm 
(mid-to-posterior VTA) and CRH-R1 IOD was analyzed between coordinates -2.92 and -
3.64 mm, as described previously (Ketchesin et al., 2016). No significant main effects or 














Figure 4.2 – CRH-BP mRNA expression is decreased in the aPVT of ethanol-treated mice following 
withdrawal from CIE (without drinking; Experiment 1). In situ autoradiograms (A) comparing CRH-
BP mRNA expression in CIE mice to CTL mice at 8 hours following last vapor exposure. A 2-way 
ANOVA revealed a significant main effect of treatment for CRH-BP IOD in the aPVT (B). Post hoc 
analyses showed that CRH-BP expression is significantly decreased in the aPVT of CIE mice compared to 
CTL mice at hour 8. Data represent the mean ± SEM. **p < 0.01 main effect of treatment; #p < 0.01 
compared to respective CTL group.  
  
































and 4.2). In the mPFC, CRH-BP mRNA expression was analyzed between Bregma 
coordinates 2.34 and 1.54 mm for PL mPFC and between coordinates 1.98 and 1.54 mm 
for IL mPFC). A 2-way ANOVA did not reveal significant main effects or interactions 
for CRH-BP expression in the PL or IL mPFC (Table 4.1).  
Lastly, in the BLA/lateral amygdala (LA), CeA, and basomedial amygdala 
(BMA), CRH-BP and CRH-R1 expression were analyzed from Bregma coordinates -0.94 
to -1.82 mm, while CRH expression was analyzed from coordinates -0.82 to -1.82 mm in 
the CeA. No significant main effects or interactions were observed for CRH-BP or CRH-
R1 expression in the CeA and BMA (Tables 4.1 and 4.2). In the BLA, significant main 
effects of time point were detected for CRH-BP (F (2, 23) = 6.91, p < 0.01) and CRH-R1 
(F (2, 20) = 3.58, p < 0.05), however main effects of treatment were not observed.  In the 
CeA, there was a significant main effect of time point for CRH expression (F (2, 23) = 
24.72, p < 0.001), but no main effect of treatment (Table 4.2). 
Experiment 2: Regulation of CRH-BP mRNA expression following CIE exposure (with 
drinking sessions) 
To determine whether voluntary intermittent ethanol drinking alters the regulation 
of CRH-BP in CIE, C57BL/6J mice underwent 4 cycles of CIE exposure with 5 days of 
limited access ethanol drinking between each vapor cycle (Figure 4.1B). Mice were 
sacrificed at various time points (hours 0, 8, 72 and day 5 of the 5-day drinking session) 
following the fifth vapor exposure and in situ hybridization was performed to compare 
changes in CRH-BP mRNA expression between CIE and CTL mice in the BNST, aPVT, 
VTA, mPFC, and amygdala. Given that one group of mice received limited access to 






























Table 4.3 – Summary of in situ hybridization data for CRH-BP following CIE exposure (with 
drinking sessions; Experiment 2). Values in the table are IODs and represent the mean ± SEM. IOD 
values within bolded lines represent independent experiments and should not be directly compared across 
independent experiments as riboprobe specific activity and exposure times are not equal. Significant main 
effects of treatment and post hoc tests are included in the table, while main effects of time are only included 
in the text.  +p < 0.05 main effect of treatment. #p < 0.05 compared between CIE 5 days (-EtOH) and CIE 5 
days (+ EtOH). *p < 0.05 compared to respective CTL group. 
CRH-BP 
 Time Point CTL CIE 
BNST 0 hrs 
8 hrs 
72 hrs 
5 days (- EtOH) 
5 days (+ EtOH) 
80.5 ± 18.6 
93.3 ± 15.3 
99.5 ± 14.9 
75.9 ± 10.8 
108.7 ± 21.8 
135.6 ± 22.7 
107.9 ± 28.8 
93.2 ± 7.0 
129.8 ± 21.5 
98.4 ± 13.4 
aPVT 0 hrs 
8 hrs 
72 hrs 
5 days (- EtOH) 
5 days (+ EtOH) 
470.9 ± 48.0 
518.9 ± 71.9 
368.9 ± 49.3 
417.5 ± 26.9 
451.5 ± 54.3 
554.7 ± 68.7 
465.8 ± 66.8 
444.6 ± 46.4 
518.7 ± 48.9 
344.1 ± 22.0 
VTA 0 hrs 
8 hrs 
72 hrs 
5 days (- EtOH) 
5 days (+ EtOH) 
83.7 ± 6.0 
105.8 ± 10.2 
79.3 ± 7.6 
111.9 ± 19.4 
89.3 ± 8.3 
81.0 ± 13.7 
75.9 ± 2.8 
84.0 ± 5.0 
70.1 ± 4.4 * 
102.5 ± 10.2 
PL mPFC 0 hrs 
8 hrs 
72 hrs 
5 days (- EtOH) 
5 days (+ EtOH) 
122.9 ± 11.0 
97.2 ± 7.9 
124.7 ± 19.8 
121.7 ± 11.0 
90.8 ± 10.1 
91.8 ± 11.6 
108.8 ± 8.7 
114.7 ± 7.5 
96.8 ± 8.1 
122.8 ± 9.2 
IL mPFC 0 hrs 
8 hrs 
72 hrs 
5 days (- EtOH) 
5 days (+ EtOH) 
168.5 ± 26.4 
137.3 ± 8.9 
195.9 ± 33.9 
168.2 ± 15.1 
144.2 ± 19.9 
131.8 ± 14.3 
144.7 ± 11.0 
168.9 ± 12.6 
144.5 ± 14.6 









5 days (- EtOH) 
5 days (+ EtOH) 
 
140.8 ± 17.2 
146.7 ± 19.1 
165.9 ± 19.3 
138.6 ± 31.6 
116.0 ± 8.6 
114.7 ± 16.8 
182.2 ± 18.8 
138.2 ± 14.5 
154.4 ± 15.2 









5 days (- EtOH) 
5 days (+ EtOH) 
 
10.1 ± 1.8 
9.8 ± 1.2 
10.0 ± 1.9 
7.8 ± 0.9 
8.3 ± 1.3 
 
7.9 ± 0.6 
11.8 ± 2.1 
10.1 ± 1.5 
9.9 ± 1.4 
7.8 ± 0.9 
BMA 0 hrs 
8 hrs 
72 hrs 
5 days (- EtOH) 
5 days (+ EtOH) 
33.5 ± 1.9 
32.9 ± 3.2 
26.8 ± 3.3 
28.1 ± 5.5 
23.5 ± 1.8 
26.0 ± 3.2 
41.6 ± 4.7 
27.7 ± 4.2 
27.6 ± 1.3 
22.7 ± 2.6 
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statistical analyses were performed for each brain region. The first analysis compared 
hours 0, 8, 72, and day 5 (no ethanol drinking) to determine the effects of ethanol 
deprivation on CRH-BP expression in dependence, whereas the second analysis 
compared day 5 (no ethanol access) with day 5 (ethanol access) to determine the effects 
of voluntary ethanol drinking on CRH-BP expression in dependence. 
 Bregma coordinates for in situ hybridization analyses of CRH-BP expression 
were the same as Experiment 1 above. In the BNST, a 2-way ANOVA [hrs 0, 8, 72, & 
day 5 (no EtOH)] revealed a significant main effect of treatment (CIE vs CTL) for CRH-
BP IOD in the BNST (F (1, 28) = 4.41, p < 0.05), indicating increased CRH-BP 
expression in the BNST of CIE mice compared to CTL mice following ethanol 
deprivation (Table 4.3). However, post hoc analyses did not reveal significant differences 
at any particular time point. A 2-way ANOVA of day 5 +/- EtOH did not reveal 
significant main effects or interactions for CRH-BP IOD in the BNST. 
 In the aPVT, a 2-way ANOVA [hrs 0, 8, 72, & day 5 (no EtOH)] did not show 
significant main effects or interactions (Table 4.3). However, a 2-way ANOVA of day 5 
+/- EtOH revealed a significant interaction (F (1, 16) = 6.65, p < 0.02). Post hoc analyses 
showed that CRH-BP expression is significantly decreased in the aPVT of CIE mice that 
received ethanol during the 5-day drinking session compared to CIE mice that did not 
receive ethanol access during this time period (p < 0.05). 
 In the VTA, a 2-way ANOVA [hrs 0, 8, 72, & day 5 (no EtOH)] revealed a 
significant main effect of treatment (CIE vs CTL) for CRH-BP (Table 4.3 and Figure 4.3; 
F (1, 32) = 6.45, p < 0.05). Post hoc analyses showed that CRH-BP expression is 
























Figure 4.3 – CRH-BP mRNA expression is decreased in the VTA of CIE mice that did not receive 
voluntary access to ethanol during the last 5-day drinking session (Experiment 2). In situ 
autoradiograms (A) comparing CRH-BP mRNA expression in CIE mice to CTL mice on day 5 of the 5-day 
drinking session (no access to ethanol). A 2-way ANOVA [hrs 0, 8, 72, & day 5 (no EtOH)] revealed a 
significant main effect of treatment for CRH-BP IOD in the VTA (B; see text for details). Post hoc analyses 
showed that CRH-BP expression is significantly decreased in the VTA of CIE mice that not receive ethanol 
during the 5-day drinking session compared to respective CTL mice. A 2-way ANOVA of day 5 (+/- 
EtOH) revealed a significant interaction (C). As observed in (B), CRH-BP expression was significantly 
decreased in the VTA of CIE mice that not receive ethanol during the 5-day drinking session compared to 
respective CTL mice. Data represent the mean ± SEM. + p < 0.05 main effect of treatment; *p < 0.05 












































































day drinking session compared to respective CTL mice (Figure 4.3; p < 0.05). A 2-way 
ANOVA of day 5 +/- EtOH revealed a significant interaction (Figure 4.3; F (1, 16) = 
5.32, p < 0.05). As observed in the previous analysis, CRH-BP expression was 
significantly decreased in the VTA of CIE mice that did not receive ethanol during the 5-
day drinking session compared to respective CTL mice (Figure 4.3; p <0.05).  
In the mPFC, a 2-way ANOVA [hrs 0, 8, 72, & day 5 (no EtOH)] did not show 
significant main effects or interactions for CRH-BP IOD in the PL or IL mPFC (Table 
4.3). However, when CRH-BP mean OD was analyzed in the PL mPFC, a 2-way 
ANOVA [hrs 0, 8, 72, & day 5 (no EtOH)] revealed a significant interaction (F (3, 31) = 
3.42, p < 0.05) and main effect of treatment (data not shown; F (1, 31) = 7.05, p < 0.05). 
Post hoc analyses showed that CRH-BP mean OD was significantly decreased in the PL 
mPFC of CIE mice compared to CTL mice at the hour 0 time point (p < 0.01). Similarly, 
when CRH-BP mean OD was analyzed in the IL mPFC, a 2-way ANOVA [hrs 0, 8, 72, 
& day 5 (no EtOH)] showed a significant main effect of treatment (data not shown F (1, 
32) = 6.03, p < 0.05). However, post hoc analyses did not reveal significant differences at 
any particular time point. A 2-way ANOVA of day 5 +/- EtOH revealed a significant 
interaction (F (1, 16) = 6.45, p < 0.05) for CRH-BP IOD in the PL mPFC, but no 
significant post hoc effects were observed. No significant main effects or interactions 
were observed for CRH-BP IOD in the IL mPFC in the day 5 +/- EtOH comparison. 
Lastly, in the BLA and CeA, a 2-way ANOVA [hrs 0, 8, 72, & day 5 (no EtOH)] 
did not reveal significant main effects or interactions for CRH-BP IOD in these regions 
(Table 4.3). In the BMA, a significant main effect of time point was detected for CRH-
BP IOD (F (3, 29) = 4.19, p < 0.05), however a main effect of treatment was not   
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observed. No significant main effects or interactions were detected for CRH-BP IOD in 
the BLA, CeA, or BMA in the day 5 +/- EtOH comparison.  
Experiment 3: Functional role of CRH-BP in CIE (with drinking sessions) using CRH-BP 
KO mice 
To test the functional role of CRH-BP in alcohol dependence, male CRH-BP KO 
mice and wild-type littermates underwent 4 cycles of CIE exposure with 5-day drinking 
sessions between each vapor cycle (Figure 4.1C) to compare voluntary ethanol intake 
between the two genotypes. Male C57BL6/J mice were also included as internal positive 
controls in this drinking paradigm. As expected, C57BL6/J mice showed an increase in 
voluntary ethanol consumption after CIE exposure (compared to CTL mice) at tests 2 and 
3 (p < 0.05; Figure 4.4). Similarly, male wild-type mice showed increases in ethanol 
consumption (compared to CTL mice) at tests 1 and 2 (p < 0.05). There was a trend for 
an increase in ethanol consumption in C57BL6/J and wild-type mice at test 4, but this did 
not reach statistical significance, likely due to the lower sample size at this time period 
(half the mice were sacrificed before the 5-day drinking session). Interestingly, CRH-BP 
KO mice exposed to CIE did not show increases in ethanol consumption at any test 
period, suggesting that the total absence of CRH-BP may prevent increases in 
dependence-induced alcohol consumption (Figure 4.4). 
Discussion 
In the current study, we determined the regulation of CRH-BP expression within 
stress and reward pathways in two variations of the CIE paradigm, a mouse model of 

















Figure 4.4 – CRH-BP KO mice do not show increases in voluntary ethanol consumption following 
CIE exposure (Experiment 3). C57BL6/J mice show increases in ethanol consumption after CIE exposure 
(compared to CTL mice) at tests 2 and 3. Similarly, male wild-type mice display increases in ethanol 
consumption (compared to CTL mice) at tests 1 and 2. There was a trend for increased ethanol 
consumption in C57BL6/J and wild-type mice at test 4, but this did not reach statistical significance, likely 
due to the lower sample size at this time period (half the mice were sacrificed before the 5-day drinking 
session). CRH-BP KO mice exposed to CIE do not show increases in ethanol consumption at any test 
period. Data represent the mean ± SEM. *p < 0.05 compared to respective CTL group. 
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drinking and was used to study the effects of forced CIE exposure on CRH-BP 
expression. The second CIE paradigm included periods of limited access to ethanol and 
was used to study the effects of voluntary ethanol drinking on CRH-BP expression in 
dependence. In the CIE paradigm without voluntary access to ethanol, we found a 
significant decrease in CRH-BP mRNA expression (IOD) in the aPVT of CIE mice 
compared to CTL mice at hour 8 of withdrawal, suggesting altered CRH signaling in this 
region or projection areas. There were no detectable changes in CRH or CRH-R1 mRNA 
levels in all brain regions analyzed. In the CIE paradigm with alternating drinking 
sessions, we discovered a decrease in CRH-BP expression in the VTA of CIE mice that 
did not receive ethanol during the last 5-day drinking session. Additionally, CRH-BP 
expression is increased in the BNST of CIE mice compared to CTL mice, suggesting 
differential regulation of CRH-BP between brain regions and CIE paradigms. Finally, 
CRH-BP KO mice exposed to CIE did not display increases in alcohol consumption, 
suggesting that complete loss of CRH-BP in brain and pituitary may prevent increased 
alcohol consumption during dependence.  
aPVT 
 Strikingly, we observed the largest change in CRH-BP expression in alcohol 
dependence the PVT, a stress-responsive brain region that interacts with multiple brain 
regions of the stress and reward system (reviewed in Hsu et al., 2014; Kirouac, 2015). 
We found that CRH-BP mRNA expression is significantly decreased in the aPVT of CIE 
mice (without drinking sessions), particularly at 8 hours following the last vapor 
exposure, suggesting dysregulation of the CRH system in this region during peak alcohol 
withdrawal. These results are consistent with recent studies that have implicated the PVT 
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in reward and drug seeking. For example, a number of studies have shown a role for the 
PVT in cue-reward learning, including both food- and drug-associated cues (reviewed in 
James and Dayas, 2013; Haight and Flagel, 2014; Martin-Fardon and Boutrel, 2012). 
Additionally, lesions of the PVT have been shown to prevent context-induced 
reinstatement of alcohol seeking (Hamlin et al., 2009).  
The role of the PVT in alcohol consumption appears to vary across the structure’s 
anatomical subdivisions. The PVT consists of both an anterior (aPVT) and a posterior 
(pPVT) subdivision, with some differences in projections between the two subregions. In 
a recent study by Barson et al., 2015, the authors showed that both voluntary ethanol 
drinking and ethanol administration via oral gavage increased neuronal activation of the 
aPVT, but not the pPVT, in rats. The authors then showed that voluntary ethanol 
consumption was enhanced by orexin administration into the aPVT, but not the pPVT 
(Barson et al., 2015). Furthermore, administration of an orexin receptor 2 antagonist into 
the aPVT, but not the pPVT, decreased voluntary ethanol consumption, suggesting that 
the orexin system in the aPVT plays an important role in excessive ethanol intake 
(Barson et al., 2015). Consistent with these findings, we observe alterations in CRH-BP 
mRNA expression in the aPVT following CIE; CRH-BP mRNA expression was not 
detected in the pPVT.  
 While we observed a decrease in CRH-BP mRNA expression in the aPVT at hour 
8 in the CIE paradigm without drinking sessions, we did not detect changes in expression 
at this time point in the CIE paradigm with drinking sessions, suggesting that changes in 
CRH-BP during peak withdrawal are specific to forced CIE exposure. However, we 
found that CRH-BP expression is significantly decreased in the aPVT of CIE mice that 
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received ethanol during the last 5-day drinking session compared to CIE mice that did not 
receive ethanol during this time period, suggesting that CRH-BP expression in the aPVT 
may also be regulated by voluntary ethanol consumption in dependent mice. It is 
important to note, however, that the decrease in CRH-BP expression was not significant 
when compared to respective CTL mice that also received ethanol during the 5-day 
drinking sessions. A decrease in CRH-BP expression in the aPVT is suggestive of 
increased CRH signaling in this region or projection areas. The PVT is mainly composed 
of glutamatergic excitatory projection neurons and does not contain GABAergic 
interneurons (Kirouac, 2015). Preliminary dual in situ hybridization experiments from 
our laboratory suggest that CRH-BP is moderately colocalized with VGLUT in this 
region, suggesting its presence in excitatory projection neurons (unpublished results). 
Thus, CRH-BP-expressing neurons likely project to regions of the stress and reward 
system where the CRH receptors are highly expressed, including the amygdala, BNST, 
and mPFC. Alterations in CRH-BP expression during alcohol dependence may lead to 
altered CRH receptor signaling in these projection areas, which may contribute to 
excessive alcohol intake. Ongoing experiments are further characterizing the 
colocalization of CRH-BP with other peptides, such as CRH, which may suggest co-
release into regions of the stress and reward system. 
VTA   
 In the CIE paradigm with alternating drinking sessions, we observed a significant 
decrease in CRH-BP expression in the VTA of CIE mice that did not receive ethanol 
during the last 5-day drinking session. This decrease in expression occurred 8 days 
following the last vapor exposure, and was not observed at earlier time points (0, 8, or 72 
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hours), indicating that CRH-BP expression in the VTA may be altered during long-term 
abstinence from ethanol. Future studies should include later time points to determine if 
this change is long-lasting and occurring at later time points in abstinence. A recent study 
from our laboratory revealed a trend for a decrease in CRH-BP expression in the VTA 
after binge drinking in mice (Ketchesin et al., 2016). The present study extends these 
findings by revealing that abstinence from CIE regulates the expression of CRH-BP in 
the VTA. A decrease in CRH-BP expression in the VTA during abstinence could lead to 
altered CRH receptor activation, which may contribute to vulnerability to stress-induced 
relapse during abstinence. In support of this, previous studies have shown that CRH-BP, 
CRH-R1, and CRH-R2 in the VTA regulate stress-induced reinstatement to cocaine 
seeking in rodents (Blacktop et al., 2011; Wang et al., 2007). Additional studies have 
established a role for the CRH system in the VTA in excessive alcohol consumption. For 
example, binge drinking in mice increases CRH-R1 activity, as determined by increased 
CRH-R1-mediated potentiation of NMDA currents by CRH (Sparta et al., 2013). 
Furthermore, CRH-R1 antagonist administration into the VTA decreases binge drinking 
(Rinker et al., 2017; Sparta et al., 2013), excessive drinking in mice exposed to a 2-bottle 
choice intermittent access to alcohol paradigm (Hwa et al., 2013), and social stress-
escalated intermittent alcohol drinking (Hwa et al., 2016). The role of CRH-R2 is less 
clear, as recent reports have suggested that administration of a CRH-R2 antagonist or 
CRH-R2 agonist into the VTA can decrease binge drinking (Albrechet-Souza et al., 2015; 
Rinker et al., 2017). Interestingly, administration of CRH6-33 into the VTA (but not the 
CeA) decreased drinking, suggesting that VTA CRH-BP may normally potentiate 
drinking (Albrechet-Souza et al., 2015). These data indicate that role of CRH-BP in 
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excessive alcohol drinking may be brain region- and/or CRH receptor subtype-specific. 
Future studies should carefully examine the interactions between CRH-BP and CRH-
R1/CRH-R2 in the VTA to better understand the role of the CRH system in this region in 
modulating ethanol consumption.  
mPFC 
 In the mPFC, we did not observe changes in CRH-BP IOD in the CIE paradigm 
with alternating drinking sessions. However, we detected a significant decrease in CRH-
BP mean OD in the PL mPFC of CIE mice compared to CTL mice at hour 0 following 
last vapor exposure. In support of this finding, previous studies from our laboratory have 
found that CRH-BP mRNA expression is significantly decreased in the PL mPFC after 
repeated cycles of binge drinking (Ketchesin et al., 2016). We have also observed that 
CRH-BP is highly expressed in GABAergic inhibitory interneurons of the mPFC, 
particularly somatostatin interneurons (unpublished results). The colocalization between 
CRH-BP and somatostatin was recently confirmed in a study that suggests CRH-BP may 
be released from somatostatin interneurons to regulate CRH-R1 activation of excitatory 
pyramidal neurons (Li et al., 2016). Thus, a decrease in CRH-BP expression suggests 
increased free CRH levels, and therefore increased CRH-R1 activation of pyramidal 
neurons. Given the connectivity of the mPFC in stress and reward pathways, alterations 
in PFC activity could influence behaviors such as alcohol seeking.  
BNST 
In the current study, we demonstrated an overall increase in CRH-BP expression 
(main effect of treatment) in the BNST of CIE mice compared to CTL mice following 
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ethanol deprivation in the CIE paradigm with alternating drinking sessions. Similarly, we 
also observed a trend for an overall increase in CRH-BP expression in the BNST of CIE 
mice in the CIE paradigm without drinking sessions. Dysregulation of the CRH system in 
the BNST has been previously linked to excessive alcohol consumption. For example, 
CRH regulates excitatory drive on BNST neurons that project to the VTA, a pathway that 
is potentiated during alcohol withdrawal (Silberman et al., 2013). Additionally, a recent 
study by Rinker et al. (2017) found that chemogenetic inhibition of VTA-projecting 
BNST CRH neurons significantly decreased binge drinking. It would be interesting for 
future studies to determine whether both CRH-BP and CRH are present in the same 
BNST-to-VTA projection neurons. Interestingly, the BNST is the only region where we 
detected an increase in CRH-BP expression after CIE, indicating differential regulation of 
CRH-BP between brain regions. In addition to CRH-R1 and CRH-BP, CRH-R2 is highly 
expressed in the posterior BNST and has been shown to play a role in recovery from 
stress in this region (Henckens et al., 2016). Future studies should investigate the 
interactions between CRH-BP and CRH, CRH-R1 and CRH-R2 in the BNST to gain 
insight into the mechanisms of differential CRH-BP regulation during alcohol 
dependence.  
Amygdala 
 In the amygdala, we did not observe any changes in CRH, CRH-R1, or CRH-BP 
mRNA expression between CIE and CTL mice. However, there were significant main 
effects of time point detected for CRH-BP and CRH-R1 in the BLA and CRH in the CeA 
after CIE (without drinking sessions). Interestingly, for CRH-BP in the BLA and CRH in 
the CeA, these effects were driven by the hour 8 time point when the mice were 
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sacrificed at a different time of day. CRH-BP mRNA expression was lowest in the BLA 
at the hour 8 time point, regardless of treatment, and CRH mRNA expression was highest 
in the CeA at hour 8, suggesting circadian regulation of expression. Future studies should 
take time of day and varying glucocorticoid levels into consideration when measuring 
CRH and CRH-BP mRNA expression in the amygdala. 
CRH-BP KO mice in CIE (with drinking sessions) 
In this study, we also sought to determine the functional role of CRH-BP in CIE 
using CRH-BP KO mice. These mice completely lack CRH-BP throughout the brain and 
pituitary. We found that male wild-type and C57BL6/J control mice showed the hallmark 
increases in ethanol consumption across cycles of CIE. Interestingly, we found that CRH-
BP KO mice exposed to CIE did not show increased alcohol consumption at any test 
cycle, suggesting that total absence of CRH-BP may prevent increased alcohol 
consumption during dependence. In support of this, a recent study found that intra-VTA 
(but not CeA) administration of the CRH-BP ligand inhibitor, CRH6-33, decreased binge 
drinking in a drinking in the dark paradigm (Albrechet-Souza et al., 2015). Furthermore, 
when CRH6-33 was injected at a subeffective dose in combination with a low dose CRH-
R2 antagonist in the VTA, there was a significant reduction in 2-bottle choice drinking 
(Albrechet-Souza et al., 2015), suggesting a potential interaction between CRH-BP and 
CRH-R2 in this region. Additionally, a recent study found that selective knockdown of 
CRH-BP expression in the CeA decreased ethanol consumption in ethanol-dependent rats 
(Haass-Koffler et al., 2016). Overall, these data suggest that the role of CRH-BP in 
excessive alcohol consumption may depend upon brain region (CRH receptors expressed 
and G-protein signaling) and drinking paradigm. The current study suggests that total 
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absence of CRH-BP in the brain and pituitary prevents dependence-induced increases in 
alcohol consumption. Future studies should focus on site-specifically manipulating CRH-
BP (knockdown and/or overexpress) to further elucidate its role in alcohol dependence. 
 Overall, the current results expand our knowledge on the role of CRH-BP in 
alcohol dependence. The regulation of CRH-BP depends on brain region and CIE 
paradigm, with the presence or absence of voluntary ethanol access as a determining 
factor. In the CIE paradigm without voluntary access to ethanol, we found that CRH-BP 
mRNA expression is decreased in the aPVT of CIE mice at peak alcohol withdrawal. In 
the CIE paradigm with alternating drinking sessions, we detected a decrease in CRH-BP 
expression in the VTA of CIE mice after 8 days of abstinence. In this paradigm, CRH-BP 
expression is increased in the BNST of CIE mice compared to CTL mice. The differences 
in CRH-BP regulation between CIE paradigms is likely due to the presence or absence of 
voluntary drinking and perhaps the length of withdrawal between each vapor exposure. 
Additionally, the CTL mice in these experiments are not ethanol-naïve. CRH-BP 
expression changes in dependence may result in altered CRH signaling and contribute to 
excessive ethanol intake and/or perhaps vulnerability to stress-induced relapse. Future 
studies should focus on characterizing the cell type-specific expression of CRH-BP in 
stress and reward pathways to better understand the circuits and mechanisms of CRH-BP 
regulation in alcohol consumption. Finally, CRH-BP KO mice exposed to CIE did not 
exhibit increases in alcohol consumption, indicating that complete absence of CRH-BP 
may prevent dependence-induced increases in alcohol consumption. Future studies 
should use viral and genetic approaches to conditionally and site-specifically knockdown 
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or overexpress CRH-BP (in a cell type-specific manner) to further understand its role in 
alcohol dependence.  
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CRH-BP Modulation of CRH Receptor Signaling via cAMP and Calcium 
Abstract 
 Corticotropin releasing hormone (CRH) is the main central nervous system 
regulator of the mammalian stress response. The CRH system includes CRH and a 
number of CRH-like ligands, including urocortin (Ucn) I, Ucn II, and Ucn III. CRH and 
the urocortins produce their effects through two G protein-coupled receptors, CRH 
receptor 1 (CRH-R1) and CRH receptor 2 (CRH-R2). CRH receptors couple largely to 
Gαs, but can also couple to other G proteins in specific tissues or cell types, including 
Gαq, Gαo, and Gαi. The CRH system also includes the CRH-binding protein (CRH-BP), a 
secreted glycoprotein that binds CRH and Ucn I with an equal or greater affinity than the 
CRH receptors. Studies in cell culture suggest that CRH-BP inhibits CRH-R1- and CRH-
R2- mediated increases in cAMP. In contrast, other studies have suggested a facilitatory 
role for CRH-BP in enhancing CRH-R2 activity in the VTA, particularly through the 
PLC/PKC signaling pathway. To better understand the mechanisms of CRH-BP 
modulation of CRH receptor activity in a physiologically relevant cell culture system, we 
performed CRH receptor cAMP signaling assays in LβT2 cells, a mouse pituitary 
gonadotroph cell line that expresses endogenous CRH receptors. We demonstrate that 
preincubation of CRH or Ucn I with CRH-BP drastically reduces cAMP levels, 
supporting an inhibitory role for CRH-BP at CRH receptors in this cell line. Treatment 
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with CRH6-33 in combination with CRH and CRH-BP produced a moderate induction of 
cAMP, suggesting that CRH6-33 is displacing CRH from CRH-BP, resulting in increased 
CRH receptor signaling. In a separate set of experiments, we optimize an assay for CRH 
receptor signaling though Gαq using stably transfected HEK293 cells expressing CRH-R1 
(HEK-R1) or CRH-R2 (HEK-R2). Using a fluorogenic calcium-binding dye to measure 
intracellular calcium levels, we find that various CRH receptor agonists (CRH, Ucn I, and 
sauvagine) increase calcium signaling in both cell lines (to different degrees). These 
studies will provide a platform for future studies to investigate the role of CRH-BP in 
modulating CRH receptor signaling through the Gαq/PLC/PKC signaling pathway. 
Introduction 
 The mammalian stress response is mediated by the corticotropin releasing 
hormone (CRH) system. The CRH system includes the 41-amino acid peptide CRH, as 
well as a number of other CRH-like ligands, including urocortin (Ucn) I, Ucn II, and Ucn 
III. CRH and the urocortins mediate their effects through two G protein-coupled 
receptors, CRH receptor 1 (CRH-R1) and CRH receptor 2 (CRH-R2). The CRH receptors 
share about 70% amino acid identity, but have distinct pharmacological profiles. CRH-
R1 binds CRH and Ucn I with very high affinity and Ucn II with a lower affinity (Jahn et 
al., 2004). CRH-R2 binds all three urocortins with high affinity and CRH with a 10-
100—fold lower affinity, thereby requiring higher concentrations of CRH than urocortin 
to be activated (Jahn et al., 2001; Jahn et al., 2004). Sauvagine, a CRH-like peptide 
isolated from frog, binds to both CRH-R1 and CRH-R2 with a very high affinity, similar 
to UcnI.  
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 Both CRH receptors couple largely to Gαs and activate cAMP/PKA signaling 
upon receptor binding. However, both CRH-R1 and CRH-R2 can also couple to other G 
protein in certain tissues or cell types, including Gαq, Gαo, and Gαi. Thus, depending on 
the cellular context, the CRH receptors can activate a diversity of signaling pathways, 
including cAMP/PKA, PLC/PKC, PKB/akt, and ERK/MAPK (reviewed in Dautzenberg 
and Hauger, 2002; Hillhouse and Grammatopoulos, 2006). Both CRH-R1 and CRH-R2 
have been shown to couple to both Gαs and Gαq in stably transfected HEK293 cells, 
stimulating transient calcium mobilization in addition to increased cAMP.  However, 
CRH-R1- and CRH-R2-stably transfected neuroblastoma (SK-N-MC) cells show only 
increased cAMP in response to CRH, with no detectable calcium release, emphasizing 
the importance of cellular context for G-protein coupling to the CRH receptors 
(Dautzenberg et al., 2004).  
 The CRH system also includes the CRH-binding protein (CRH-BP), a secreted 
glycoprotein that is structurally distinct from the CRH receptors, yet binds CRH and Ucn 
I with an equal or higher affinity than the receptors. The CRH-BP does not bind Ucn III, 
the CRH-R2 selective ligand. However, it does bind CRH6-33 with very high affinity, 
while this peptide does not bind to or activate either CRH receptor.  In rodents, CRH-BP 
is highly expressed in pituitary and brain, including cortex, hippocampus, amygdala, and 
ventral tegmental area (Chan et al., 2000; Potter et al., 1992). This CRH-BP expression 
profile localizes to multiple sites of CRH expression, several sites of CRH receptor 




 Based on this diverse expression profile, it is not surprising that a variety of 
functional roles have been postulated for CRH-BP. In an inhibitory role, CRH-BP 
reduces CRH receptor activation, likely by sequestering CRH or Ucn I and targeting them 
for degradation. Consistent with this role, CRH-BP reduces CRH-R1-mediated ACTH 
release from anterior pituitary cultures or AtT-20 cells (Cortright et al., 1995; Potter et 
al., 1991; Sutton et al., 1995). Furthermore, CRH-BP attenuates CRH-R1-mediated 
increases in cAMP activity (Boorse et al., 2006; Huising et al., 2008). A recent study 
from our laboratory demonstrates that CRH-BP also has an inhibitory effect on cAMP 
signaling at CRH-R2 (Figure 5.1; Ryan Evans, unpublished data). In this study, CRH-BP 
clearly attenuated CRH-mediated increases in cAMP activity in CHO cells stably 
transfected with CRH-R2 (Figure 5.1). In contrast to this inhibitory role, several recent 
studies with CRH6-33 suggested a potential facilitatory role for CRH-BP in enhancing 
CRH-R2 signaling, particularly in the VTA (Ungless et al., 2003). Strikingly, this 
positive effect at CRH-R2 was mediated via the PLC/PKC signaling pathway, suggesting 
that CRH-BP may play a role in CRH activation of CRH-R2 via Gαq.  Finally, other 
studies have suggested that the CRH-BP may help traffic CRH-R2 to the membrane 
(Slater et al., 2016) or have a CRH- and/or CRH receptor-independent role (Chan et al., 
2000). To fully elucidate the role(s) of the CRH-BP, a better understanding of its 
mechanisms of action is required, especially related to CRH receptor specificity, G-
protein and signaling pathway specificity, and cell type specificity. Additional studies are 
also needed to further characterize the actions of the CRH-BP ligand inhibitor CRH6-33 in 



















Figure 5.1 – CRH-BP attenuates CRH-R2-mediated increases in cAMP activity in CHO CRH-R2α 
cells. Experimental design (A) showing treatments in CHO cells stably transfected with CRH-R2α. Cells 
were treated with CRH alone (0.3 nM) or in the presence of CRH-BP (varying concentrations) and a cAMP 
assay was performed. CRH-BP was either pre-incubated with CRH for 30 minutes prior to cell treatment or 
added simultaneously with CRH (A).  In the absence of CRH-BP, CRH caused a robust induction of 
cAMP, which lasted for over 60 minutes (B & C). Pre-incubation of CRH with CRH-BP prior to cell 
treatment (B) drastically reduced CRH-induced increases in cAMP. With CRH-BP in molar excess over 
CRH (B), cAMP levels did not differ from basal. Under simultaneous treatment conditions (C), CRH-BP 
did not prevent cAMP induction at early time points, but inhibited cAMP at later time points. Modified 
from the dissertation of Ryan T. Evans (2011). 
 







To begin to probe the mechanisms of CRH-BP modulation of CRH receptor 
activity in a more physiologically relevant cell culture system, we performed CRH 
receptor signaling assays in LβT2 cells, a mouse pituitary gonadotroph cell line that 
expresses endogenous CRH-R1 and CRH-R2, but not CRH-BP (Ketchesin, unpublished 
data; Westphal et al., 2009). These cells were treated with CRH or Ucn I in the presence 
or absence of purified recombinant CRH-BP and assayed for changes in cAMP levels as 
an indicator of Gαs signaling.  Cells were also treated with CRH6-33 to confirm the role of 
this peptide in displacing ligand from CRH-BP and enhancing CRH receptor activation. 
Future studies will use receptor-specific agonists and antagonists to further explore CRH 
receptor activation via Gαs and Gαq in this cell line. Finally, we performed experiments to 
optimize an assay for CRH receptor signaling through Gαq using stably transfected 
HEK293 cells expressing CRH-R1 (HEK-R1) or CRH-R2 (HEK-R2). We assayed 
intracellular calcium levels using a fluorogenic calcium-binding dye in cells treated with 
CRH-receptor specific agonists. These studies will form the basis for future experiments 
to better characterize the role of CRH-BP in modulating CRH receptor activity through 
the PLC/PKC/calcium signaling pathway. 
Methods 
Cell culture 
LβT2 (mouse gonadotrope-like cells) were obtained from Dr. Pamela Mellon at 
University of California San Diego and maintained in DMEM (Life Technologies) + 10% 
fetal calf serum (FCS; Hyclone, Logan, UT). Stably transfected HEK293 cells expressing 
CRH-R1 or CRH-R2 (HEK-R1 and HEK-R2) were maintained in DMEM + 10% FCS + 
0.5 µg/ml puromycin and 100 µg/ml G418. All cells were grown at 37ºC in 5% CO2. 
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Purification of recombinant mCRH-BP HISV5 
Media (DMEM + 1% FBS + 0.5x ITS (insulin/transferrin/selenium, Gibco)) 
containing secreted CRH-BP was collected from mouse anterior pituitary corticotroph 
AtT-20 (subclone G7) cells stably transfected with CRH-BP HISV5 and grown to 70%-
100% confluence. Conditioned media was concentrated ~10-fold using Amicon-Ultra-4 
Filters (Millipore, Billerica, MA), and buffer exchanged with 1x Native Purification 
Buffer (NPB; 500mM NaCl, 50 mM sodium phosphate, pH 8) using the same filters. 
Buffer exchanged media was combined with 3 mL 50% Ni-NTA agarose (Invitrogen, 
Carlsbad, CA) and incubated overnight at 4ºC while rotating. After incubation, this 
mixture was loaded onto a column. The column was washed with 10 mL 1x NPB and 10 
mL NPB + 45 mM imidazole, and then eluted with 15 mL NPB + 250 mM imidazole. 
Fractions were analyzed via SDS-PAGE followed by ruby red staining (Spyro, Eugene, 
OR) to determine the purity and concentration of CRH-BP HISV5 in the elution 
fractions. 
cAMP assays 
LβT2 cells were plated (200,000 cells/well) onto 12-well plates and used 2-3 days 
after plating. Cells were washed once with DMEM and then pretreated with DMEM 
containing 1 mM isobutylmethylxanthine (IBMX; Sigma) for 1 hour at 37ºC to inhibit 
cAMP phosphodiesterase activity. The cells were treated with CRH (50nM), urocortin I 
(Ucn I, 50nM), CRH6-33 (300nM), or CRH-BP (150nM) alone or in combinations. All 
peptides and protein stocks were diluted in DMEM containing 1 mM IBMX (500ul/well), 
and cells were treated for 10 minutes which was previously determined to produce peak 
cAMP levels in these cells.  For treatments with CRH-BP in combination with CRH or 
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Ucn I, CRH-BP was preincubated with ligand for 30 minutes at 37ºC. Reactions were 
stopped after 10 min by removal of media and cell lysis with 500 µl 0.1 M HCl. The cell 
lysates were centrifuged at 600 g at room temperature for 5 min and the supernatants 
were stored at -20ºC until use. cAMP levels in the supernatants were determined using a 
Direct Cyclic AMP EIA Kit (ADI-901-066, Enzo Life Sciences, Ann Arbor, MI). 
Calcium assays  
HEK cells stably transfected with CRH-R1 (HEK-R1) or CRH-R2 (HEK-R2) 
were plated (80,000 cells/well) onto 96-well plates and used the next day. Following 
overnight incubation, media was removed and cells were incubated with 100 µl of the 
fluorogenic calcium-binding dye FluoForte loading solution (FLUOFORTE Calcium 
Assay Kit (51017); Enzo Life Sciences, Ann Arbor, MI). Cells were incubated for 45 
minutes at 37ºC and then 15 minutes at room temperature. Following incubation, the 
HEK-R1 and HEK-R2 cells were treated with CRH, Ucn I, sauvagine, and ATP (positive 
control) at various concentrations. Siliconized tubes and tips were used to prepare 
compounds. Fluorescence was monitored over time (excitation = 490 nm/emission = 525 
nm) using a FlexStation 3 Multiplate Reader (Molecular Devices, Sunnyvale, CA). 
Results 
The effects of CRH-BP and CRH6-33 on CRH-mediated increases in cAMP levels in LβT2 
cells 
 Numerous studies have shown that CRH and Ucn I increase cAMP levels in cells 
expressing endogenous CRH receptors or cells that have been stably transfected with 
CRH-R1 or CRH-R2 (Dautzenberg et al., 2004; Hillhouse and Grammatopoulos, 2006; 
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Seasholtz et al., 2009). Many fewer studies have examined the effects of CRH-BP on 
CRH-mediated cAMP signaling in transfected cells or those with endogenous CRH 
receptors. We examined the effect of CRH-BP on endogenous CRH receptor signaling in 
LβT2 cells. These cells have previously been shown to express both CRH-R1 and CRH-
R2 (Westphal et al., 2009); however, they do not express the CRH-BP (unpublished 
data). Cells were treated with CRH or Ucn I in the presence or absence of CRH-BP 
(and/or CRH6-33) and cAMP levels were determined as an indicator of Gαs activation 
upon receptor binding. As expected, ten-minute treatment of Ucn I (50 nM) caused a 
robust induction (~20-fold) of cAMP levels (Figure 5.2). Preincubation of Ucn I with 
CRH-BP (150 nM) prior to treatment led to a drastic reduction in cAMP levels. Similar to 
Ucn I, ten-minute treatment of CRH (50 nM) produced a large induction (~15 fold) of 
cAMP levels, and preincubation of CRH with CRH-BP (150 nM) resulted in a significant 
reduction in cAMP (Figure 5.2). Interestingly, when cells were treated with CRH6-33 (300 
nM) in combination with CRH and CRH-BP, there was a moderate induction of cAMP (~ 
9-fold), suggesting that CRH6-33 is displacing CRH from CRH-BP resulting in increased 
CRH receptor signaling. Treatment with CRH-BP or CRH6-33 alone did not produce 
significant changes in cAMP levels (1.3- and 1.6-fold induction, respectively), consistent 
with the fact that CRH6-33 does not bind to or activate CRH-R1 or CRH-R2. Additionally, 
when Ucn I and CRH6-33 were administered together, cAMP levels (~18-fold) were not 
significantly different from Ucn I treatment alone (~20 fold).  These studies are the first, 
to our knowledge, to demonstrate that CRH6-33 reverses the CRH-BP inhibition of CRH-







Figure 5.2 – CRH-BP attenuates CRH receptor-mediated increases in cAMP by Ucn I and CRH, an 
effect that is partially reversed by CRH6-33. LβT2 cells were treated with CRH (50nM), urocortin I (Ucn 
I, 50nM), CRH6-33 (300nM), or CRH-BP (150nM) alone or in combinations for 10 minutes (n = 1). CRH-
BP appears to completely attenuate CRH receptor-mediated increases in cAMP by Ucn I and CRH. CRH6-
33 in combination with CRH and CRH-BP causes an induction of cAMP, suggesting that CRH6-33 displaces 
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CRH-R1- and CRH-R2-mediated calcium signaling in HEK-R1 and HEK-R2 cells 
To begin to analyze CRH receptor signaling via the Gαq pathway, we performed 
preliminary studies to investigate CRH-R1- and CRH-R2- mediated calcium signaling in 
HEK293 cells stably transfected with mCRH-R1 (HEK-R1) or mCRH-R2 (HEK-R2). 
HEK-R1 and HEK-R2 cells were treated with CRH, Ucn I, or sauvagine and intracellular 
calcium levels were detected using a fluorogenic calcium-binding dye as an indicator of 
Gαq activation upon receptor binding. In the HEK-R1 cells, CRH, Ucn I, and sauvagine 
produced significant increases in fluorescence (100 – 150 relative fluorescent units 
(RFUs)) compared to vehicle, indicating enhanced CRH-R1 calcium signaling (Figure 
5.3). Fluorescence peaked between 40 – 60 seconds after addition of ligand and returned 
to baseline by 3 minutes from the onset of treatment. The positive control, ATP (200 µM, 
binds P2Y receptors in HEK cells), produced a large increase in fluorescence in HEK-R1 
cells that peaked ~45 seconds from the onset of treatment. CRH at both concentrations 
(50 nM and 300 nM) produced a dose-dependent increase in fluorescence in HEK-R1 
cells that peaked between 40 – 60 seconds from the onset of treatment. Sauvagine (50 nM 
and 300 nM) also produced a dose-dependent increase in fluorescence that was 
comparable to CRH. Lastly, Ucn I (300 nM) treatment caused an increase in fluorescence 
to levels comparable in magnitude to CRH and sauvagine treatment (Figure 5.3), which 
would be expected as all bind to CRH-R1 with similar high affinity.   
In the HEK-R2 cells, all of the peptides produced increases in fluorescence (5 – 
50 RFUs), although to a lower degree than the HEK-R1 experiment. ATP (200 µM) 
























Figure 5.3 – The effects of CRH, Ucn I, and sauvagine on CRH receptor-mediated calcium signaling 
in HEK-R1 cells. HEK-R1 cells were treated with CRH, Ucn I, sauvagine, and ATP (positive control) at 
various concentrations (n = 1). Intracellular calcium levels were detected using a fluorogenic calcium-
binding dye and fluorescence was monitored over time (excitation = 490 nm/emission = 525 nm) using a 
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Figure 5.4 – The effects of CRH, Ucn I, and sauvagine on CRH receptor-mediated calcium signaling 
in HEK-R2 cells.  HEK-R2 cells were treated with CRH, Ucn I, sauvagine, and ATP (positive control) at 
various concentrations (n = 1). Intracellular calcium levels were detected using a fluorogenic calcium-
binding dye and fluorescence was monitored over time (excitation = 490 nm/emission = 525 nm) using a 
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and 300 nM) produced small dose-dependent increases in fluorescence that peaked 
between 75 – 100 seconds. Sauvagine (50 nM and 300 nM) and Ucn I (300 nM) caused 
comparable increases in fluorescence, higher in magnitude than CRH, as expected due to 
the lower affinity of CRH for CRH-R2 (Figure 5.3). The increases in fluorescence peaked 
between 50 – 60 seconds for these peptides.  Future studies will optimize this calcium 
assay and assess the effect of CRH-BP in modulation of CRH-mediated calcium 
signaling via CRH-R1 and CRH-R2. 
Discussion 
 In this study, we begin to examine the mechanisms by which CRH-BP modulates 
endogenous CRH receptor activation by CRH or Ucn I. In the LβT2 cells, we found that 
preincubation of CRH or Ucn I with CRH-BP resulted in a drastic reduction in cAMP 
levels, supporting an inhibitory role for CRH-BP at CRH receptors in this cell line. When 
cells were treated with CRH6-33 in combination with CRH and CRH-BP, there was a 
moderate induction of cAMP, indicating that CRH6-33 is displacing CRH from CRH-BP, 
resulting in increased CRH receptor signaling. To our knowledge, these studies are the 
first to demonstrate that CRH6-33 reverses the CRH-BP inhibition of CRH-mediated 
cAMP signaling in vitro. In the preliminary calcium signaling experiments, we found that 
CRH, Ucn I, and sauvagine increase calcium signaling in HEK-R1 cells, and to a lower 
degree in HEK-R2 cells.  
 The observation that CRH-BP attenuates CRH receptor-mediated increases in 
cAMP is in agreement with previous findings for both CRH-R1 (Boorse et al., 2006; 
Huising et al., 2008) and CRH-R2 (Ryan Evans, unpublished data). It is unclear from our 
experiments in LβT2 cells whether CRH-BP is modulating the activity of CRH-R1 or 
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CRH-R2 or both, as LβT2 cells endogenously express both receptors. Future experiments 
will utilize CRH receptor-specific ligands (e.g., cortagine for CRH-R1 or Ucn III for 
CRH-R2) and/or CRH receptor antagonists to determine the specific receptor(s) through 
which alterations in cAMP activation are occurring (both receptors are likely 
contributing). In the current study, all treatments with CRH-BP involved preincubations 
with ligand for 30 minutes before treatment. Future experiments should apply both 
preincubation and simultaneous treatments of CRH-BP with ligand, as previous studies in 
our laboratory have shown that CRH-BP modulation of CRH-R2 activity depends on the 
temporal interaction of CRH-BP with ligand (Figure 5.1; Ryan Evans, unpublished data). 
Additional time points should be performed as well to determine how cAMP levels 
change over time in response to various treatments. 
 In contrast to our results, previous studies have found that CRH-BP may have an 
enhancing role at CRH-R2 in the VTA. CRH6-33 decreased CRH-mediated potentiation of 
NMDA EPSCs on VTA dopamine neurons, suggesting that CRH-BP may be required for 
CRH-R2 activation by CRH in VTA (Ungless et al., 2003). Moreover, this effect 
specifically occurs through the PLC/PKC signaling pathway. These data are supported by 
in vivo studies that show that intra-VTA administration of CRH6-33 decreases binge 
drinking and stress-induced relapse to cocaine seeking (Albrechet-Souza et al., 2015; 
Wang et al., 2007). Interestingly, both effects are also reduced by CRH-R2 antagonist 
administration into the VTA. Thus, the effect of CRH-BP on CRH receptor activity may 
depend upon a number of factors, including receptor subtype/signaling pathway, brain 
region, and/or cell type. Through our preliminary calcium signaling experiments, we 
show that various CRF receptor agonists increase calcium signaling in HEK-R1 and 
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HEK-R2 cells. These experiments will form the basis for future experiments to 
investigate the role of CRH-BP in modulation of CRH receptor signaling through the 
Gαq-PLC/PKC/calcium signaling pathway to address potential signaling pathway-
dependent effects. In addition to stably transfected cell lines, these experiments should 
utilize physiologically relevant cell lines, such as MN9D cells, an immortalized midbrain 
cell line that is dopaminergic and expresses endogenous CRH receptors. These cells may 
be a particularly useful model of signaling in the VTA. 
 Overall, the current results further our knowledge on the role of CRH-BP in 
modulating CRH receptor activity. We show that CRH-BP attenuates CRH receptor-
mediated increases in cAMP by CRH or Ucn I in LβT2 cells, which endogenously 
express the CRH receptors. We find that CRH6-33 in combination with CRH and CRH-BP 
increases cAMP accumulation, confirming the role of CRH6-33 in displacing ligand from 
CRH-BP and enhancing CRH receptor activity. Lastly, we show that various CRH 
receptor agonists increase calcium signaling in HEK293 cells stably transfected with 
CRH-R1 or CRH-R2.  Future studies are necessary to determine the potential brain 
region- and/or signaling pathway-specific effects of CRH-BP in modulating CRH 
receptor activity. 
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Conclusions and Future Directions 
 There were three main objectives for this thesis. The first objective was to 
determine the role and regulation of CRH-BP in mouse models of binge drinking and 
alcohol dependence. The second objective was to examine the cell type-specific 
expression of CRH-BP to begin to define the neural circuits in which it is expressed. The 
third objective was to begin to determine the molecular mechanisms by which CRH-BP 
modulates CRH signaling at the CRH receptors. The summaries of our findings and 
future directions are discussed in the following sections.  
Role of CRH-BP in Binge Drinking (Chapter II) and the Cell-Type Specific 
Expression of CRH-BP in the PFC (Chapter III) 
It is well-established that the CRH receptors play a role in rodent models of 
excessive alcohol consumption, with a clear role for CRH-R1 in promoting binge-like 
ethanol consumption and drinking during dependence (reviewed in Lowery and Thiele, 
2010; Phillips et al., 2015). Although less well-characterized, CRH-R2 is also implicated 
in both binge drinking and alcohol dependence (Lowery and Thiele, 2010; Phillips et al., 
2015). Given the role for CRH receptors in excessive alcohol intake, we sought to 
determine the role of CRH-BP, a key regulator of CRH receptor activity, in mouse 
models of binge drinking (Chapter II) and alcohol dependence (Chapter IV), as this had 
not been previously examined. 
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Regulation of CRH-BP mRNA expression in binge drinking 
In Chapter II, we used in situ hybridization to examine how CRH-BP, CRH-R1, 
and CRH mRNA expression are regulated within stress and reward pathways following 
drinking in the dark (DID), a mouse model of binge drinking. We demonstrated that 
CRH-BP mRNA expression is significantly decreased in the medial prefrontal cortex 
(mPFC) following repeated cycles binge drinking. CRH-BP mRNA was decreased in the 
prelimbic (PL) mPFC and infralimbic (IL) mPFC after 3 cycles of DID and in the PL 
mPFC after 6 cycles of DID. CRH and CRH-R1 mRNA levels were unchanged in the 
amygdala, ventral tegmental area (VTA), bed nucleus of the stria terminalis (BNST), and 
mPFC after 3 cycles of DID. The regulation of CRH-BP mRNA in the mPFC is 
particularly intriguing, as this region is involved in executive function and regulation of 
emotion and behavior, including responses to stress. The persistent decrease in CRH-BP 
mRNA expression following binge drinking may result in increased free CRH levels, 
resulting in enhanced CRH signaling at CRH-R1 in the mPFC, contributing to excessive 
binge-like ethanol consumption. Consistent with this hypothesis, a recent study has 
shown that administration of a CRH-R1 antagonist into the mPFC attenuates early life-
stress induced increases in alcohol self-administration (Gondré-Lewis et al., 2016). Other 
studies have also revealed dysregulation of the mPFC CRH system in excessive alcohol 
consumption (George et al., 2012; Goldstein and Volkow, 2011; Gondré-Lewis et al., 
2016).  
Cell-type specific expression of CRH-BP in PFC 
The observation of decreased CRH-BP expression in the mPFC following binge 
drinking led us to investigate the cell type-specific expression of CRH-BP in this region, 
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as the molecular phenotype of CRH-BP expressing cells in the PFC had not been 
previously examined. We were particularly interested in whether CRH-BP was expressed 
in excitatory or inhibitory neurons to determine if CRH-BP mainly acts locally within the 
PFC or projects to other regions to mediate its effects. To address this question (Chapter 
III), we used dual in situ hybridization to examine the colocalization of CRH-BP with 
VGLUT or GAD mRNA in different regions of the PFC. We found that CRH-BP 
predominantly colocalized with GAD, revealing the presence of CRH-BP in inhibitory 
interneurons in the PFC. Upon further examination of the colocalization of CRH-BP with 
various interneuron molecular markers, we found that CRH-BP mainly colocalizes with 
SST in the PFC. To our knowledge, these studies represent the first anatomical 
characterization of CRH-BP in the rodent PFC. While working on these studies, a paper 
was published by Li et al., 2016 that confirmed our results by showing that CRH-BP is 
highly enriched in mPFC oxytocin receptor-expressing interneurons, a specific 
subpopulation of SST interneurons. Further analysis suggested that CRH-BP may be 
released from SST (oxytocin receptor) interneurons and bind CRH to inhibit CRH-R1 
activation of layer II/III pyramidal neurons (Li et al., 2016). CRH-BP modulation of 
CRH-R1 activity on pyramidal neurons may regulate anxiety-like behavior, as 
knockdown of CRH-BP in oxytocin receptor interneurons in the mPFC increases anxiety 
in male mice (Li et al., 2016) and selective deletion of CRH-R1 in forebrain 
glutamatergic neurons reduces anxiety-like behavior (Refojo et al., 2011). These data, in 
combination with the findings from the binge drinking studies in Chapter II, suggest that 
decreased CRH-BP expression in the mPFC may increase CRH activity at CRH-R1 on 






Figure 6.1 – Proposed model of CRH-BP action in the PFC. CRH activates pyramidal neurons via 
CRH-R1 and promotes anxiety-like behavior (Gallopin et al., 2006; Li et al., 2016; Refojo et al., 2011). 
CRH-R1 activation in the mPFC also promotes alcohol drinking behavior (Gondré-Lewis et al., 2016). 
CRH-BP may be released from somatostatin (SST)/oxytocin receptor (OxtR) interneurons and bind CRH to 
inhibit CRH-R1 activation of pyramidal neurons in the cortex. Thus, alterations in CRH-BP expression 
could influence stress-related behaviors, including excessive alcohol drinking. CRH may be expressed in 
the same neurons as CRH-BP or perhaps a different population of SST-expressing interneurons (or 
different interneuron subtype).  
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excessive alcohol consumption (Figure 6.1). Future studies should investigate cell-type 
specific changes in CRH-BP following binge drinking to confirm that the decrease in 
CRH-BP mRNA expression is occurring in SST/oxytocin receptor interneurons of the 
mPFC.  
We have recently initiated studies using the technique RNAscope, which allows 
for the simultaneous detection of 3 mRNA targets. We are using this technique to 
investigate the colocalization of CRH-BP with CRH and the CRH receptors in the PFC 
and other brain regions of the stress and reward system (i.e., BNST and VTA). This 
method could also be coupled with other molecular markers to gain a better 
understanding of the cellular phenotype of CRH-BP-expressing cells in the PFC and the 
relation to CRH and CRH receptor-expressing cells. 
Functional role of CRH-BP in binge drinking – mouse models of altered CRH-BP 
expression 
In Chapter II, we utilized CRH-BP KO mice to investigate the functional role of 
CRH-BP in binge drinking, however no changes in drinking were observed between 
CRH-BP KO and wild type mice in this paradigm. These data are not consistent with our 
hypothesis, as we predicted an elevation in binge drinking due to enhanced CRH-R1 
activity in the absence of an inhibitory CRH-BP. Our data contrast with a recent study by 
Albrechet-Souza et al., 2015 that demonstrated decreased binge drinking (in DID) 
following administration of the CRH-BP ligand inhibitor, CRH6-33, into the VTA (but not 
the central nucleus of the amygdala (CeA)). These data suggest that CRH-BP in the VTA 
facilitates binge-like ethanol consumption. An important difference between these two 
studies is the method by which CRH-BP is inhibited/removed. In the Albrechet et al., 
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2015 study, the activity of CRH-BP is site-specifically inhibited in the VTA (or CeA) by 
administration of the CRH6-33 peptide. In our studies, global CRH-BP KO mice were used 
that lack CRH-BP throughout the brain and pituitary (Karolyi et al., 1999). Complete loss 
of CRH-BP in the brain may produce global alterations in CRH signaling that could mask 
the influence of one particular brain region on drinking behavior. Additionally, these 
mice lack CRH-BP throughout development, which could potentially result in 
compensatory changes in CRH signaling via altered CRH or CRH receptor levels. 
Finally, any intracellular roles of CRH-BP would not be altered by administration of 
CRH6-33, as this peptide targets extracellular CRH-BP. Thus, future studies should use 
viral and genetic approaches to conditionally and site-specifically knockdown or 
overexpress CRH-BP in stress and reward pathways to further elucidate its role in mouse 
models of binge drinking. The colocalization studies from Chapter III provide a basis for 
future studies to manipulate CRH-BP in a cell-type specific manner. It would be 
interesting to manipulate CRH-BP in SST-expressing neurons of the PFC and study the 
effects on binge drinking or drinking during dependence. To perform these experiments, 
SST-Cre or oxytocin receptor-Cre mice could be injected with Cre-dependent viral 
vectors to knockdown or overexpress CRH-BP in SST/oxytocin receptor interneurons in 
the mPFC. 
Roles of CRH-R1 and CRH-R2 in binge drinking 
The studies described above suggest that the role of CRH-BP in binge drinking 
may depend on brain region and/or CRH receptor. Most of the data in the literature 
indicate that CRH-R1 facilitates binge drinking (reviewed in Lowery and Thiele, 2010; 
Phillips et al., 2015). Binge drinking is reduced by both peripheral administration of 
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CRH-R1 antagonists (Sparta et al., 2008) and administration of CRH-R1 antagonists into 
the CeA (Lowery-Gionta et al., 2012) or VTA (Rinker et al., 2017; Sparta et al., 2013). 
The role of CRH-R2 in binge drinking is less clear, with both positive and negative 
effects on drinking being reported. ICV administration of a CRH-R2 agonist (Ucn III) 
decreased binge drinking (Lowery et al., 2010; Sharpe and Phillips, 2009). Others have 
reported that intra-VTA administration of a CRH-R2 antagonist (Astressin-2B) decreased 
binge drinking in a 2-bottle choice paradigm (Albrechet-Souza et al., 2015). In contrast, a 
recent study by Rinker et al. (2017) showed that administration of a CRH-R2 agonist 
(Ucn III) into the VTA decreased binge drinking. Interestingly, the authors show that 
intra-VTA administration of CRH-R1 antagonist also reduced drinking, but when both 
CRH-R1 and CRH-R2 are blocked simultaneously, there is no change in drinking (Rinker 
et al., 2017). These data suggest that the blunted binge drinking by CRH-R1 antagonism 
requires intact CRH-R2 signaling. The authors hypothesize that when CRH-R1 
antagonists are administered into the VTA, CRH is free to bind to the lower affinity 
CRH-R2, resulting in decreased drinking (Rinker et al., 2017). The reasons for the 
conflicting results between the two VTA CRH-R2 studies are currently unclear, but could 
perhaps be due to differences in paradigms between the two studies (1-bottle vs. 2-bottle 
choice DID). In Chapter II, we examined changes in CRH, CRH-R1, and CRH-BP 
mRNA expression following binge drinking, but we did not examine CRH-R2 mRNA 
expression in any region. CRH-R2 mRNA is detected in the VTA by qRT-PCR 
(Korotkova et al., 2006; Ungless et al., 2003), but is not detected with in situ 
hybridization under basal conditions (Van Pett et al., 2000; Gwen Stinnett, unpublished 
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data). Thus, future studies should investigate the regulation of VTA CRH-R2 by binge 
drinking using techniques such as qRT-PCR or western blot for protein expression. 
Role of CRH-BP in Alcohol Dependence (Chapter IV)  
Regulation of CRH-BP mRNA expression in dependence 
In Chapter IV, we used in situ hybridization to study how CRH-BP, CRH-R1, and 
CRH mRNA expression are regulated within stress and reward pathways in alcohol 
dependence, using a chronic intermittent ethanol (CIE) exposure model. In this study, we 
used two different CIE paradigms. The first CIE paradigm did not include voluntary 
access to ethanol and was used to study the effects of forced CIE exposure on the CRH 
system, while the second CIE paradigm contained periods of voluntary drinking and was 
used to study the effects of voluntary ethanol consumption on the CRH system in 
dependence. In CIE without voluntary ethanol drinking, CRH-BP mRNA expression was 
significantly decreased in the aPVT of CIE mice at peak alcohol withdrawal. We also 
observed a decrease in CRH-BP expression in the aPVT of CIE mice after voluntary 
ethanol consumption in CIE (compared to CIE mice without access to ethanol). These 
data are consistent with recent studies that have implicated the PVT in alcohol seeking 
(Hamlin et al., 2009) and excessive voluntary ethanol consumption (Barson et al., 2015).  
Decreases in CRH-BP in the PVT suggest increased free levels of CRH, which 
may result in increased CRH receptor signaling. The PVT is primarily composed of 
glutamatergic projection neurons (Kirouac, 2015) and preliminary colocalization studies 
in our laboratory have demonstrated a moderate degree of colocalization between CRH-
BP and VGLUT mRNA in the PVT (unpublished observations). Thus, we hypothesize 
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that CRH-BP is produced in the aPVT and released from projection neurons into areas of 
the stress and reward system to regulate CRH receptor activation. However, it should be 
noted that while studies in cell culture have demonstrated that CRH-BP is secreted via 
regulated (and constitutive) secretory pathways (Behan et al., 1995; Blanco et al., 2011; 
Westphal and Seasholtz, 2005), the release of CRH-BP from terminals has not been 
demonstrated in vivo. Future studies should confirm this through techniques such as in 
vivo microdialysis to better understand the actions of CRH-BP within circuits of the 
stress and reward system. 
In CIE with voluntary access to ethanol, CRH-BP mRNA expression is decreased 
in the VTA of CIE mice after 8 days of abstinence, suggesting dysregulation of the CRH 
system in long-term abstinence from ethanol. As discussed in detail in Chapter IV, these 
data are supported by studies implicating dysregulation of the VTA CRH system in 
excessive alcohol drinking (Albrechet-Souza et al., 2015; Rinker et al., 2017; Sparta et 
al., 2013). Future studies should include later time points to determine the extent of the 
decrease in VTA CRH-BP in abstinence. Ongoing experiments also include additional in 
situ hybridization experiments to look at the regulation of CRH and CRH receptors in the 
VTA (and other regions) in the CIE paradigm with voluntary drinking, as done in CIE 
without drinking. These studies will be valuable in determining how the CRH system is 
changing in response to CRH-BP alterations and the results will be compared to the CRH 
and CRH-R1 results from the CIE paradigm without drinking.  
Interestingly, the BNST is the only brain region where we observed an increase in 
CRH-BP expression after CIE. There was an overall increase in CRH-BP expression in 
CIE mice following ethanol deprivation in CIE with voluntary drinking and a trend for an 
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increase in CIE without voluntary drinking. These data indicate differential regulation of 
CRH-BP expression between brain regions in dependence. Experiments investigating the 
regulation of CRH and the CRH receptors (1 and 2) in this region in CIE will likely 
provide insight into the significance of increased CRH-BP expression in abstinence. 
Additional studies should use RNAscope to determine the cellular colocalization of 
CRH-BP with CRH and the CRH receptors in this region. 
Overall, these data suggest that the regulation of CRH-BP in CIE depends on the 
presence or absence of voluntary ethanol drinking and/or the length of time between each 
CIE cycle. Additionally, it is important to note that the CTL mice in the CIE paradigm 
with voluntary drinking are not ethanol naïve, which could contribute to differences in 
CRH-BP expression between the two paradigms. The inclusion of CRH and CRH 
receptor in situ hybridization experiments in these studies will provide a more complete 
picture of CRH system dysregulation in CIE.  
Binge drinking vs alcohol dependence – circuit-based approaches 
It is interesting to note that CRH-BP appears to be differentially regulated 
between the binge drinking model (Chapter II) and the alcohol dependence models 
(Chapter IV). In binge drinking, CRH-BP mRNA expression is decreased in the mPFC. 
In the alcohol dependence studies, CRH-BP mRNA expression is decreased in the PVT 
and VTA, and increased in the BNST, depending on which variation of the CIE paradigm 
was used. The differential regulation of CRH-BP between the two drinking models is 
consistent with the idea that different neural circuits may be engaged in the transition 
from binge drinking to alcohol dependence (Koob, 2014). Recent studies have begun to 
take circuit-based approaches to understanding the role of stress and the CRH system in 
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addiction, including alcohol addiction. For example, a recent study by Rinker et al. 
(2017) utilized designer receptors exclusively activated by designer drugs (DREADDs) in 
CRH-Cre mice to chemogenetically manipulate CRH-expressing neurons that project 
from the BNST to the VTA. Interestingly, they found that chemogenetic inhibition of 
VTA-projecting BNST CRH neurons decreased binge drinking in a DID paradigm 
(Rinker et al., 2017). Future studies should utilize techniques and approaches such as 
these to identify the specific neural circuits by which CRH-BP modulates binge drinking 
and drinking in dependence. 
Functional role of CRH-BP in alcohol dependence 
CRH-BP KO mice were utilized to investigate the functional role of CRH-BP in 
alcohol dependence. We demonstrated that CRH-BP KO mice exposed to CIE show a 
suppression in CIE-induced escalations in drinking, suggesting that total loss of CRH-BP 
may reduce increased alcohol intake in dependence. The suppressed drinking in CRH-BP 
KO mice suggests that CRH-BP may have other roles in addition to inhibiting CRH-R1 
activation by CRH. Since the initiation of these studies, a study by Haass-Koffler et al., 
2016 found that selective knockdown of CRH-BP expression in the CeA decreased 
ethanol consumption in a rat model of alcohol dependence. These data suggest that the 
effects of CRH-BP on drinking during dependence may be brain region-specific. As 
mentioned above, total loss of CRH-BP in the brain may result in global alterations in 
CRH signaling that could mask the influence of particular brain regions on drinking 
behavior. Hence, viral and genetic approaches to conditionally and site-specifically 
knockdown or overexpress CRH-BP would be valuable in determining region-specific 
influence on drinking behavior. A particularly interesting experiment for future studies 
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would be to virally overexpress CRH-BP in specific brain regions (such as VTA or CeA) 
of CRH-BP KO mice to attempt to reverse the phenotype of suppressed drinking in CIE.  
While global CRH-BP KO mice have been useful in determining the role of 
CRH-BP in stress-related behaviors such as anxiety and addiction, a number of questions 
remain regarding the state of CRH signaling in the brains of these mice during basal and 
stressed states. For example, in the chronic absence of CRH-BP, are there increased free 
levels of CRH in stress and reward pathways? Are there compensatory decreases in CRH 
receptor levels due to chronic receptor activation? How do CRH and receptor levels 
change during stress in the absence of CRH-BP? Future experiments can begin to address 
these questions by performing in situ hybridization (or qRT-PCR) to compare CRH, 
CRH-R1, and CRH-R2 mRNA levels between CRH-BP KO and wild type mice basally 
and after various stressors (previous experiments show no change in CRH in the PVN or 
CeA under basal conditions – unpublished data). Protein levels could also be measured 
through western blotting or immunohistochemistry. These experiments will be valuable 
in interpreting the results from the binge drinking and dependence studies and may also 
provide insight into the functional role of CRH-BP in modulating CRH receptor activity.  
CRH-BP Modulation of CRH Receptor Signaling via cAMP and Calcium (Chapter 
V) 
 A variety of functional roles have been proposed for CRH-BP. Many studies in 
cell culture suggest an inhibitory role for CRH-BP in reducing CRH receptor activation. 
CRH-BP reduces CRH-R1-mediated ACTH release from anterior pituitary cultures 
(Cortright et al., 1995; Potter et al., 1991; Sutton et al., 1995) and attenuates CRH-R1 
increases in cAMP activity (Figure 6.2; Boorse et al., 2006; Huising et al., 2008). Other 
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studies suggest a facilitatory role for CRH-BP in enhancing CRH-R2 activity in the VTA, 
particularly via the PLC/PKC signaling pathway (Figure 6.2; Ungless et al., 2003). To 
begin to address these discrepancies, studies were previously conducted in our laboratory 
to investigate the role of CRH-BP in modulating CRH-R2-mediated cAMP signaling in 
cell culture. These studies revealed that CRH-BP attenuates CRH-mediated increases in 
cAMP activity in CHO cells stably transfected with CRH-R2 (Figure 6.2). However, 
many questions remain about CRH-BP modulation of CRH-R2 signaling. Studies in 
chapter V represent preliminary experiments designed to: 1) investigate the mechanisms 
by which CRH-BP modulates CRH receptor cAMP signaling using a more 
physiologically relevant cell culture system, and 2) optimize a calcium assay to assess 
CRH receptor signaling through Gαq. 
To investigate the CRH-BP modulation of CRH receptor cAMP signaling, we 
used LβT2 cells, a mouse pituitary gonadotroph cell line that expresses endogenous 
CRH-R1 and CRH-R2 (Westphal et al., 2009), but not CRH-BP (unpublished results). 
We demonstrated that preincubation of CRH or Ucn I with purified CRH-BP drastically 
reduced cAMP levels, supporting an inhibitory role for CRH-BP at CRH receptors. These 
data are supported by the studies described above showing that CRH-BP attenuates CRH-
R1- (Boorse et al., 2006; Huising et al., 2008) and CRH-R2- (Ryan Evans, unpublished 
data) mediated increases in cAMP. Given that LβT2 cells endogenously express both 
CRH-R1 and CRH-R2, an important next step would be to utilize CRH receptor-specific 
agonists and/or antagonists to determine the receptor(s) through which these effects are 
occurring. Previous studies in our laboratory have shown that CRH-BP modulation of 






Figure 6.2 – CRH-BP modulation of CRH receptor signaling. (A) Studies in cell culture suggest that 
CRH-BP inhibits CRH-R1 and CRH-R2 activation of the Gs/cAMP/PKA signaling pathway (Boorse et al., 
2006; Huising et al., 2008; Ryan Evans, unpublished data). (B) An ex vivo study suggests a role for CRH-
BP in enhancing CRH-R2 activation of the Gq/PLC/PKC signaling pathway in the VTA (Ungless et al., 
2003). CRH-BP modulation of CRH-R2 signaling through the PLC/PKC signaling pathway has not been 
investigated in cell culture. (C, D) Two additional roles have been proposed for CRH-BP, including a 
CRH-receptor independent (Chan et al., 2000) and a cellular trafficking role (Slater et al., 2016). Modified 
from Ketchesin et al., 2017 with permission from Taylor & Francis.  
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whether CRH-BP is preincubated with ligand or administered simultaneously with ligand 
(Ryan Evans, unpublished data). When CRH is preincubated with CRH-BP, there is a 
dose-dependent reduction in CRH-induced increases in cAMP. When CRH and CRH-BP 
are administered simultaneously, CRH-BP does not prevent cAMP accumulation at early 
time points, but inhibits cAMP at later time points. Together, these data suggest that 
CRH-BP has an inhibitory effect on CRH-R2 activation that may depend upon 
physiological context, with the amount of time CRH is able to interact with CRH-BP 
before it reaches the receptors as a major determinant. In the current studies, CRH-BP 
was preincubated with CRH or Ucn I for 30 minutes before treatment. Future studies 
should include simultaneous treatments to address the temporal interactions of CRH-BP 
with ligand. Lastly, the experiments performed in this chapter were preliminary and 
included one time point (10 minutes). Future experiments will increase the sample size 
and include multiple time points to determine time-effects in CRH-BP modulation of 
CRH receptor activity. 
 We also used the CRH-BP ligand inhibitor, CRH6-33, which binds CRH-BP with 
very high affinity, but does not bind to or activate either CRH receptor. We demonstrated 
that cells treated with CRH6-33 in combination CRH and CRH-BP show a moderate 
induction of cAMP, suggesting that CRH6-33 is displacing CRH from CRH-BP and 
resulting in enhanced CRH receptor signaling. These studies are the first to show that 
CRH6-33 reverses the CRH-BP inhibition of CRH receptor-mediated cAMP signaling in 
vitro.  
Ex vivo studies using CRH6-33 have shown that this peptide decreases CRH-
mediated potentiation of NMDA EPSCs on VTA dopamine neurons, suggesting that 
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CRH-BP may be required for CRH-R2 activation by CRH in this region (Ungless et al., 
2003). Interestingly, this effect occurred through the PLC/PKC, but not the cAMP/PKA, 
signaling pathway. Furthermore, in vivo studies have revealed that CRH6-33 
administration into the VTA decreases binge drinking (Albrechet-Souza et al., 2015) and 
stress-induced relapse to cocaine seeking (Wang et al., 2007), suggesting that CRH-BP in 
the VTA facilitates these behaviors. These effects were also observed following CRH-R2 
antagonist administration into the VTA (Albrechet-Souza et al., 2015; Wang et al., 2007). 
Thus, the role of CRH-BP in modulating CRH receptor activation may depend upon 
cellular context, with CRH receptor, signaling pathway, brain region, and cell type as 
determining factors (Figure 6.2). It should be noted that two additional roles have been 
proposed for CRH-BP, including a CRH-receptor independent (Chan et al., 2000) and an 
intracellular trafficking role (Slater et al., 2016; Figure 6.2). 
 In the last part of this study, we focused on optimizing an assay to asses CRH 
receptor signaling through Gαq using stably transfected HEK293 cells expressing CRH-
R1 (HEK-R1) or CRH-R2 (HEK-R2). Intracellular calcium levels were measured by 
using a fluorogenic calcium-binding dye in response to various CRH receptor agonists. 
CRH, Ucn I, and sauvagine resulted in enhanced calcium signaling in the HEK-R1 and 
HEK-R2 cells, consistent with previous studies showing that CRH-R1 and CRH-R2 
couple to Gαq in stably transfected HEK293 cells (Dautzenberg et al., 2004). CRH, Ucn I, 
and sauvagine stimulated a calcium response similar in magnitude to each other, 
consistent with their high affinities for CRH-R1. Calcium signaling in HEK-R2 cells was 
overall much lower. Sauvagine and Ucn I produced larger calcium responses than CRH, 
consistent with the lower affinity of CRH for CRH-R2. The fluorescent responses in each 
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of these assays was much lower than previous reports (Dautzenberg et al., 2004), 
suggesting further optimization of experimental parameters is necessary. Future studies 
will use the FluoForte calcium assay to determine the role of CRH-BP in modulating 
CRH receptor signaling through the Gαq-PLC/PKC/calcium signaling pathway. In 
addition to using stably transfected cells, these studies should use more physiologically 
relevant cell lines that endogenously express CRH receptors and/or CRH-BP. A good 
example of a cell line to use would be MN9D cells, an immortalized midbrain cell line 
that is dopaminergic and expresses endogenous CRH-R1 and CRH-R2, as well as CRH-
BP upon differentiation. These cells would be a particularly useful model of CRH-BP 
modulation of CRH receptor signaling in the VTA. 
Conclusion 
 In conclusion, the studies presented in this thesis advance our knowledge on the 
role of the CRH system in binge drinking and alcohol dependence. Our binge drinking 
and alcohol dependence studies reveal that CRH-BP, a key regulator of CRH signaling, is 
differentially regulated in stress and reward pathways, suggesting potential alterations in 
CRH signaling that may alter further drinking in these models. Our studies using CRH-
BP KO mice reveal that the complete absence of CRH-BP in the brain is protective 
against increases in dependence-induced alcohol consumption. Future studies using viral 
and genetic approaches to manipulate CRH-BP in a site-specific manner will be critical 
in defining the precise role of CRH-BP in stress and reward circuits that modulate 
drinking behavior. Our cellular colocalization studies begin to identify the neural circuits 
in which CRH-BP is expressed and provide the basis for future studies to manipulate 
CRH-BP in a cell-type specific manner, with a careful consideration of sex-specific 
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differences. Finally, our molecular studies investigating CRH-BP modulation of CRH 
receptor activity begin to define CRH-BP’s mechanism of action. Future studies should 
carefully examine CRH-BP modulation of CRH receptor signaling through the 
Gαq/PLC/PKC pathway. A better understanding of CRH-BP at the molecular and cellular 






Albrechet-Souza, L., Hwa, L. S., Han, X., Zhang, E. Y., Debold, J. F. & Miczek, K. A. 
(2015). Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in 
the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J 
Mice. Alcohol Clin Exp Res 39: 1609-18. 
Barson, J. R., Ho, H. T. & Leibowitz, S. F. (2015). Anterior thalamic paraventricular 
nucleus is involved in intermittent access ethanol drinking: role of orexin receptor 
2. Addict Biol 20: 469-81. 
Behan, D. P., Maciejewski, D., Chalmers, D. & De Souza, E. B. (1995). Corticotropin 
releasing factor binding protein (CRF-BP) is expressed in neuronal and astrocytic 
cells. Brain Res 698: 259-64. 
Blanco, E. H., Zuniga, J. P., Andres, M. E., Alvarez, A. R. & Gysling, K. (2011). 
Corticotropin-releasing factor binding protein enters the regulated secretory 
pathway in neuroendocrine cells and cortical neurons. Neuropeptides 45: 273-9. 
Boorse, G. C., Kholdani, C. A., Seasholtz, A. F. & Denver, R. J. (2006). Corticotropin-
releasing factor is cytoprotective in Xenopus tadpole tail: coordination of ligand, 
receptor, and binding protein in tail muscle cell survival. Endocrinology 147: 
1498-507. 
Chan, R. K., Vale, W. W. & Sawchenko, P. E. (2000). Paradoxical activational effects of 
a corticotropin-releasing factor-binding protein "ligand inhibitor" in rat brain. 
Neuroscience 101: 115-29. 
Cortright, D. N., Nicoletti, A. & Seasholtz, A. F. (1995). Molecular and biochemical 
characterization of the mouse brain corticotropin-releasing hormone-binding 
protein. Mol Cell Endocrinol 111: 147-57. 
Dautzenberg, F. M., Gutknecht, E., Van Der Linden, I., Olivares-Reyes, J. A., 
Durrenberger, F. & Hauger, R. L. (2004). Cell-type specific calcium signaling by 
corticotropin-releasing factor type 1 (CRF1) and 2a (CRF2(a)) receptors: 
phospholipase C-mediated responses in human embryonic kidney 293 but not SK-
N-MC neuroblastoma cells. Biochem Pharmacol 68: 1833-44. 
Gallopin, T., Geoffroy, H., Rossier, J. & Lambolez, B. (2006). Cortical sources of CRF, 
NKB, and CCK and their effects on pyramidal cells in the neocortex. Cereb 
Cortex 16: 1440-52. 
George, O., Sanders, C., Freiling, J., Grigoryan, E., Vu, S., Allen, C. D., Crawford, E., 
Mandyam, C. D. & Koob, G. F. (2012). Recruitment of medial prefrontal cortex 
170 
 
neurons during alcohol withdrawal predicts cognitive impairment and excessive 
alcohol drinking. Proc Natl Acad Sci U S A 109: 18156-61. 
Goldstein, R. Z. & Volkow, N. D. (2011). Dysfunction of the prefrontal cortex in 
addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 12: 
652-69. 
Gondré-Lewis, M. C., Warnock, K. T., Wang, H., June, H. L., Jr., Bell, K. A., Rabe, H., 
Tiruveedhula, V. V., Cook, J., Luddens, H., Aurelian, L. & June, H. L., Sr. 
(2016). Early life stress is a risk factor for excessive alcohol drinking and 
impulsivity in adults and is mediated via a CRF/GABA(A) mechanism. Stress 19: 
235-47. 
Haass-Koffler, C. L., Henry, A. T., Melkus, G., Simms, J. A., Naemmuddin, M., Nielsen, 
C. K., Lasek, A. W., Magill, M., Schwandt, M. L., Momenan, R., Hodgkinson, C. 
A., Bartlett, S. E., Swift, R. M., Bonci, A. & Leggio, L. (2016). Defining the role 
of corticotropin releasing factor binding protein in alcohol consumption. Transl 
Psychiatry 6: e953. 
Hamlin, A. S., Clemens, K. J., Choi, E. A. & Mcnally, G. P. (2009). Paraventricular 
thalamus mediates context-induced reinstatement (renewal) of extinguished 
reward seeking. Eur J Neurosci 29: 802-12. 
Huising, M. O., Vaughan, J. M., Shah, S. H., Grillot, K. L., Donaldson, C. J., Rivier, J., 
Flik, G. & Vale, W. W. (2008). Residues of corticotropin releasing factor-binding 
protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1. 
J Biol Chem 283: 8902-12. 
Karolyi, I. J., Burrows, H. L., Ramesh, T. M., Nakajima, M., Lesh, J. S., Seong, E., 
Camper, S. A. & Seasholtz, A. F. (1999). Altered anxiety and weight gain in 
corticotropin-releasing hormone-binding protein-deficient mice. Proc Natl Acad 
Sci U S A 96: 11595-600. 
Ketchesin, K. D., Stinnett, G. S. & Seasholtz, A. F. (2017). Corticotropin-releasing 
hormone-binding protein and stress: from invertebrates to humans. Stress 1-16. 
Kirouac, G. J. (2015). Placing the paraventricular nucleus of the thalamus within the 
brain circuits that control behavior. Neurosci Biobehav Rev 56: 315-29. 
Koob, G. F. (2014). Neurocircuitry of alcohol addiction: synthesis from animal models. 
Handb Clin Neurol 125: 33-54. 
Korotkova, T. M., Brown, R. E., Sergeeva, O. A., Ponomarenko, A. A. & Haas, H. L. 
(2006). Effects of arousal- and feeding-related neuropeptides on dopaminergic 




Li, K., Nakajima, M., Ibanez-Tallon, I. & Heintz, N. (2016). A Cortical Circuit for 
Sexually Dimorphic Oxytocin-Dependent Anxiety Behaviors. Cell 167: 60-72 
e11. 
Lowery-Gionta, E. G., Navarro, M., Li, C., Pleil, K. E., Rinker, J. A., Cox, B. R., Sprow, 
G. M., Kash, T. L. & Thiele, T. E. (2012). Corticotropin releasing factor signaling 
in the central amygdala is recruited during binge-like ethanol consumption in 
C57BL/6J mice. J Neurosci 32: 3405-13. 
Lowery, E. G., Spanos, M., Navarro, M., Lyons, A. M., Hodge, C. W. & Thiele, T. E. 
(2010). CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking 
in C57BL/6J mice independent of the HPA axis. Neuropsychopharmacology 35: 
1241-52. 
Lowery, E. G. & Thiele, T. E. (2010). Pre-clinical evidence that corticotropin-releasing 
factor (CRF) receptor antagonists are promising targets for pharmacological 
treatment of alcoholism. CNS Neurol Disord Drug Targets 9: 77-86. 
Phillips, T. J., Reed, C. & Pastor, R. (2015). Preclinical evidence implicating 
corticotropin-releasing factor signaling in ethanol consumption and 
neuroadaptation. Genes Brain Behav 14: 98-135. 
Potter, E., Behan, D. P., Fischer, W. H., Linton, E. A., Lowry, P. J. & Vale, W. W. 
(1991). Cloning and characterization of the cDNAs for human and rat 
corticotropin releasing factor-binding proteins. Nature 349: 423-6. 
Refojo, D., Schweizer, M., Kuehne, C., Ehrenberg, S., Thoeringer, C., Vogl, A. M., 
Dedic, N., Schumacher, M., Von Wolff, G., Avrabos, C., Touma, C., Engblom, 
D., Schutz, G., Nave, K. A., Eder, M., Wotjak, C. T., Sillaber, I., Holsboer, F., 
Wurst, W. & Deussing, J. M. (2011). Glutamatergic and dopaminergic neurons 
mediate anxiogenic and anxiolytic effects of CRHR1. Science 333: 1903-7. 
Rinker, J. A., Marshall, S. A., Mazzone, C. M., Lowery-Gionta, E. G., Gulati, V., Pleil, 
K. E., Kash, T. L., Navarro, M. & Thiele, T. E. (2017). Extended Amygdala to 
Ventral Tegmental Area Corticotropin-Releasing Factor Circuit Controls Binge 
Ethanol Intake. Biol Psychiatry 81: 930-940. 
Sharpe, A. L. & Phillips, T. J. (2009). Central urocortin 3 administration decreases 
limited-access ethanol intake in nondependent mice. Behav Pharmacol 20: 346-
51. 
Slater, P. G., Cerda, C. A., Pereira, L. A., Andres, M. E. & Gysling, K. (2016). CRF 
binding protein facilitates the presence of CRF type 2alpha receptor on the cell 
surface. Proc Natl Acad Sci U S A 113: 4075-80. 
Sparta, D. R., Hopf, F. W., Gibb, S. L., Cho, S. L., Stuber, G. D., Messing, R. O., Ron, D. 
& Bonci, A. (2013). Binge ethanol-drinking potentiates corticotropin releasing 
172 
 
factor R1 receptor activity in the ventral tegmental area. Alcohol Clin Exp Res 37: 
1680-7. 
Sparta, D. R., Sparrow, A. M., Lowery, E. G., Fee, J. R., Knapp, D. J. & Thiele, T. E. 
(2008). Blockade of the corticotropin releasing factor type 1 receptor attenuates 
elevated ethanol drinking associated with drinking in the dark procedures. Alcohol 
Clin Exp Res 32: 259-65. 
Sutton, S. W., Behan, D. P., Lahrichi, S. L., Kaiser, R., Corrigan, A., Lowry, P., Potter, 
E., Perrin, M. H., Rivier, J. & Vale, W. W. (1995). Ligand requirements of the 
human corticotropin-releasing factor-binding protein. Endocrinology 136: 1097-
102. 
Ungless, M. A., Singh, V., Crowder, T. L., Yaka, R., Ron, D. & Bonci, A. (2003). 
Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA 
receptors via CRF receptor 2 in dopamine neurons. Neuron 39: 401-7. 
Van Pett, K., Viau, V., Bittencourt, J. C., Chan, R. K., Li, H. Y., Arias, C., Prins, G. S., 
Perrin, M., Vale, W. & Sawchenko, P. E. (2000). Distribution of mRNAs 
encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 
428: 191-212. 
Wang, B., You, Z. B., Rice, K. C. & Wise, R. A. (2007). Stress-induced relapse to 
cocaine seeking: roles for the CRF(2) receptor and CRF-binding protein in the 
ventral tegmental area of the rat. Psychopharmacology (Berl) 193: 283-94. 
Westphal, N. J., Evans, R. T. & Seasholtz, A. F. (2009). Novel expression of type 1 
corticotropin-releasing hormone receptor in multiple endocrine cell types in the 
murine anterior pituitary. Endocrinology 150: 260-7. 
Westphal, N. J. & Seasholtz, A. F. (2005). Gonadotropin-releasing hormone (GnRH) 
positively regulates corticotropin-releasing hormone-binding protein expression 
via multiple intracellular signaling pathways and a multipartite GnRH response 
element in alphaT3-1 cells. Mol Endocrinol 19: 2780-97. 
 
 
